<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C - Hauser, G - 2014 | Cochrane Library</title> <meta content="Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C - Hauser, G - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005642.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C - Hauser, G - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005642.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD005642.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C" name="citation_title"/> <meta content="Goran Hauser" name="citation_author"/> <meta content="ghauser@medri.hr" name="citation_author_email"/> <meta content="Tahany Awad" name="citation_author"/> <meta content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Kristian Thorlund" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="Davor Štimac" name="citation_author"/> <meta content="Clinical Hospital Centre Rijeka" name="citation_author_institution"/> <meta content="Mahasen Mabrouk" name="citation_author"/> <meta content="Faculty of Medicine, Cairo University" name="citation_author_institution"/> <meta content="Christian Gluud" name="citation_author"/> <meta content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD005642.pub3" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/02/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005642.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005642.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005642.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antiviral Agents [*therapeutic use]; Drug Administration Schedule; Drug Therapy, Combination [methods]; Hepatitis C, Chronic [*drug therapy]; Interferon alpha‐2; Interferon‐alpha [*therapeutic use]; Polyethylene Glycols [*therapeutic use]; Randomized Controlled Trials as Topic; Recombinant Proteins [therapeutic use]; Ribavirin [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005642.pub3&amp;doi=10.1002/14651858.CD005642.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005642.pub3&amp;doi=10.1002/14651858.CD005642.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005642.pub3&amp;doi=10.1002/14651858.CD005642.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005642.pub3&amp;doi=10.1002/14651858.CD005642.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005642.pub3&amp;doi=10.1002/14651858.CD005642.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005642.pub3&amp;doi=10.1002/14651858.CD005642.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005642.pub3&amp;doi=10.1002/14651858.CD005642.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005642.pub3&amp;doi=10.1002/14651858.CD005642.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005642.pub3&amp;doi=10.1002/14651858.CD005642.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005642.pub3&amp;doi=10.1002/14651858.CD005642.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005642.pub3&amp;doi=10.1002/14651858.CD005642.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005642.pub3&amp;doi=10.1002/14651858.CD005642.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005642.pub3&amp;doi=10.1002/14651858.CD005642.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005642.pub3&amp;doi=10.1002/14651858.CD005642.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005642.pub3&amp;doi=10.1002/14651858.CD005642.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005642.pub3&amp;doi=10.1002/14651858.CD005642.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005642.pub3&amp;doi=10.1002/14651858.CD005642.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005642.pub3&amp;doi=10.1002/14651858.CD005642.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005642.pub3&amp;doi=10.1002/14651858.CD005642.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005642.pub3&amp;doi=10.1002/14651858.CD005642.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005642.pub3&amp;doi=10.1002/14651858.CD005642.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005642.pub3&amp;doi=10.1002/14651858.CD005642.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005642.pub3&amp;doi=10.1002/14651858.CD005642.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="PrHmaMrX";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD005642\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD005642\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005642\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005642\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD005642.pub3",title:"Peginterferon alpha\\u20102a versus peginterferon alpha\\u20102b for chronic hepatitis C",firstPublishedDate:"Feb 28, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Hepato‐Biliary Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PrHmaMrX&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005642.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005642.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD005642.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD005642.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005642.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD005642.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD005642.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD005642.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD005642.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD005642.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>773 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD005642.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005642.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005642.pub3/full#CD005642-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005642.pub3/full#CD005642-sec-0080"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005642.pub3/full#CD005642-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005642.pub3/full#CD005642-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005642.pub3/full#CD005642-sec-0027"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005642.pub3/full#CD005642-sec-0028"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005642.pub3/full#CD005642-sec-0057"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005642.pub3/full#CD005642-sec-0074"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005642.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005642.pub3/appendices#CD005642-sec-0085"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005642.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005642.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/table_n/CD005642StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/table_n/CD005642StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005642.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005642.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005642.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005642.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005642.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD005642.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005642.pub3/information#CD005642-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Goran Hauser</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005642.pub3/information#CD005642-cr-0003">Tahany Awad</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005642.pub3/information#CD005642-cr-0004">Kristian Thorlund</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005642.pub3/information#CD005642-cr-0005">Davor Štimac</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005642.pub3/information#CD005642-cr-0006">Mahasen Mabrouk</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005642.pub3/information#CD005642-cr-0007">Christian Gluud</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/information/en#CD005642-sec-0088">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 February 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD005642.pub3">https://doi.org/10.1002/14651858.CD005642.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD005642-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005642-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005642-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005642-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005642-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD005642-abs-0001" lang="en"> <section id="CD005642-sec-0001"> <h3 class="title" id="CD005642-sec-0001">Background</h3> <p>A combination of weekly pegylated interferon (peginterferon) alpha and daily ribavirin still represents standard treatment of chronic hepatitis C infection in the majority of patients. However, it is not established which of the two licensed peginterferon products, peginterferon alpha‐2a or peginterferon alpha‐2b, is the most effective and has a better safety profile. </p> </section> <section id="CD005642-sec-0002"> <h3 class="title" id="CD005642-sec-0002">Objectives</h3> <p>To systematically evaluate the benefits and harms of peginterferon alpha‐2a versus peginterferon alpha‐2b in head‐to‐head randomised clinical trials in patients with chronic hepatitis C. </p> </section> <section id="CD005642-sec-0003"> <h3 class="title" id="CD005642-sec-0003">Search methods</h3> <p>We searched the Cochrane Hepato‐Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) in <i>The Cochrane Library,</i> MEDLINE, EMBASE, Science Citation Index Expanded, and LILACS until October 2013<i>.</i> We also searched conference abstracts, journals, and grey literature. </p> </section> <section id="CD005642-sec-0004"> <h3 class="title" id="CD005642-sec-0004">Selection criteria</h3> <p>We included randomised clinical trials comparing peginterferon alpha‐2a versus peginterferon alpha‐2b given with or without co‐intervention(s) (for example, ribavirin) for chronic hepatitis C. Quasi‐randomised studies and observational studies as identified by the searches were also considered for assessment of harms. Our primary outcomes were all‐cause mortality, liver‐related morbidity, serious adverse events, adverse events leading to treatment discontinuation, other adverse events, and quality of life. The secondary outcome was sustained virological response in the blood serum. </p> </section> <section id="CD005642-sec-0005"> <h3 class="title" id="CD005642-sec-0005">Data collection and analysis</h3> <p>Two authors independently used a standardised data collection form. We meta‐analysed data with both the fixed‐effect and the random‐effects models. For each outcome we calculated the relative risk (RR) with 95% confidence interval (CI) based on intention‐to‐treat analysis. We used domains of the trials to assess the risk of systematic errors (bias) and trial sequential analyses to assess the risks of random errors (play of chance). Intervention effects on the outcomes were assessed according to GRADE. </p> </section> <section id="CD005642-sec-0006"> <h3 class="title" id="CD005642-sec-0006">Main results</h3> <p>We included 17 randomised clinical trials which compared peginterferon alpha‐2a plus ribavirin versus peginterferon alpha‐2b plus ribavirin in 5847 patients. All trials had a high risk of bias. Very few trials reported data on very few patients for the patient‐relevant outcomes all‐cause mortality, liver‐related morbidity, serious adverse events, and quality of life. Accordingly, we were unable to conduct meta‐analyses on all‐cause mortality, liver‐related morbidity, and quality of life. Twelve trials reported on adverse events leading to discontinuation of treatment without clear evidence of a difference between the two peginterferons (197/2171 (9.1%) versus 311/3169 (9.9%); RR 0.84, 95% CI 0.57 to 1.22; I<sup>2</sup> = 44%; low quality evidence). A trial sequential analysis showed that we could exclude a relative risk reduction of 20% or more on this outcome. Peginterferon alpha‐2a significantly increased the number of patients who achieved a sustained virological response in the blood serum compared with peginterferon alpha‐2b (1069/2099 (51%) versus 1327/3075 (43%); RR 1.12, 95% CI 1.06 to 1.18; I<sup>2</sup>= 0%, 12 trials; moderate quality evidence). Trial sequential analyses supported this result. Subgroup analyses based on risk of bias, viral genotype, and treatment history yielded similar results. Trial sequential analyses supported the results in patients with genotypes 1 and 4, but not in patients with genotypes 2 and 3. </p> </section> <section id="CD005642-sec-0007"> <h3 class="title" id="CD005642-sec-0007">Authors' conclusions</h3> <p>There is lack of evidence on patient‐important outcomes and paucity of evidence on adverse events. Moderate quality evidence suggests that peginterferon alpha‐2a is associated with a higher sustained virological response in serum than with peginterferon alpha‐2b. This finding may be affected by the high risk of bias of the included studies . The clinical consequences of peginterferon alpha‐2a versus peginterferon alpha‐2b are unknown, and we cannot translate an effect on sustained virological response into comparable clinical effects because sustained virological response is still an unvalidated surrogate outcome for patient‐important outcomes. The lack of evidence on patient‐important outcomes and the paucity of evidence on adverse events means that we are unable to draw any conclusions about the effects of one peginterferon over the other. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD005642-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005642-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005642-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005642-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005642-abs-0005">Français</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD005642-abs-0004" lang="en"> <h3>Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C</h3> <p><b><i>Importance of the review or background on the condition</i> </b> </p> <p>Hepatitis C is a disease of the liver caused by the hepatitis C virus. Globally, an estimated 170 million people are chronically infected with hepatitis C virus. Chronic hepatitis C can cause liver damage in the form of inflammation and scarring of the liver (cirrhosis). Liver damage can lead to liver failure and other complications, including liver cancer. The aim of the treatment for chronic hepatitis C is to prevent complications of hepatitis C infection. This might be achieved by clearing the virus from the blood of the patient. However, we still need to understand if clearance of virus from blood has any association with patient‐relevant and clinically‐relevant outcomes. A combination of weekly injections of peginterferon alpha and daily oral ribavirin still represents the standard of care for the majority of patients with chronic hepatitis C. Currently, there are two licensed products of peginterferon, peginterferon alpha‐2a and peginterferon alpha‐2b, on the market. </p> <p><b><i>The main findings of the review</i> </b> </p> <p>The review identified 17 randomised clinical trials. The trials reported on patient‐relevant outcomes only occasionally. All trials had high risk of bias ie, a trial might systematically overestimate benefits or underestimate harms of the treatments). Both treatments were associated with a high risk of experiencing adverse events, which may lead to discontinuation of the treatment. Twelve trials reported on clearing the virus from blood six months after the end of treatment. A summary of the current evidence in this review suggests that peginterferon alpha‐2a has higher chances of clearing the virus from the patient's blood than peginterferon alpha‐2b (in 50% compared with 43%). </p> <p><b><i>Conclusions</i> </b> </p> <p>We were unable to identify any evidence on the benefits of one peginterferon over the other on patient‐important outcomes. </p> <p><b><i>Any limitations of the review</i> </b> </p> <p>There is lack of data regarding patient‐important outcomes on this topic.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD005642-sec-0080" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD005642-sec-0080"></div> <h3 class="title" id="CD005642-sec-0081">Implications for practice</h3> <section id="CD005642-sec-0081"> <p>There is lack of evidence on patient‐important outcomes such as mortality, liver complications, cirrhosis, hepatocellular carcinoma, and quality of life. Both drugs look comparable regarding harms (adverse events), but the reporting of adverse events in trials was insufficient. Moderate quality evidence suggests that peginterferon alpha‐2a is superior to peginterferon alpha‐2b in achieving a sustained virological response. However, sustained virological response is still an unvalidated surrogate outcome for patient‐important outcomes. The lack of evidence on patient‐important outcomes and the paucity of evidence on adverse events means we are unable to draw definitive conclusions about the effects of one peginterferon over the other. </p> </section> <h3 class="title" id="CD005642-sec-0082">Implications for research</h3> <section id="CD005642-sec-0082"> <p>Future randomised clinical trials need to study the association between achieving a sustained virological response and patient‐relevant outcomes such as liver complications, quality of life, and mortality. Furthermore, future trials ought to be designed according to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines (<a href="./references#CD005642-bbs2-0042" title="ChanAW , TetzlaffJM , AltmanDG , LaupacisA , GøtzschePC , Krleža‐JerićK . SPIRIT 2013 statement: defining standard protocol items for clinical trials. Annals of Internal Medicine2013;158:200‐7. ">Chan 2013</a>) and be reported following the CONSORT statement (<a href="./references#CD005642-bbs2-0084" title="MoherD , HopewellS , SchulzKF , MontoriV , GøtzschePC , DevereauxPJ , et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. International Journal of Surgery2012;10:28‐55. ">Moher 2012</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD005642-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD005642-sec-0022"></div> <div class="table" id="CD005642-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with chronic hepatitis C.<br/> <b>Settings:</b> mainly out‐patients in tertiary and teaching hospitals.<br/> <b>Intervention:</b> peginterferon alpha‐2a versus peginterferon alpha‐2b. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Peginterferon alpha‐2b</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Peginterferon alpha‐2a </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>All‐cause mortality</b> <br/> Deaths during and after the treatment<br/> Follow‐up: 48 to 72 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.97</b> <br/> (0.64 to 6.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3070<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> <br/> (2 to 18) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> <br/> (2 to 18) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Liver‐related morbidity</b> <br/> Number of events<br/> Follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3</b> <br/> (0.7 to 12.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>36<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>2</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>111 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>333 per 1000</b> <br/> (78 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>111 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>333 per 1000</b> <br/> (78 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Serious adverse events</b> <br/> Number of events<br/> Follow‐up: 48 to 72 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.12</b> <br/> (0.95 to 1.3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3900<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>114 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>127 per 1000</b> <br/> (108 to 148) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b> <br/> (66 to 91) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events leading to treatment discontinuation</b> <br/> Number of events<br/> Follow‐up: 48‐72 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.84</b> <br/> (0.57 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>5340<br/> (12 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,4,5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>99 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> <br/> (56 to 120) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>80 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> <br/> (46 to 98) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All other (non‐serious) adverse events</b> <br/> Follow‐up: 48 to 72 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4981<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>4,5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> <br/> SF 36 and CLDQ<br/> Follow‐up: 48 to 71 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>434<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>7,8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Sustained virological response</b> <br/> Absence of viraemia 24 weeks after the treatment<br/> Follow‐up: 48 to 72 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.12</b> <br/> (1.06 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>5013<br/> (12 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<sup>9,10</sup> <br/> <b>moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>421 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>480 per 1000</b> <br/> (451 to 510) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>510 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>581 per 1000</b> <br/> (546 to 617) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> The trial is at low risk of bias due to the allocation sequence generation and allocation concealment.<br/> <sup>2</sup>Data from only one trial, wide confidence interval. Incomplete outcome data. Very low due to imprecision.<br/> <sup>3</sup>Post hoc required information size calculation based on a 10% risk of adverse events in the peginterferon alpha‐2b group, a minimally important difference of 10%, a 5% type I error, and a 80% power, suggests that a minimum of 27,000 patients need to be randomised for a conclusive meta‐analysis on adverse events. The current number of patients is only approximately 5000.<br/> <sup>4</sup>Wide confidence interval. Low due to imprecision.<br/> <sup>5</sup>Trials yield widely differing estimates of effect. Low due to imprecision.<br/> <sup>6</sup> Reporting of all other adverse events was poor and inconsistent across all included trials. The proportions of observed adverse events differ substantially across the trials, and the direction of effect is heterogeneous. Because the event proportion is relatively low across all trials, all of the included trials may be subject to considerable random errors, thus explaining the apparent heterogeneity in direction of estimates.<br/> <sup>7</sup> Data from only one trial. Low due to imprecision<br/> <sup>8</sup> Investigators fail to report the details necessary for calculating the effect estimate of the quality of life assessment. Very low due to imprecision.<br/> <sup>9</sup>Sustained virological response does not seem to be a valid surrogate marker for assessing HCV treatment efficacy of interferon retreatment. Moderate quality of evidence due to indirectness due to surrogate and risk of bias.<br/> <sup>10</sup>All trials are with high risk of bias. Sensitivity analyses did not show any important change in the intervention effects when we focused on trials with lower risk of bias. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD005642-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD005642-sec-0023"></div> <section id="CD005642-sec-0024"> <h3 class="title" id="CD005642-sec-0024">Description of the condition</h3> <p>Globally, an estimated 170 million people are chronically infected with hepatitis C virus, and three to four million people are newly infected each year (<a href="./references#CD005642-bbs2-0110" title="World Health Organization. Global surveillance and control of hepatitis C. Journal of Viral Hepatitis1999;6(1):35‐47. ">WHO 1999</a>). In the majority of patients, acute hepatitis C infection is asymptomatic. Hepatitis C infection is generally recognised in the chronic phase (<a href="./references#CD005642-bbs2-0069" title="HodgsonHJF . Viral hepatitis ‐ clinical aspects. In: WarrellDA , CoxTM , FirthJD , BenzEJJr editor(s). Oxford Textbook of Medicine. 4th Edition. Oxford/ New York: Oxford University Press, 2003. ">Hodgson 2003</a>). Around 85% of patients who become infected with hepatitis C fail to clear the virus and become chronic carriers of hepatitis C virus. Among these individuals, 5% to 20% are reported to develop cirrhosis over a period of approximately 20 to 25 years (<a href="./references#CD005642-bbs2-0101" title="SeeffLB , HoofnagleJH . National institutes of health consensus development conference: Management of hepatitis C: 2002. Hepatology2002;36(S1):S1‐S2. [DOI: 10.1002/hep.1840360702] ">Seeff 2002</a>; <a href="./references#CD005642-bbs2-0100" title='SeeffLB . The history of the "natural history" of hepatitis C (1968‐2009). Liver International2009;29(S1):89‐99. '>Seef 2009</a>). Patients with advanced fibrosis or cirrhosis develop liver complications such as hepatocellular carcinoma with an annual proportion of 2% to 4% (<a href="./references#CD005642-bbs2-0038" title="BenvegnuL , AlbertiA . Patterns of hepatocellular carcinoma development in hepatitis B virus and hepatitis C virus‐related cirrhosis. Antiviral Research2001;52:199‐207. ">Benvegnu 2001</a>; <a href="./references#CD005642-bbs2-0053" title="FattovichG , PantalenaM , ZagniI , RealdiG , SchalmSW , ChristensenE , European Concerted Action on Viral Hepatitis (EUROHEP). Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. American Journal of Gastroenterology2002;97(11):288‐95. ">Fattovich 2002</a>). Furthermore, chronic hepatitis C is the single most common indication for liver transplantation (<a href="./references#CD005642-bbs2-0087" title="United Network for Organ Sharing. Chapter VI ; Liver and Intestine Transplantation in the United States, 1998‐2007. optn.transplant.hrsa.gov/ar2008/chapter_iv_AR_cd.htm?cp=5 (accessed 27 May 2013). ">OPTN 2008</a>). </p> <p>Hepatitis C virus is an enveloped RNA virus that constitutes the genus <i>Hepacivirus</i> within the <i>Flaviviridae</i> family (<a href="./references#CD005642-bbs2-0107" title="vanRegenmortelMHV , FauquetCM , BishopDHL , CarstensEB , EstesMK , LemonSM , et al. Virus Taxonomy: The Classification and Nomenclature of Viruses. The Seventh Report of the International Committee on Taxonomy of Viruses. San Diego: Academic Press, 2000:599‐621. ">van Regenmorte 2000</a>; <a href="./references#CD005642-bbs2-0089" title="PeninF , DubuissonJ , ReyFA , MoradpourD , PawlotskyJ . Structural biology of hepatitis C virus. Hepatology2004;39(1):5‐19. [DOI: 10.1002/hep.20032] ">Penin 2004</a>). Hepatitis C virus is divided into six genotypes, which differ from each other by up to 30% in the nucleotide sequence, and has a large and growing number of subtypes (<a href="./references#CD005642-bbs2-0094" title="RosenbergS . Recent advances in the molecular biology of hepatitis C virus. Journal of Molecular Biology2001;313:451‐64. ">Rosenberg 2001</a>). Hepatitis C virus genotypes differ with geographic region (<a href="./references#CD005642-bbs2-0046" title="DavisGL . Hepatitis C virus genotypes and quasi species. American Journal of Medicine1999;107(6B):21S‐6S. ">Davis 1999</a>). Although a genotype does not predict the outcome of the infection, it does predict the likelihood of virologic treatment response and, in many cases, determines the duration of treatment (<a href="./references#CD005642-bbs2-0082" title="MannsMP , McHutchisonJG , GordonSC , RustgiVK , ShiffmanM , ReindollarR , et al. Peginterferon alfa‐2b plus ribavirin compared with interferon alfa‐2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet2001;358(9286):958‐65. ">Manns 2001</a>; <a href="./references#CD005642-bbs2-0057" title="FriedMW , ShiffmanML , ReddyKR , SmithC , MarinosG , GoncalesFLJr , et al. Peginterferon alfa‐2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Human Services2002;347:975–82. ">Fried 2002</a>; <a href="./references#CD005642-bbs2-0065" title="HadziyannisSJ , SetteH , MorganTR , BalanV , DiagoM , MarcellinP , et al. Peginterferon alfa‐2a (40 kilodaltons) and ribavirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Annals of Internal Medicine2004;140:346–55. ">Hadziyannis 2004</a>). </p> </section> <section id="CD005642-sec-0025"> <h3 class="title" id="CD005642-sec-0025">Description of the intervention</h3> <p>The aim of treatment of chronic hepatitis C is to prevent complications of the hepatitis C infection. This is principally sought by eradication of the infection in the serum (<a href="./references#CD005642-bbs2-0058" title="GhanyMG , StraderDB , ThomasDL , SeeffLB . American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology2009;49(4):1335‐74. ">Ghany 2009</a>). Accordingly, treatment is aimed to achieve a virological response, defined as the absence of hepatitis C virus RNA in the blood serum, measured by a sensitive test six months after the end of treatment (that is, a sustained virological response). Monotherapy with interferon produces a sustained virological response in less than 20% of patients (<a href="./references#CD005642-bbs2-0086" title="MyersRP , RegimbeauC , ThevenotT , LeroyV , MathurinP , OpolonP , et al. Interferon for interferon naive patients with chronic hepatitis C. Cochrane Database of Systematic Reviews2002, Issue 2. [DOI: 10.1002/14651858.CD000370] ">Myers 2002</a>). The introduction of combination therapy with interferon plus ribavirin was considered a major advance due to a greater effect on the sustained virological response in the blood (<a href="./references#CD005642-bbs2-0039" title="BrokJ , GluudLL , GluudC . Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD005445] ">Brok 2005</a>). The next improvement in chronic hepatitis C treatment was the development of direct‐acting antiviral (DAA) agents, boceprevir (BOC) and teleprevir (TVR). The two DAAs have demonstrated significant inhibition of hepatitis C virus (HCV) genotype 1 replication and markedly improved the sustained virological response rate (<a href="./references#CD005642-bbs2-0059" title="GhanyMG , NelsonDR , StraderDB , ThomasDL , SeeffLB . An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology2011;54:1433–44. [DOI: 10.1002/hep.24641] ">Ghany 2011</a>). Unfortunately due to the high price of such a triple regimen it is still not affordable to patients in many countries. Furthermore, we do not have sufficient data about the efficacy of BOC and TVR in the treatment of HCV genotype 2 and 3 infections, which leaves pegylated interferon (peginterferon) plus ribavirin as the major treatment option for the majority of patients. Combination therapy with interferon and ribavirin produces a sustained virological response in approximately 40% of previously untreated patients (<a href="./references#CD005642-bbs2-0039" title="BrokJ , GluudLL , GluudC . Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD005445] ">Brok 2005</a>). The majority of randomised clinical trials primarily assess sustained virological response, which is a surrogate marker, instead of outcomes which might be of more interest for patients and clinicians such as all‐cause mortality, liver‐related morbidity, and progression to hepatocellular carcinoma (HCC) (<a href="./references#CD005642-bbs2-0061" title="GluudC , BrokJ , GongY , KoretzRL . Hepatology may have problems with putative surrogate outcome measures. Journal of Hepatology2007;46(4):734‐42. ">Gluud 2007</a>). Recently, some groups have published results of trials with longer duration of follow‐up of patients with advanced hepatitis C who achieved a sustained virological response (<a href="./references#CD005642-bbs2-0054" title="Fernández‐RodríguezCM , AlonsoS , MartinezSM , FornsX , Sanchez‐TapiasJM , RincónD . Peginterferon plus ribavirin and sustained virological response in HCV‐related cirrhosis: outcomes and factors predicting response. American Journal of Gastroenterology2010;105:2164‐72. ">Fernandez‐ Rodriguez 2010</a>; <a href="./references#CD005642-bbs2-0085" title="MorganTR , GhanyMG , KimHY , SnowKK , ShiffmanML , DeSantoJL , et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology2010;52:833‐44. ">Morgan 2010</a>; <a href="./references#CD005642-bbs2-0049" title="DiBisceglieAM , StoddardAM , DienstagJL , ShiffmanML , SeeffLB , BonkovskyHL , et al. Excess mortality in patients with advanced chronic hepatitis C treated with long‐term peginterferon. Hepatology2011;53:1100‐8. ">Di Biscceglie 2011</a>). The authors reported marked reductions in liver‐related morbidity, no significant difference in liver‐related mortality, and a significantly higher mortality in those treated with long‐term peginterferon (<a href="./references#CD005642-bbs2-0049" title="DiBisceglieAM , StoddardAM , DienstagJL , ShiffmanML , SeeffLB , BonkovskyHL , et al. Excess mortality in patients with advanced chronic hepatitis C treated with long‐term peginterferon. Hepatology2011;53:1100‐8. ">Di Biscceglie 2011</a>). Furthermore, we still lack data about adverse events, quality of life during the treatment, all‐cause morbidity and mortality due to suicide, anaemia, or infections. Therefore, sustained virological response should still be considered as a non‐validated surrogate outcome, that is, an outcome which should not be used to guide clinical decision making (<a href="./references#CD005642-bbs2-0061" title="GluudC , BrokJ , GongY , KoretzRL . Hepatology may have problems with putative surrogate outcome measures. Journal of Hepatology2007;46(4):734‐42. ">Gluud 2007</a>; <a href="./references#CD005642-bbs2-0076" title="KoretzRL , PleguezueloM , ArvanitiV , BaenaPB , CiriaR , GurusamyKS , et al. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD003617.pub2] ">Koretz 2013</a>; <a href="./references#CD005642-bbs2-0063" title="GurusamyKS , WilsonE , KoretzRL , AllenVB , DavidsonBR , BurroughsAK , et al. Is sustained virological response a marker of treatment efficacy in patients with chronic hepatitis C viral infection with no response or relapse to previous antiviral intervention?. PLoS ONE2014;8(12):e83313. ">Gurusamy 2014</a>). A combination of weekly subcutaneous injections of long‐acting peginterferon alpha and oral ribavirin has achieved the highest overall sustained virological response rates of 56% (<a href="./references#CD005642-bbs2-0058" title="GhanyMG , StraderDB , ThomasDL , SeeffLB . American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology2009;49(4):1335‐74. ">Ghany 2009</a>). This still represents the standard of care for the majority of patients according to The American Association for the Study of Liver Diseases and European Association for the Study of Liver Disease guidelines (<a href="./references#CD005642-bbs2-0058" title="GhanyMG , StraderDB , ThomasDL , SeeffLB . American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology2009;49(4):1335‐74. ">Ghany 2009</a>; <a href="./references#CD005642-bbs2-0059" title="GhanyMG , NelsonDR , StraderDB , ThomasDL , SeeffLB . An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology2011;54:1433–44. [DOI: 10.1002/hep.24641] ">Ghany 2011</a>; <a href="./references#CD005642-bbs2-0051" title="European Association for the Study of the Liver. European Association for the Study of the Liver, EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. Journal of Hepatology2011;55(2):245‐64. ">EASL 2012</a>). However, approximately 75% of those treated with either peginterferon alpha or interferon alpha experience one or more adverse events (for example, influenza‐like symptoms, depression, neutropenia, thrombocytopenia, etc.) (<a href="./references#CD005642-bbs2-0058" title="GhanyMG , StraderDB , ThomasDL , SeeffLB . American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology2009;49(4):1335‐74. ">Ghany 2009</a>). Pegylation involves the addition of polyethylene glycol molecules to the interferon molecule, thus decreasing renal clearance, altering metabolism, and increasing the half life of the peginterferon molecule in the circulation. This necessitates fewer doses (<a href="./references#CD005642-bbs2-0091" title="ReddyKR , WrightTL , PockrosPJ , ShiffmanM , EversonG , ReindollarR , et al. Efficacy and safety of pegylated (40‐kd) interferon alpha‐2a compared with interferon alpha‐2a in noncirrhotic patients with chronic hepatitis C. Hepatology2001;33(2):433–8. ">Reddy 2001</a>). Currently, there are two licensed products of peginterferon, peginterferon alpha‐2a (Pegasys®, Hoffmann‐La Roche), which consists of a 40 kDa branched pegylated chain linked to the interferon molecule (<a href="./references#CD005642-bbs2-0035" title="BailonP , PalleroniA , SchafferCA , SpenceCL , FungW‐J , PorterJE , et al. Rational design of a potent, long‐lasting form of interferon: a 40 kDa branched polyethylene glycol‐conjugated interferon alpha‐2a for the treatment of hepatitis. Bioconjugate Chemistry2001;12(2):195‐202. ">Bailon 2001</a>), and peginterferon alpha‐2b (Peg‐Intron®, Schering‐Plough Corporation) consisting of a 12 kDa linear pegylated chain linked to the interferon molecule (<a href="./references#CD005642-bbs2-0060" title="GlueP , FangJWS , Rouzier‐PanisR , RaffanelC , SaboR , GuptaSK , et al. Pegylated interferon‐alpha 2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clinical Pharmacology and Therapeutics2000;68(5):556‐67. ">Glue 2000</a>; <a href="./references#CD005642-bbs2-0056" title="FosterGR . Pegylated interferons: chemical and clinical differences. Alimentary Pharmacology &amp; Therapeutics2004;20(8):825‐30. ">Foster 2004</a>). In particular, pegylation reduces the rapid kidney clearance of a given protein by increasing its hydrodynamic volume, prevents immunogenicity by acting at different levels, reduces protein aggregation owing to a repulsion between pegylated surfaces, and increases the thermal stability of proteins (<a href="./references#CD005642-bbs2-0088" title="PasutG , VeroneseFM . State of the art in PEGylation: The great versatility achieved after forty years of research. Journal of Controlled Release2011;161:461‐72. ">Pasut 2011</a>). The pegylate and its conjugates are mainly excreted by kidney clearance and the excretion rate is significantly reduced for molecular weights over 40 kDa (<a href="./references#CD005642-bbs2-0088" title="PasutG , VeroneseFM . State of the art in PEGylation: The great versatility achieved after forty years of research. Journal of Controlled Release2011;161:461‐72. ">Pasut 2011</a>). The different mechanisms of the pegylated interferon induced different pharmacokinetic and pharmacodynamic properties include that peginterferon alpha‐2a has a higher molecular weight (40 kDa versus 12 kDa), a longer half‐life, a lower body distribution volume, and different routes of elimination because peginterferon alpha‐2a is mainly eliminated by the liver while peginterferon alpha‐2b is mainly eliminated by the kidney (<a href="./references#CD005642-bbs2-0060" title="GlueP , FangJWS , Rouzier‐PanisR , RaffanelC , SaboR , GuptaSK , et al. Pegylated interferon‐alpha 2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clinical Pharmacology and Therapeutics2000;68(5):556‐67. ">Glue 2000</a>; <a href="./references#CD005642-bbs2-0035" title="BailonP , PalleroniA , SchafferCA , SpenceCL , FungW‐J , PorterJE , et al. Rational design of a potent, long‐lasting form of interferon: a 40 kDa branched polyethylene glycol‐conjugated interferon alpha‐2a for the treatment of hepatitis. Bioconjugate Chemistry2001;12(2):195‐202. ">Bailon 2001</a>; <a href="./references#CD005642-bbs2-0056" title="FosterGR . Pegylated interferons: chemical and clinical differences. Alimentary Pharmacology &amp; Therapeutics2004;20(8):825‐30. ">Foster 2004</a>). </p> </section> <section id="CD005642-sec-0026"> <h3 class="title" id="CD005642-sec-0026">Why it is important to do this review</h3> <p>Lately, there has been considerable controversy over which treatment option of peginterferon is the most effective one (<a href="./references#CD005642-bbs2-0010" title="McHutchisonJG , LawitzEJ , ShiffmanML , MuirAJ , GallerGW , McConeJ , et al. Peginterferon alfa‐2b or alfa‐2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine2009;361(6):580‐93. ">McHutchison 2009</a>; <a href="./references#CD005642-bbs2-0028" title="LeeS , KimIH , KimSH , KimSW , LeeSO , LeeST . Efficacy and tolerability of pegylated interferon‐alpha 2a plus ribavirin versus pegylated interferon‐ alpha 2b plus ribavirin in treatment‐naive chronic hepatitis C patients. Intervirology2010;53:146‐53. ">Lee 2010</a>; <a href="./references#CD005642-bbs2-0005" title="KamalMS , AhmedA , MahmoudS , NabeghL , ElGoharyI , ObadanI , et al. Enhanced efficacy of pegylated interferon alpha‐2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomised trial and quality of life analysis. Liver International2011;31:401‐11. ">Kamal 2011</a>; <a href="./references#CD005642-bbs2-0011" title="MiyaseS , HaraokaK , OuchidaY , MorishitaY , FujiyamaS . Randomized trial of peginterferon a‐2a plus ribavirin versus peginterferon a‐2b plus ribavirin for chronic hepatitis C in Japanese patients. Journal of Gastroenterology2012;47(9):1014‐21. MiyaseS , MorishitaY , HaraokaK , OuchidaY , FujiyamaS . PEGIFNalpha‐2A plus ribavirin shows higher SVR rate compare with PEGIFNalpha‐2B plus ribavirin in elderly patients with chronic hepatitis C specially in IL‐28B major allele. Journal of Hepatology2012;56(Suppl 2):S451. ">Miyase 2012</a>). A large randomised clinical trial has recently concluded that the two peginterferons are comparable in both benefits and harms (<a href="./references#CD005642-bbs2-0010" title="McHutchisonJG , LawitzEJ , ShiffmanML , MuirAJ , GallerGW , McConeJ , et al. Peginterferon alfa‐2b or alfa‐2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine2009;361(6):580‐93. ">McHutchison 2009</a>) but the majority of other trials, although with smaller numbers of patients, conclude that there are significant differences between the two peginterferons (<a href="./references#CD005642-bbs2-0005" title="KamalMS , AhmedA , MahmoudS , NabeghL , ElGoharyI , ObadanI , et al. Enhanced efficacy of pegylated interferon alpha‐2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomised trial and quality of life analysis. Liver International2011;31:401‐11. ">Kamal 2011</a>; <a href="./references#CD005642-bbs2-0008" title="MachTH , CieślaA , WarunekW , Janas‐SkulinaU , CiborD , OwczarekD . Efficacy of pegylated interferon alfa‑2aor alfa‑2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b. Polskie Archiwum Medycyny Wewnetrznej2011;121:434‐40. ">Mach 2011</a>; <a href="./references#CD005642-bbs2-0011" title="MiyaseS , HaraokaK , OuchidaY , MorishitaY , FujiyamaS . Randomized trial of peginterferon a‐2a plus ribavirin versus peginterferon a‐2b plus ribavirin for chronic hepatitis C in Japanese patients. Journal of Gastroenterology2012;47(9):1014‐21. MiyaseS , MorishitaY , HaraokaK , OuchidaY , FujiyamaS . PEGIFNalpha‐2A plus ribavirin shows higher SVR rate compare with PEGIFNalpha‐2B plus ribavirin in elderly patients with chronic hepatitis C specially in IL‐28B major allele. Journal of Hepatology2012;56(Suppl 2):S451. ">Miyase 2012</a>). However, findings from a single randomised trial, even a very large one, are rarely definitive and caution should be taken to ensure reproducibility of the findings (<a href="./references#CD005642-bbs2-0078" title="LauJ , SchmidC , ChalmersT . Cumulative meta‐analysis of clinical trials builds evidence for exemplary medical care. Journal of Clinical Epidemiology1995;48(1):45‐57. ">Lau 1995</a>; <a href="./references#CD005642-bbs2-0077" title="LacchettiC , GuyattG . Therapy and validity: surprising results of randomized controlled trials. In: GuyattG , RennieD editor(s). Users' Guides to the Medical Literature: A Manual for Evidence‐Based Clinical Practice. Chicago: AMA Press, 2002:247‐65. ">Lacchetti 2002</a>; <a href="./references#CD005642-bbs2-0106" title="TrikalinosTA , ChurchillR , FerriM , LeuchtS , TuunainenA , WahlbeckK , et al. Effect sizes in cumulative meta‐analyses of mental health randomized trials evolved over time. Journal of Clinical Epidemiology2004;57(11):1124‐30. ">Trikalinos 2004</a>; <a href="./references#CD005642-bbs2-0073" title="IoannidisJP . Contradicted and initially stronger effects in highly cited clinical research. JAMA2005;294(2):218‐28. ">Ioannidis 2005</a>; <a href="./references#CD005642-bbs2-0074" title="IoannidisJP . Why most published research findings are false. PLoS Medicine2005;2(8):e124. ">Ioannidis 2005a</a>; <a href="./references#CD005642-bbs2-0103" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJPA , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses?. International Journal of Epidemiology2009;38(1):276‐86. [DOI: 10.1093/ije/dyn179] ">Thorlund 2009</a>). Systematic reviews and meta‐analyses including all available trials are considered the highest level of evidence as they provide valuable information on the quality of the available evidence and provide the greatest statistical strength. Hence, the risks of systematic errors as well as random errors are smaller in systematic reviews than in single trials. We have, therefore, conducted a Cochrane Hepato‐Biliary Group systematic review to identify, assess, and analyse all randomised trials to add to the existing body of evidence and strengthen inferences about which peginterferon would work best with fewer possible harms to the patient. A previous version of this review that was published in Hepatology suggested that peginterferon alpha‐2a leads to a significantly higher proportion of patients with sustained virological response than with peginterferon alpha‐2b (<a href="./references#CD005642-bbs2-0116" title="AwadT , ThorlundK , HauserG , StimacD , MabroukM , GluudC . Peginterferon alpha‐2a is associated with higher sustained virological response than peginterferon alfa‐2b in chronic hepatitis C: systematic review of randomized trials. Hepatology2010;51(4):1176‐84. ">Awad 2010</a>), while the safety profile remained comparable. The present review provides an update with improved methodology and includes three more randomised clinical trials. There are several meta‐analyses that have been published recently which compare the efficacy and safety of the two pegylated interferons (<a href="./references#CD005642-bbs2-0033" title="AlavianSM , BehnavaB , TabatabaeiSV . The comparative efficacy and safety of peginterferon alpha‐2a vs. 2b for the treatment of chronic HCV infection: a meta‐analysis. Hepatitis Monthly2010;10:121‐31. ">Alavian 2010</a>; <a href="./references#CD005642-bbs2-0037" title="BarrosFMR , CheinquerH , BorgesLG , SantosE . Is there any difference between the effects of therapy with peginterferon‐alpha‐2a versus standard‐dose peginterferon‐alpha‐2b? A meta‐analysis comparing both treatments plus ribavirin in genotype 1/4 chronic hepatitis C virus (HCV) infection patients. Value in Health2010;13:A368. ">Barros 2010c</a>; <a href="./references#CD005642-bbs2-0043" title="CheinquerH , BarrosFMR , BorgesLG , SantosE , BuschinelliCT . Systematic review and meta‐analysis of published randomised controlled trials comparing the efficacy of peginterferon‐alpha‐2a versus peginterferon alpha‐2b both plus ribavirin in chronic hepatitis C patients. Value in Health2010;13:A69. ">Cheinquer 2010</a>; <a href="./references#CD005642-bbs2-0114" title="ZhaoS , LiuE , ChenP , ChengD , LuS , YuQ , et al. A comparison of peginterferon α‐2a and α‐2b for treatment‐naive patients with chronic hepatitis C virus: A meta‐analysis of randomised trials. Clinical Therapeutics2010;32:1565‐77. ">Zhao 2010</a>; <a href="./references#CD005642-bbs2-0044" title="CoppolaN , PisaturoM , SagnelliC , TonzielloG , SagnelliE , AngelilloIF . Efficacy and tolerability of peginterferon α‐2a and α‐2b in patients with chronic hepatitis C by genotype 1: A meta‐analysis. Digestive and Liver Diseases2011;43(Suppl):S94. ">Coppola 2011</a>; <a href="./references#CD005642-bbs2-0102" title="SingalAK , JampanaSC , AnandBS . Peginterferon alfa‐2a is superior to peginterferon alfa‐2b in the treatment of naïve patients with hepatitis C virus infection: meta‐analysis of randomized controlled trials. Digestive Diseases and Sciences2011;56:2221‐26. ">Singal 2011</a>; <a href="./references#CD005642-bbs2-0050" title="DruytsE , MillsEJ , NachegaJ , O’ReganC , CooperCL . Differences in clinical outcomes among hepatitis C genotype 1‐infected patients treated with peginterferon alpha‐2a or peginterferon alpha‐2b plus ribavirin: a meta‐analysis. Clinical and Experimental Gastroenterology2012;5:11‐21. ">Druyits 2012</a>; <a href="./references#CD005642-bbs2-0093" title="Romero‐GomezM , PlanasR , SolaR , Garcıa‐SamaniegoJ , DiagoM , CrespoJ , et al. Peginterferon alpha‐2A achieves higher early virological responses (RVR and CEVR) than peginterferon alpha‐2B in chronic Hepatitis C: Meta‐analysis of randomized clinical trials (RCT). Journal of Hepatology2012;56:S456. ">Romero‐Gomez 2012</a>; <a href="./references#CD005642-bbs2-0055" title="FloriN , FunakoshiN , DunyY , ValatsJC , BismuthM , ChristophorouD , et al. Pegylated interferon‐a2a and ribavirin versus pegylated interferon‐a2b and ribavirin in chronic hepatitis C. A meta‐analysis. Drugs2013;73:263‐77. ">Flori 2013</a>; <a href="./references#CD005642-bbs2-0113" title="YangZ , ZhuangL , YangL , ChenX . Efficacy and tolerability of peginterferon A‐2a and peginterferon A‐2b, both plus ribavirin, for chronic hepatitis C: A meta‐analysis of randomized controlled trials. Gastroenterology Research and Practice2013;2013:739029. ">Yang 2013</a>). Four of them have been published as abstracts only (<a href="./references#CD005642-bbs2-0037" title="BarrosFMR , CheinquerH , BorgesLG , SantosE . Is there any difference between the effects of therapy with peginterferon‐alpha‐2a versus standard‐dose peginterferon‐alpha‐2b? A meta‐analysis comparing both treatments plus ribavirin in genotype 1/4 chronic hepatitis C virus (HCV) infection patients. Value in Health2010;13:A368. ">Barros 2010c</a>; <a href="./references#CD005642-bbs2-0043" title="CheinquerH , BarrosFMR , BorgesLG , SantosE , BuschinelliCT . Systematic review and meta‐analysis of published randomised controlled trials comparing the efficacy of peginterferon‐alpha‐2a versus peginterferon alpha‐2b both plus ribavirin in chronic hepatitis C patients. Value in Health2010;13:A69. ">Cheinquer 2010</a>; <a href="./references#CD005642-bbs2-0044" title="CoppolaN , PisaturoM , SagnelliC , TonzielloG , SagnelliE , AngelilloIF . Efficacy and tolerability of peginterferon α‐2a and α‐2b in patients with chronic hepatitis C by genotype 1: A meta‐analysis. Digestive and Liver Diseases2011;43(Suppl):S94. ">Coppola 2011</a>; <a href="./references#CD005642-bbs2-0093" title="Romero‐GomezM , PlanasR , SolaR , Garcıa‐SamaniegoJ , DiagoM , CrespoJ , et al. Peginterferon alpha‐2A achieves higher early virological responses (RVR and CEVR) than peginterferon alpha‐2B in chronic Hepatitis C: Meta‐analysis of randomized clinical trials (RCT). Journal of Hepatology2012;56:S456. ">Romero‐Gomez 2012</a>) and despite the different numbers of included studies and different outcomes observed, their common conclusion is that pegylated interferon alpha‐2a has advances in terms of efficacy over the pegylated interferon alpha‐2b. Six meta‐analyses that were published as full papers uniformly report superior efficacy of pegylated interferon alpha‐2a over pegylated interferon alpha‐2b while the safety profile remains comparable for both treatments (<a href="./references#CD005642-bbs2-0033" title="AlavianSM , BehnavaB , TabatabaeiSV . The comparative efficacy and safety of peginterferon alpha‐2a vs. 2b for the treatment of chronic HCV infection: a meta‐analysis. Hepatitis Monthly2010;10:121‐31. ">Alavian 2010</a>; <a href="./references#CD005642-bbs2-0114" title="ZhaoS , LiuE , ChenP , ChengD , LuS , YuQ , et al. A comparison of peginterferon α‐2a and α‐2b for treatment‐naive patients with chronic hepatitis C virus: A meta‐analysis of randomised trials. Clinical Therapeutics2010;32:1565‐77. ">Zhao 2010</a>; <a href="./references#CD005642-bbs2-0102" title="SingalAK , JampanaSC , AnandBS . Peginterferon alfa‐2a is superior to peginterferon alfa‐2b in the treatment of naïve patients with hepatitis C virus infection: meta‐analysis of randomized controlled trials. Digestive Diseases and Sciences2011;56:2221‐26. ">Singal 2011</a>; <a href="./references#CD005642-bbs2-0050" title="DruytsE , MillsEJ , NachegaJ , O’ReganC , CooperCL . Differences in clinical outcomes among hepatitis C genotype 1‐infected patients treated with peginterferon alpha‐2a or peginterferon alpha‐2b plus ribavirin: a meta‐analysis. Clinical and Experimental Gastroenterology2012;5:11‐21. ">Druyits 2012</a>; <a href="./references#CD005642-bbs2-0055" title="FloriN , FunakoshiN , DunyY , ValatsJC , BismuthM , ChristophorouD , et al. Pegylated interferon‐a2a and ribavirin versus pegylated interferon‐a2b and ribavirin in chronic hepatitis C. A meta‐analysis. Drugs2013;73:263‐77. ">Flori 2013</a>; <a href="./references#CD005642-bbs2-0113" title="YangZ , ZhuangL , YangL , ChenX . Efficacy and tolerability of peginterferon A‐2a and peginterferon A‐2b, both plus ribavirin, for chronic hepatitis C: A meta‐analysis of randomized controlled trials. Gastroenterology Research and Practice2013;2013:739029. ">Yang 2013</a>). One meta‐analysis (<a href="./references#CD005642-bbs2-0050" title="DruytsE , MillsEJ , NachegaJ , O’ReganC , CooperCL . Differences in clinical outcomes among hepatitis C genotype 1‐infected patients treated with peginterferon alpha‐2a or peginterferon alpha‐2b plus ribavirin: a meta‐analysis. Clinical and Experimental Gastroenterology2012;5:11‐21. ">Druyits 2012</a>) is not comparable to ours because it has a different search strategy and inclusion criteria. The author did not assess the risk of bias and included studies which were not head‐to‐head comparisons. Four meta‐analyses (<a href="./references#CD005642-bbs2-0033" title="AlavianSM , BehnavaB , TabatabaeiSV . The comparative efficacy and safety of peginterferon alpha‐2a vs. 2b for the treatment of chronic HCV infection: a meta‐analysis. Hepatitis Monthly2010;10:121‐31. ">Alavian 2010</a>; <a href="./references#CD005642-bbs2-0114" title="ZhaoS , LiuE , ChenP , ChengD , LuS , YuQ , et al. A comparison of peginterferon α‐2a and α‐2b for treatment‐naive patients with chronic hepatitis C virus: A meta‐analysis of randomised trials. Clinical Therapeutics2010;32:1565‐77. ">Zhao 2010</a>; <a href="./references#CD005642-bbs2-0102" title="SingalAK , JampanaSC , AnandBS . Peginterferon alfa‐2a is superior to peginterferon alfa‐2b in the treatment of naïve patients with hepatitis C virus infection: meta‐analysis of randomized controlled trials. Digestive Diseases and Sciences2011;56:2221‐26. ">Singal 2011</a>; <a href="./references#CD005642-bbs2-0113" title="YangZ , ZhuangL , YangL , ChenX . Efficacy and tolerability of peginterferon A‐2a and peginterferon A‐2b, both plus ribavirin, for chronic hepatitis C: A meta‐analysis of randomized controlled trials. Gastroenterology Research and Practice2013;2013:739029. ">Yang 2013</a>) have similar search strategies and outcomes as in <a href="./references#CD005642-bbs2-0116" title="AwadT , ThorlundK , HauserG , StimacD , MabroukM , GluudC . Peginterferon alpha‐2a is associated with higher sustained virological response than peginterferon alfa‐2b in chronic hepatitis C: systematic review of randomized trials. Hepatology2010;51(4):1176‐84. ">Awad 2010</a>, but they included fewer trials and smaller numbers of patients. They included seven trials with 3518 patients (<a href="./references#CD005642-bbs2-0033" title="AlavianSM , BehnavaB , TabatabaeiSV . The comparative efficacy and safety of peginterferon alpha‐2a vs. 2b for the treatment of chronic HCV infection: a meta‐analysis. Hepatitis Monthly2010;10:121‐31. ">Alavian 2010</a>); seven trials with 3212 patients (<a href="./references#CD005642-bbs2-0114" title="ZhaoS , LiuE , ChenP , ChengD , LuS , YuQ , et al. A comparison of peginterferon α‐2a and α‐2b for treatment‐naive patients with chronic hepatitis C virus: A meta‐analysis of randomised trials. Clinical Therapeutics2010;32:1565‐77. ">Zhao 2010</a>); nine trials with 3546 patients (<a href="./references#CD005642-bbs2-0102" title="SingalAK , JampanaSC , AnandBS . Peginterferon alfa‐2a is superior to peginterferon alfa‐2b in the treatment of naïve patients with hepatitis C virus infection: meta‐analysis of randomized controlled trials. Digestive Diseases and Sciences2011;56:2221‐26. ">Singal 2011</a>); and seven trials with 3668 patients (<a href="./references#CD005642-bbs2-0113" title="YangZ , ZhuangL , YangL , ChenX . Efficacy and tolerability of peginterferon A‐2a and peginterferon A‐2b, both plus ribavirin, for chronic hepatitis C: A meta‐analysis of randomized controlled trials. Gastroenterology Research and Practice2013;2013:739029. ">Yang 2013</a>). They excluded conference abstracts or limited participants only to patients naive to previous antiviral intervention. However, results of those meta‐analyses are in concordance with our conclusions on the higher efficacy of pegylated interferon alpha‐2a and similar safety profile among the pegylated interferons (<a href="./references#CD005642-bbs2-0116" title="AwadT , ThorlundK , HauserG , StimacD , MabroukM , GluudC . Peginterferon alpha‐2a is associated with higher sustained virological response than peginterferon alfa‐2b in chronic hepatitis C: systematic review of randomized trials. Hepatology2010;51(4):1176‐84. ">Awad 2010</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD005642-sec-0027" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD005642-sec-0027"></div> <p>To systematically evaluate the benefits and harms of peginterferon alpha‐2a versus peginterferon alpha‐2b for patients with chronic hepatitis C. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD005642-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD005642-sec-0028"></div> <section id="CD005642-sec-0029"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD005642-sec-0030"> <h4 class="title">Types of studies</h4> <p>We included randomised clinical trials irrespective of language, publication status, or year of publication for assessment of benefits and harms. We also included for assessment of harms quasi‐randomised studies and observational studies that were identified during our searches for randomised trials. </p> </section> <section id="CD005642-sec-0031"> <h4 class="title">Types of participants</h4> <p>Patients with chronic hepatitis C were included. Patients could have been treatment naive (not previously treated with antivirals), relapsers (patients with a transient response to previous antiviral treatment), or non‐responders (patients without a response to previous antiviral treatment). We also included patients with comorbidities such as liver cirrhosis and human immunodeficiency virus (HIV) co‐infection. Patients who had undergone liver transplantation or were positive for chronic hepatitis B infection were excluded. </p> </section> <section id="CD005642-sec-0032"> <h4 class="title">Types of interventions</h4> <p>Peginterferon alpha‐2a compared with peginterferon alpha‐2b given with or without co‐intervention(s) (for example, ribavirin, telaprevir) regardless of the dose or the duration of the interventions. Co‐interventions were permitted if received equally by all intervention groups and applied equally. </p> </section> <section id="CD005642-sec-0033"> <h4 class="title">Types of outcome measures</h4> <section id="CD005642-sec-0034"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD005642-list-0001"> <li> <p>All‐cause mortality.</p> </li> <li> <p>Liver‐related morbidity: number of patients who developed ascites, variceal bleeding, progression of bilirubinaemia, hepatic encephalopathy, or hepatocellular carcinoma. </p> </li> <li> <p>Adverse events: serious adverse events, adverse events leading to treatment discontinuation, and all other (non‐serious) adverse events. The number and type of adverse events are defined as patients with any untoward medical occurrence not necessarily having a causal relationship with the treatment. We defined serious adverse events according to the International Conference on Harmonisation (ICH) Guidelines (<a href="./references#CD005642-bbs2-0072" title="International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR &amp; ICH Guidelines. Vol. 1, PA 19063‐2043, USA: Barnett International/PAREXEL, 1997. ">ICH‐GCP 1997</a>) as "any event that leads to death, is life‐threatening, requires in‐patient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability, and any important medical event, which may jeopardise the patient or requires intervention to prevent it". All other adverse events were considered non‐serious. </p> </li> <li> <p>Quality of life as defined in the individual trials.</p> </li> </ul> </p> </section> <section id="CD005642-sec-0035"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD005642-list-0002"> <li> <p>Sustained virological response: number of patients with undetectable hepatitis C virus RNA in their serum by a sensitive test six months after the end of treatment. </p> </li> </ul> </p> </section> </section> </section> <section id="CD005642-sec-0036"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD005642-sec-0037"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Hepato‐Biliary Group Controlled Trials Register (<a href="./references#CD005642-bbs2-0062" title="GluudC , NikolovaD , KlingenbergSL , AlexakisN , Als‐NielsenB , ColliA , et al. Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2013, Issue 12. Art. No.: LIVER. ">Gluud 2013</a>)<i>,</i> Cochrane Central Register of Controlled Trials (CENTRAL) in <i>The Cochrane Library,</i> MEDLINE, EMBASE, Science Citation Index Expanded (<a href="./references#CD005642-bbs2-0095" title="RoyleP , MilneR . Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care2003;19(4):591‐603. ">Royle 2003</a>), and LILACS using the search strategies and time spans given in <a href="./appendices#CD005642-sec-0086">Appendix 1</a>. The last search was conducted in October 2013. </p> </section> <section id="CD005642-sec-0038"> <h4 class="title">Searching other resources</h4> <p>We identified further trials by searching national and topic‐specific databases, bibliographies, conference abstracts, journals, and the grey literature. Furthermore, we reviewed the reference lists of the other meta‐analyses and the included studies and contacted the principal authors of the identified trials if needed. </p> </section> </section> <section id="CD005642-sec-0039"> <h3 class="title" id="CD005642-sec-0039">Data collection and analysis</h3> <p>We performed the review and meta‐analyses following the recommendations of The Cochrane Collaboration (<a href="./references#CD005642-bbs2-0067" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) and the Cochrane Hepato‐Biliary Group (<a href="./references#CD005642-bbs2-0062" title="GluudC , NikolovaD , KlingenbergSL , AlexakisN , Als‐NielsenB , ColliA , et al. Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2013, Issue 12. Art. No.: LIVER. ">Gluud 2013</a>). The analyses were performed using Review Manager 5.1 (<a href="./references#CD005642-bbs2-0092" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>) and Trial Sequential Analysis (TSA) version 0.9 (<a href="./references#CD005642-bbs2-0045" title="Copenhagen Trial Unit. TSA ‐ Trial Sequential Analysis. ctu.dk/tsa/ 2011 (accessed 27 May 2013). ">CTU 2011</a>; <a href="./references#CD005642-bbs2-0105" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 23 April 2013):1‐115. ">Thorlund 2011</a>). </p> <section id="CD005642-sec-0040"> <h4 class="title">Selection of studies</h4> <p>Two authors (GH and TA) independently screened titles and abstracts for potential eligibility and the full‐texts for final eligibility. Disagreements were resolved by discussion and arbitrated with a third author (CG). </p> </section> <section id="CD005642-sec-0041"> <h4 class="title">Data extraction and management</h4> <p>Two authors (GH and TA) independently extracted data using a standardised data collection form to record trial design and methodological characteristics, patient characteristics, interventions, outcomes, and missing outcome data. Authors of included trials were contacted for additional information that was not described in the published reports. Disagreements were resolved by discussion and arbitration with a third author (CG). Any further information required from the original authors was requested by written correspondence and any relevant information obtained in this manner was included in the review. </p> </section> <section id="CD005642-sec-0042"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Trials with adequate generation of the allocation sequence, adequate allocation concealment, adequate blinding, adequate outcome data reporting, no selective outcome reporting, and without vested interests were considered as trials with low risk of bias (high methodological quality) (<a href="./references#CD005642-bbs2-0099" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. ">Schulz 1995</a>; <a href="./references#CD005642-bbs2-0083" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet1998;352:609‐13. ">Moher 1998</a>; <a href="./references#CD005642-bbs2-0075" title="KjaergardLL , VillumsenJ , GluudC . Reported methodological quality and discrepancies between small and large randomized trials in meta‐analyses. Annals of Internal Medicine2001;135(11):982‐9. ">Kjaergard 2001</a>; <a href="./references#CD005642-bbs2-0112" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanGD , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed.)2008;336:601‐5. ">Wood 2008</a>; <a href="./references#CD005642-bbs2-0081" title="LundhA , SismondoS , LexchinJ , BusuiocOA , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2] ">Lundh 2012</a>; <a href="./references#CD005642-bbs2-0097" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157:429‐38. ">Savovic 2012</a>; <a href="./references#CD005642-bbs2-0098" title="SavovicJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment2012;16(35):1‐82. ">Savovic 2012a</a>). Trials with one or more unclear or inadequate quality component were considered as trials with high risk of bias (low methodological quality) (<a href="./references#CD005642-bbs2-0099" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. ">Schulz 1995</a>; <a href="./references#CD005642-bbs2-0083" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet1998;352:609‐13. ">Moher 1998</a>; <a href="./references#CD005642-bbs2-0075" title="KjaergardLL , VillumsenJ , GluudC . Reported methodological quality and discrepancies between small and large randomized trials in meta‐analyses. Annals of Internal Medicine2001;135(11):982‐9. ">Kjaergard 2001</a>; <a href="./references#CD005642-bbs2-0112" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanGD , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed.)2008;336:601‐5. ">Wood 2008</a>; <a href="./references#CD005642-bbs2-0081" title="LundhA , SismondoS , LexchinJ , BusuiocOA , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2] ">Lundh 2012</a>; <a href="./references#CD005642-bbs2-0097" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157:429‐38. ">Savovic 2012</a>; <a href="./references#CD005642-bbs2-0098" title="SavovicJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment2012;16(35):1‐82. ">Savovic 2012a</a>). The methodological quality of the trials, hence risk of bias, was assessed based on the following domains. </p> <section id="CD005642-sec-0043"> <h5 class="title"><i>Sequence generation</i> </h5> <p> <ul id="CD005642-list-0003"> <li> <p>Low risk of bias: sequence generation was achieved using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice are adequate if performed by an independent person not otherwise involved in the trial. </p> </li> <li> <p>Uncertain risk of bias: the method of sequence generation was not specified.</p> </li> <li> <p>High risk of bias: the sequence generation method was not random.</p> </li> </ul> </p> </section> <section id="CD005642-sec-0044"> <h5 class="title"><i>Allocation concealment</i> </h5> <p> <ul id="CD005642-list-0004"> <li> <p>Low risk of bias: the participant allocations could not have been foreseen in advance of, or during, enrolment. Allocation was controlled by a central and independent randomisation unit. The allocation sequence was unknown to the investigators (for example, if the allocation sequence was hidden in sequentially numbered, opaque, and sealed envelopes). </p> </li> <li> <p>Uncertain risk of bias: the method used to conceal the allocation was not described so that intervention allocations may have been foreseen in advance of, or during, enrolment. </p> </li> <li> <p>High risk of bias: the allocation sequence was likely to be known to the investigators who assigned the participants. </p> </li> </ul> </p> </section> <section id="CD005642-sec-0045"> <h5 class="title"><i>Blinding of outcome assessors</i> </h5> <p> <ul id="CD005642-list-0005"> <li> <p>Low risk of bias: blinding was performed adequately, or the assessment of outcomes was not likely to be influenced by lack of blinding. </p> </li> <li> <p>Uncertain risk of bias: there was insufficient information to assess whether blinding was likely to induce bias on the results. </p> </li> <li> <p>High risk of bias: no blinding or incomplete blinding, and the assessment of outcomes were likely to be influenced by lack of blinding. </p> </li> </ul> </p> </section> <section id="CD005642-sec-0046"> <h5 class="title"><i>Incomplete outcome data</i> </h5> <p> <ul id="CD005642-list-0006"> <li> <p>Low risk of bias: missing data were unlikely to make treatment effects depart from plausible values. Sufficient methods, such as multiple imputation, have been employed to handle missing data. </p> </li> <li> <p>Uncertain risk of bias: there was insufficient information to assess whether missing data in combination with the method used to handle missing data were likely to introduce bias in the results. </p> </li> <li> <p>High risk of bias: the results were likely to be biased due to missing data.</p> </li> </ul> </p> </section> <section id="CD005642-sec-0047"> <h5 class="title"><i>Selective outcome reporting</i> </h5> <p> <ul id="CD005642-list-0007"> <li> <p>Low risk of bias: all outcomes were predefined and reported, or all clinically relevant and reasonably expected outcomes were reported. </p> </li> <li> <p>Uncertain risk of bias: it is unclear whether all predefined and clinically relevant and reasonably expected outcomes were reported. </p> </li> <li> <p>High risk of bias: one or more clinically relevant and reasonably expected outcomes were not reported, and data on these outcomes were likely to have been recorded. </p> </li> </ul> </p> </section> <section id="CD005642-sec-0048"> <h5 class="title"><i>Other sources of bias</i> </h5> <p> <ul id="CD005642-list-0008"> <li> <p>Low risk of bias: the trial appears to be free of other components (for example, academic bias) that could put it at risk of bias. </p> </li> <li> <p>Uncertain risk of bias: the trial may or may not be free of other components that could put it at risk of bias. </p> </li> <li> <p>High risk of bias: there are other factors in the trial that could put it at risk of bias (for example, authors have conducted trials on the same topic, etc). </p> </li> </ul> </p> <p>All the above bias risk domains were assessed independently by two authors (GH and TA). Disagreements were resolved by discussion and arbitrated by a third author (CG). To minimise bias in our findings and recommendations, we used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) summary of findings (SoF) table for outcomes to rate the available evidence (<a href="./references#CD005642-bbs2-0064" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical Research Ed.)2008;336(7650):924‐6. ">Guyatt 2008</a>). </p> </section> </section> <section id="CD005642-sec-0049"> <h4 class="title">Measures of treatment effect</h4> <p>Dichotomous data were expressed as risk ratios (RR) with 95% confidence intervals (CI). Furthermore, the number needed to treat (NNT) was derived from the risk differences (RD) in meta‐analyses where the 95% confidence interval did not include zero. Rare events (morbidity and mortality) were estimated using the odds ratios as a measure of association. </p> </section> <section id="CD005642-sec-0050"> <h4 class="title">Dealing with missing data</h4> <p>We planned to perform all analyses according to the intention‐to‐treat method, including all participants irrespective of compliance or follow‐up. However, we performed analyses according to the intention‐to‐treat method only for dichotomous outcomes. For continuous outcomes we performed available case analysis and included data only on those whose results were known. Regarding the primary outcome measures we planned to include patients with incomplete or missing data in the sensitivity analyses by imputing them according to the two scenarios below (<a href="./references#CD005642-bbs2-0070" title="HollisS , CampbellF . What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ (Clinical Research Ed.)1999;319:670‐4. ">Hollis 1999</a>; <a href="./references#CD005642-bbs2-0062" title="GluudC , NikolovaD , KlingenbergSL , AlexakisN , Als‐NielsenB , ColliA , et al. Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2013, Issue 12. Art. No.: LIVER. ">Gluud 2013</a>). </p> <p> <ul id="CD005642-list-0009"> <li> <p>'Best‐worst' case scenario analyses: participants with missing outcome data are considered successes in the experimental group and failures in the control group. The denominator will include all the participants in the trial. </p> </li> <li> <p>'Worst‐best' case scenario analyses: participants with missing outcome data are considered failures in the experimental group and successes in the control group. The denominator will include all the participants in the trial. </p> </li> </ul> </p> <p>For trials with missing data we assessed the adequacy of the methods used to deal with missing data. When patients were lost to follow‐up and missing data methods were not applied, data were analysed according to the intention‐to‐treat principle. The intention‐to‐treat analysis was performed assuming poor outcome in both groups where dropouts were considered as failures and the total number of patients was used as denominator. </p> </section> <section id="CD005642-sec-0051"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity was explored by the Chi<sup>2</sup> test, and the quantity of heterogeneity was measured by the I<sup>2</sup> statistic (<a href="./references#CD005642-bbs2-0066" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21(11):1539‐58. ">Higgins 2002;</a><a href="./references#CD005642-bbs2-0067" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Sources of heterogeneity were assessed with subgroup analysis and meta‐regression whenever possible. Subgroup analyses were only carried out when data from at least two trials were available for each subgroup. Meta‐regression was only carried out for meta‐analyses including more than 10 trials. Sensitivity analyses were identified during the review process. </p> </section> <section id="CD005642-sec-0052"> <h4 class="title">Assessment of reporting biases</h4> <p>Different types of reporting biases (for example, publication bias, time lag bias, outcome reporting bias, etc.) were handled following the recommendations of The Cochrane Collaboration (<a href="./references#CD005642-bbs2-0067" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). For continuous outcomes with intervention effects measured as mean difference, the test proposed by <a href="./references#CD005642-bbs2-0052" title="EggerM , SmithGD , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.)1997;315(7109):629‐34. ">Egger 1997</a> was planned to be used to test for funnel plot asymmetry. For dichotomous outcomes with intervention effects measured as odds ratios, the arcsine test proposed by <a href="./references#CD005642-bbs2-0096" title="RückerG , SchwarzerG , CarpenterJ . Arcsine test for publication bias in meta‐analyses with binary outcomes. Statistics in Medicine2008;27:746‐63. ">Rücker 2008</a> was planned to be used to test for funnel plot asymmetry. Due to sufficient trials (<a href="./references#CD005642-bbs2-0067" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) included in the meta‐analyses, we could perform the test for funnel plot asymmetry for two outcomes, namely adverse events leading to treatment discontinuation and sustained virological response. </p> </section> <section id="CD005642-sec-0053"> <h4 class="title">Data synthesis</h4> <p>For all analyses, we used both random‐effects (<a href="./references#CD005642-bbs2-0048" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7(3):177‐88. ">DerSimonian 1986</a>) and fixed‐effect model (<a href="./references#CD005642-bbs2-0047" title="DeMetsDL . Methods of combining randomized clinical trials: strengths and limitations. Statistics in Medicine1987;6(3):341‐50. ">DeMets 1987</a>) analyses. Due to the underlying assumptive differences, results from the random‐effects model and the fixed‐effect model may differ to an extent that cannot be ignored. In case such discrepancies were observed, results were interpreted according to the implications of the subgroup and heterogeneity analyses, and according to the confidence intervals of the two models. </p> <section id="CD005642-sec-0054"> <h5 class="title">Assessment of risks of random errors (play of chance)</h5> <p>Random errors may play an important role in the evaluation of meta‐analyses due to sparse data and multiplicity from repetitive testing. To assess the reliability of inferences from our meta‐analysis on sustained virological response, we calculated the required information size which is the required sample size for the meta‐analysis to detect a 10% relative risk reduction in sustained virological response. We assumed an average event proportion of 50% in the control group, assuming that 30% of the variation in the meta‐analysis would be explained by variation across trials, and used statistical error levels of alpha = 5% and beta = 10% (90% power) or beta = 20% (80% power). Meta‐analyses conducted before surpassing the required sample size are considered analogous to interim analyses in a single randomised trial, and thus they necessitate adjustment of the threshold for statistical significance to maintain the predetermined maximum risk of obtaining a false positive result (set to alpha = 5% in our analysis). We, therefore, substituted the conventional 5% threshold for statistical significance with those of the Lan‐DeMets trial sequential monitoring boundaries (<a href="./references#CD005642-bbs2-0036" title="BangaloreS , WetterslevJ , PraneshS , SawhneyS , GluudC , MesserliF . Perioperative β blockers in patients having non‐cardiac surgery: a meta‐analysis. Lancet2008;372(9654):1962‐76. ">Bangalore 2008</a>; <a href="./references#CD005642-bbs2-0040" title="BrokJ , ThorlundK , GluudC , WetterslevJ . Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta‐analyses. Journal of Clinical Epidemiology2008;61(8):763‐9. ">Brok 2008</a>; <a href="./references#CD005642-bbs2-0090" title="RambaldiA , SaconatoHH , ChristensenE , ThorlundK , WetterslevJ , GluudC . Glucocorticosteroids for alcoholic hepatitis – a Cochrane Hepato‐Biliary Group Systematic Review with meta‐analyses and trial sequential analyses of randomised clinical trials. Alimentary Pharmacology &amp; Therapeutics2008;27(12):1167‐78. ">Rambaldi 2008</a>; <a href="./references#CD005642-bbs2-0108" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. ">Wetterslev 2008</a>; <a href="./references#CD005642-bbs2-0041" title="BrokJ , ThorlundK , GluudC , WetterslevJ . Apparently conclusive meta‐analyses may be inconclusive ‐ Trial sequential analysis adjustment for random error risk in conclusive Cochrane neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. [DOI: 10.1093/ije/dyn188] ">Brok 2009</a>; <a href="./references#CD005642-bbs2-0103" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJPA , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses?. International Journal of Epidemiology2009;38(1):276‐86. [DOI: 10.1093/ije/dyn179] ">Thorlund 2009</a>). We used trial sequential analysis (<a href="./references#CD005642-bbs2-0045" title="Copenhagen Trial Unit. TSA ‐ Trial Sequential Analysis. ctu.dk/tsa/ 2011 (accessed 27 May 2013). ">CTU 2011</a>; <a href="./references#CD005642-bbs2-0105" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 23 April 2013):1‐115. ">Thorlund 2011</a>). On the basis of the required information size and risk for type I (5%) and type II (10% or 20%) errors, trial sequential monitoring boundaries were constructed (<a href="./references#CD005642-bbs2-0040" title="BrokJ , ThorlundK , GluudC , WetterslevJ . Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta‐analyses. Journal of Clinical Epidemiology2008;61(8):763‐9. ">Brok 2008</a>; <a href="./references#CD005642-bbs2-0108" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. ">Wetterslev 2008</a>; <a href="./references#CD005642-bbs2-0041" title="BrokJ , ThorlundK , GluudC , WetterslevJ . Apparently conclusive meta‐analyses may be inconclusive ‐ Trial sequential analysis adjustment for random error risk in conclusive Cochrane neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. [DOI: 10.1093/ije/dyn188] ">Brok 2009</a>; <a href="./references#CD005642-bbs2-0103" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJPA , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses?. International Journal of Epidemiology2009;38(1):276‐86. [DOI: 10.1093/ije/dyn179] ">Thorlund 2009</a>; <a href="./references#CD005642-bbs2-0109" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses.. BMC Medical Research Methodology2009;9:86. ">Wetterslev 2009</a>; <a href="./references#CD005642-bbs2-0104" title="ThorlundK , AnemaA , MillsE . Interpreting meta‐analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV‐infected individuals. Clinical Epidemiology2010;2:57‐66. ">Thorlund 2010</a>). These boundaries determine the statistical inference one may draw regarding the cumulative meta‐analysis that has not reached the required information size. If a trial sequential monitoring boundary is crossed by the cumulative Z‐score before the required information size is reached in a cumulative meta‐analysis, firm evidence may have been established and further trials may be superfluous. On the other hand, if the boundaries are not surpassed, it is most probably necessary to continue doing further trials in order to detect or reject a certain intervention effect. We used as the default a type I error of 5%, type II error of 10% or 20%, and adjusted the information size for heterogeneity within diversity unless otherwise stated (<a href="./references#CD005642-bbs2-0040" title="BrokJ , ThorlundK , GluudC , WetterslevJ . Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta‐analyses. Journal of Clinical Epidemiology2008;61(8):763‐9. ">Brok 2008</a>; <a href="./references#CD005642-bbs2-0108" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. ">Wetterslev 2008</a>; <a href="./references#CD005642-bbs2-0041" title="BrokJ , ThorlundK , GluudC , WetterslevJ . Apparently conclusive meta‐analyses may be inconclusive ‐ Trial sequential analysis adjustment for random error risk in conclusive Cochrane neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. [DOI: 10.1093/ije/dyn188] ">Brok 2009</a>; <a href="./references#CD005642-bbs2-0103" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJPA , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses?. International Journal of Epidemiology2009;38(1):276‐86. [DOI: 10.1093/ije/dyn179] ">Thorlund 2009</a>; <a href="./references#CD005642-bbs2-0109" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses.. BMC Medical Research Methodology2009;9:86. ">Wetterslev 2009</a>; <a href="./references#CD005642-bbs2-0104" title="ThorlundK , AnemaA , MillsE . Interpreting meta‐analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV‐infected individuals. Clinical Epidemiology2010;2:57‐66. ">Thorlund 2010</a>). </p> </section> </section> <section id="CD005642-sec-0055"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>The following subgroup analyses were considered and performed when possible.</p> <p> <ul id="CD005642-list-0010"> <li> <p>Risk of bias: trials that were assessed to be at low risk of bias compared to trials at high risk of bias. </p> </li> <li> <p>Risk of detection bias: trials with blinded outcome assessment compared to trials without blinded outcome assessment. </p> </li> <li> <p>Participants: trials with treatment‐naive patients compared to trials with relapsers or non‐responders. </p> </li> <li> <p>Genotype: trials with patients infected with different hepatitis C virus genotypes were compared. </p> </li> <li> <p>Co‐infections and comorbidities: patients with HIV, haemolytic disease, etc. compared to patients without any of these. </p> </li> </ul> </p> </section> <section id="CD005642-sec-0056"> <h4 class="title">Sensitivity analysis</h4> <p>Suitable sensitivity analyses were identified during the review process. We did not plan specific sensitivity analyses but screened our results to examine if suitable sensitivity analyses could examine the robustness of our results. We conducted a sensitivity analysis excluding trials that included patients with HIV. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD005642-sec-0057" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD005642-sec-0057"></div> <section id="CD005642-sec-0058"> <h3 class="title">Description of studies</h3> <section id="CD005642-sec-0059"> <h4 class="title">Results of the search</h4> <p>We identified a total of 6638 references through electronic searches of the Cochrane Hepato‐Biliary Group Controlled Trials Register and Cochrane Central Register of Controlled Trials in<i>The Cochrane Library</i> (n = 1663)<i>,</i> MEDLINE (n = 1087)<i>,</i> EMBASE (n = 2070), Science Citation Index Expanded (n = 1794), LILACS (n = 24), and in the reference lists of other meta‐analyses (n = 1) until October 2013. After removing 1906 duplicates, limiting the search to humans, the number of references in the final list was 4732. Reading the titles and abstracts of the remaining references we excluded clearly irrelevant references and, accordingly, 39 references were retrieved for further assessment. Twelve publications were excluded due to irrelevant outcome measures (for example, cost effectiveness analysis) or being a review article or a retrospective, non‐randomised study. Twenty‐seven publications describing 17 trials were eligible for inclusion in our meta‐analysis. </p> </section> <section id="CD005642-sec-0060"> <h4 class="title">Included studies</h4> <p>Seventeen trials, published in 27 publications, fulfilled our inclusion criteria and included a total number of 5847 patients (<a href="./references#CD005642-bbs2-0003" title="BrunoR , SacchiP , CiappinaV , ZochettiC , PatrunoS , MaiocchiL , et al. Viral dynamics and pharmacokinetics of peginterferon alpha‐2a and peginterferon alpha‐2b in naive patients with chronic hepatitis C: a randomized, controlled study. Antiviral Therapy2004;9(4):491‐7. BrunoR , SacchiP , MaiocchiL , ZocchettiC , CiappinaV , PatrunoS , et al. Area‐under‐the‐curve for peginterferon alpha‐2a and peginterferon alpha‐2b is not related to body weight in treatment‐naive patients with chronic hepatitis C. Antiviral Therapy2005;10(2):201‐5. BrunoR , SacchiP , ScagnolariC , TorrianiF , MaiocchiL , PatrunoS , et al. Pharmacodynamics of peginterferon alpha‐2a and peginterferon alpha‐2b in interferon‐naïve patients with chronic hepatitis C: a randomized, controlled study. Alimentary Pharmacology &amp; Therapeutics2007;26(3):369‐76. ">Bruno 2004</a>; <a href="./references#CD005642-bbs2-0015" title="SinhaS , GulurP , PatelV , Hage‐NassarG , TennerS . A randomized prospective clinical trial comparing pegylated interferon alpha 2a/ribavirin versus pegylated interferon alpha 2b/ribavirin in the treatment of chronic hepatitis C. American Journal of Gastroenterology2004;99(10):237. ">Sinha 2004</a>; <a href="./references#CD005642-bbs2-0002" title="BerakH , HorbanA , WasilewskiM , StanczakJJ , Kolakowska‐RzadzkaA . Randomized, open label trial comparing efficacy and safety of pegylated interferon alfa 2A vs alfa 2B treatment of patients with chronic hepatitis C infected with non 2/3 genotypes‐12 week virological response analysis. Hepatology2005;42(4 S1):684A. ">Berak 2005</a>; <a href="./references#CD005642-bbs2-0014" title="SilvaM , PooJ , WagnerF , JacksonM , CutlerD , GraceM , et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa‐2b and peginterferon alfa‐2a in patients with chronic hepatitis C (COMPARE). Hepatology2006;45(2):204‐13. SilvaM , Poo‐RamirezJL , WagnerF , JacksonM , LaughlinM . Compare trial: Updated data. Hepatology2008;49(2):288‐9. SilvaM , Poo‐RamirezJL , WagnerF , JacksonM , LaughlinM . Comparison of peginterferon‐alpha2a and peginterferon‐alpha2B pharmacokinetics and pharmacodynamic in compare, a randomized, prospective, blinded trial. Hepatology2004;40(4 S1):192A. ">Silva 2006</a>; <a href="./references#CD005642-bbs2-0016" title="SporeaI , DanilaM , SirliR , PopescuA , LazaA , BaditoiuL . Comparative study concerning the efficacy of Peg‐IFN alpha‐2a versus Peg‐IFN alpha‐2b on the early virological response (EVR) in patients with chronic viral C hepatitis. Journal of Gastrointestinal and Liver Diseases2006; Vol. 15, issue 2:125‐30. ">Sporea 2006</a>; <a href="./references#CD005642-bbs2-0017" title="YeniceN , MehtapO , GumrahM , AricanN . The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turkish Journal of Gastroenterology2006;17(2):94‐8. ">Yenice 2006</a>; <a href="./references#CD005642-bbs2-0004" title="DiBisceglieAM , GhalibRH , HamzehFM , RustgiVK . Early virologic response after peginterferon alpha‐2a plus ribavirin or peginterferon alpha‐2b plus ribavirin treatment in patients with chronic hepatitis C. Viral Hepatitis2007;14(10):721‐9. DiBisceglieAM , RustgiVK , ThuluvathP , DavisM , GhalibR , LyonsMF , et al. Pharmacokinetics and pharmacodynamics of pegylated interferon alfa‐2A or alfa‐2B with ribavirin in treatment naive patients with genotype 1 chronic hepatitis C. Hepatology2004;40(S4):734A. ">Di Bisceglie 2007</a>; <a href="./references#CD005642-bbs2-0006" title="KolakowskaA , BerokH , WasilewskiM , HorbonA . Relevance between fibrosis and response to treatment with peginterferon alfa2a vs alfa2b with ribavirin in chronic hepatitis C genotype 3 patients. Randomized open label study. Hepatology2008;48(4):1278. ">Kolakowska 2008</a>; <a href="./references#CD005642-bbs2-0013" title="ScottoG , FazioV , FornabaioC , TartagliaA , DiTullioR , SaracinoA , et al. Early and sustained virological response in non‐responders with chronic hepatitis C; a randomized open‐label study of pegylated interferon‐α‐2a versus pegylated interferon‐α‐2b. Drugs2008;68(6):791‐801. ScottoG , FazioV , FornabaioC , TartagliaA , DiTullioR , SaracinoA , et al. Peg‐interferon alpha‐2a versus peg‐interferon alpha‐2b in non responders with HCV active chronic hepatitis: A pilot study. Interferon and Cytokine Research2008;28:623–30. ">Scotto 2008</a>; <a href="./references#CD005642-bbs2-0007" title="LagunoM , CifuentesC , MurillasJ , VelosoS , LarrousseM , PayerasA , et al. Randomized trial comparing pegylated interferon alpha‐2b versus pegylated interferon alpha‐2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology2009;49(1):22‐31. ">Laguno 2009</a>; <a href="./references#CD005642-bbs2-0010" title="McHutchisonJG , LawitzEJ , ShiffmanML , MuirAJ , GallerGW , McConeJ , et al. Peginterferon alfa‐2b or alfa‐2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine2009;361(6):580‐93. ">McHutchison 2009;</a><a href="./references#CD005642-bbs2-0001" title="AscioneA , DeLucaM , TartaglioneMT , LampasiF , LanzaAG , PicciottoFP , et al. Peginterferon alfa‐2a plus ribavirin Is more effective than peginterferon alfa‐2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology2010;138(1):116‐22. AscioneA , DeLucaM , TartaglioneMT , LampasiF , LanzaAG , PicciottoFP , et al. Peginterferon alpha‐2a plus ribavirin versus peginterferon alpha‐2b plus ribavirin in naive patients with chronic hepatitis C virus infection: results of a prospective randomised trial. Abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver. Hepatology2008;48(S2):370. ">Ascione 2010</a>; <a href="./references#CD005642-bbs2-0012" title="RumiM , AghemoA , PratiGM , D'AmbrosioR , DonatoMF , RussoR , et al. Randomized study comparing peginterferon‐alfa2a plus ribavirin and peginterferon‐alfa2b plus ribavirin in naïve patients with chronic hepatitis C: final results of the Milan Safety Tolerability (MIST) study. Hepatology2008;48(4):A212. RumiM , AghemoA , PratiGM , D'AmbrosioR , DonatoMF , RussoR , et al. Randomized study of peginterferon‐∝2a plus ribavirin vs peginterferon‐∝2b plus ribavirin in chronic hepatitis C. Gastroenterology2010;138(1):108‐15. ">Rumi 2010</a>; <a href="./references#CD005642-bbs2-0005" title="KamalMS , AhmedA , MahmoudS , NabeghL , ElGoharyI , ObadanI , et al. Enhanced efficacy of pegylated interferon alpha‐2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomised trial and quality of life analysis. Liver International2011;31:401‐11. ">Kamal 2011</a>; <a href="./references#CD005642-bbs2-0008" title="MachTH , CieślaA , WarunekW , Janas‐SkulinaU , CiborD , OwczarekD . Efficacy of pegylated interferon alfa‑2aor alfa‑2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b. Polskie Archiwum Medycyny Wewnetrznej2011;121:434‐40. ">Mach 2011</a>; <a href="./references#CD005642-bbs2-0009" title="MarcellinP , FornsX , GoeserT , FerenciP , NevensF , CarosiG , et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa‐2a or ‐2b to patients with chronic hepatitis C. Gastroenterology2011;140:459‐68. [DOI: 10.1053/j.gastro.2010.10.046] ">Marcellin 2011</a>; <a href="./references#CD005642-bbs2-0011" title="MiyaseS , HaraokaK , OuchidaY , MorishitaY , FujiyamaS . Randomized trial of peginterferon a‐2a plus ribavirin versus peginterferon a‐2b plus ribavirin for chronic hepatitis C in Japanese patients. Journal of Gastroenterology2012;47(9):1014‐21. MiyaseS , MorishitaY , HaraokaK , OuchidaY , FujiyamaS . PEGIFNalpha‐2A plus ribavirin shows higher SVR rate compare with PEGIFNalpha‐2B plus ribavirin in elderly patients with chronic hepatitis C specially in IL‐28B major allele. Journal of Hepatology2012;56(Suppl 2):S451. ">Miyase 2012</a>). All trials compared peginterferon alpha‐2a (180 µg/week) versus peginterferon alpha‐2b (1.0 to 1.5 µg/kg/week). All trials administered ribavirin as a co‐intervention to both peginterferon groups. The dose of ribavirin was according to the weight of the patient, ranging from 800 mg to 1400 mg. One trial included telaprevir as a co‐intervention to both peginterferon groups (<a href="./references#CD005642-bbs2-0009" title="MarcellinP , FornsX , GoeserT , FerenciP , NevensF , CarosiG , et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa‐2a or ‐2b to patients with chronic hepatitis C. Gastroenterology2011;140:459‐68. [DOI: 10.1053/j.gastro.2010.10.046] ">Marcellin 2011</a>). The hepatitis C genotype of the included patients varied among the trials. Eleven trials included patients with no previous chronic hepatitis C treatment (naive patients) (<a href="./references#CD005642-bbs2-0015" title="SinhaS , GulurP , PatelV , Hage‐NassarG , TennerS . A randomized prospective clinical trial comparing pegylated interferon alpha 2a/ribavirin versus pegylated interferon alpha 2b/ribavirin in the treatment of chronic hepatitis C. American Journal of Gastroenterology2004;99(10):237. ">Sinha 2004</a>; <a href="./references#CD005642-bbs2-0006" title="KolakowskaA , BerokH , WasilewskiM , HorbonA . Relevance between fibrosis and response to treatment with peginterferon alfa2a vs alfa2b with ribavirin in chronic hepatitis C genotype 3 patients. Randomized open label study. Hepatology2008;48(4):1278. ">Kolakowska 2008</a>; <a href="./references#CD005642-bbs2-0007" title="LagunoM , CifuentesC , MurillasJ , VelosoS , LarrousseM , PayerasA , et al. Randomized trial comparing pegylated interferon alpha‐2b versus pegylated interferon alpha‐2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology2009;49(1):22‐31. ">Laguno 2009</a>; <a href="./references#CD005642-bbs2-0010" title="McHutchisonJG , LawitzEJ , ShiffmanML , MuirAJ , GallerGW , McConeJ , et al. Peginterferon alfa‐2b or alfa‐2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine2009;361(6):580‐93. ">McHutchison 2009</a>; <a href="./references#CD005642-bbs2-0001" title="AscioneA , DeLucaM , TartaglioneMT , LampasiF , LanzaAG , PicciottoFP , et al. Peginterferon alfa‐2a plus ribavirin Is more effective than peginterferon alfa‐2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology2010;138(1):116‐22. AscioneA , DeLucaM , TartaglioneMT , LampasiF , LanzaAG , PicciottoFP , et al. Peginterferon alpha‐2a plus ribavirin versus peginterferon alpha‐2b plus ribavirin in naive patients with chronic hepatitis C virus infection: results of a prospective randomised trial. Abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver. Hepatology2008;48(S2):370. ">Ascione 2010</a>; <a href="./references#CD005642-bbs2-0012" title="RumiM , AghemoA , PratiGM , D'AmbrosioR , DonatoMF , RussoR , et al. Randomized study comparing peginterferon‐alfa2a plus ribavirin and peginterferon‐alfa2b plus ribavirin in naïve patients with chronic hepatitis C: final results of the Milan Safety Tolerability (MIST) study. Hepatology2008;48(4):A212. RumiM , AghemoA , PratiGM , D'AmbrosioR , DonatoMF , RussoR , et al. Randomized study of peginterferon‐∝2a plus ribavirin vs peginterferon‐∝2b plus ribavirin in chronic hepatitis C. Gastroenterology2010;138(1):108‐15. ">Rumi 2010</a>; <a href="./references#CD005642-bbs2-0005" title="KamalMS , AhmedA , MahmoudS , NabeghL , ElGoharyI , ObadanI , et al. Enhanced efficacy of pegylated interferon alpha‐2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomised trial and quality of life analysis. Liver International2011;31:401‐11. ">Kamal 2011</a>; <a href="./references#CD005642-bbs2-0008" title="MachTH , CieślaA , WarunekW , Janas‐SkulinaU , CiborD , OwczarekD . Efficacy of pegylated interferon alfa‑2aor alfa‑2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b. Polskie Archiwum Medycyny Wewnetrznej2011;121:434‐40. ">Mach 2011</a>; <a href="./references#CD005642-bbs2-0009" title="MarcellinP , FornsX , GoeserT , FerenciP , NevensF , CarosiG , et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa‐2a or ‐2b to patients with chronic hepatitis C. Gastroenterology2011;140:459‐68. [DOI: 10.1053/j.gastro.2010.10.046] ">Marcellin 2011</a>; <a href="./references#CD005642-bbs2-0011" title="MiyaseS , HaraokaK , OuchidaY , MorishitaY , FujiyamaS . Randomized trial of peginterferon a‐2a plus ribavirin versus peginterferon a‐2b plus ribavirin for chronic hepatitis C in Japanese patients. Journal of Gastroenterology2012;47(9):1014‐21. MiyaseS , MorishitaY , HaraokaK , OuchidaY , FujiyamaS . PEGIFNalpha‐2A plus ribavirin shows higher SVR rate compare with PEGIFNalpha‐2B plus ribavirin in elderly patients with chronic hepatitis C specially in IL‐28B major allele. Journal of Hepatology2012;56(Suppl 2):S451. ">Miyase 2012</a>) and two trials included non‐responders (<a href="./references#CD005642-bbs2-0013" title="ScottoG , FazioV , FornabaioC , TartagliaA , DiTullioR , SaracinoA , et al. Early and sustained virological response in non‐responders with chronic hepatitis C; a randomized open‐label study of pegylated interferon‐α‐2a versus pegylated interferon‐α‐2b. Drugs2008;68(6):791‐801. ScottoG , FazioV , FornabaioC , TartagliaA , DiTullioR , SaracinoA , et al. Peg‐interferon alpha‐2a versus peg‐interferon alpha‐2b in non responders with HCV active chronic hepatitis: A pilot study. Interferon and Cytokine Research2008;28:623–30. ">Scotto 2008;</a><a href="./references#CD005642-bbs2-0005" title="KamalMS , AhmedA , MahmoudS , NabeghL , ElGoharyI , ObadanI , et al. Enhanced efficacy of pegylated interferon alpha‐2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomised trial and quality of life analysis. Liver International2011;31:401‐11. ">Kamal 2011</a>). Three trials included patients with a clear or unclear history of previous hepatitis C treatment (<a href="./references#CD005642-bbs2-0002" title="BerakH , HorbanA , WasilewskiM , StanczakJJ , Kolakowska‐RzadzkaA . Randomized, open label trial comparing efficacy and safety of pegylated interferon alfa 2A vs alfa 2B treatment of patients with chronic hepatitis C infected with non 2/3 genotypes‐12 week virological response analysis. Hepatology2005;42(4 S1):684A. ">Berak 2005</a>; <a href="./references#CD005642-bbs2-0013" title="ScottoG , FazioV , FornabaioC , TartagliaA , DiTullioR , SaracinoA , et al. Early and sustained virological response in non‐responders with chronic hepatitis C; a randomized open‐label study of pegylated interferon‐α‐2a versus pegylated interferon‐α‐2b. Drugs2008;68(6):791‐801. ScottoG , FazioV , FornabaioC , TartagliaA , DiTullioR , SaracinoA , et al. Peg‐interferon alpha‐2a versus peg‐interferon alpha‐2b in non responders with HCV active chronic hepatitis: A pilot study. Interferon and Cytokine Research2008;28:623–30. ">Scotto 2008</a>; <a href="./references#CD005642-bbs2-0005" title="KamalMS , AhmedA , MahmoudS , NabeghL , ElGoharyI , ObadanI , et al. Enhanced efficacy of pegylated interferon alpha‐2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomised trial and quality of life analysis. Liver International2011;31:401‐11. ">Kamal 2011</a>). One trial included patients with HIV co‐infection (<a href="./references#CD005642-bbs2-0007" title="LagunoM , CifuentesC , MurillasJ , VelosoS , LarrousseM , PayerasA , et al. Randomized trial comparing pegylated interferon alpha‐2b versus pegylated interferon alpha‐2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology2009;49(1):22‐31. ">Laguno 2009</a>). Three trials were published in an abstract form only (<a href="./references#CD005642-bbs2-0015" title="SinhaS , GulurP , PatelV , Hage‐NassarG , TennerS . A randomized prospective clinical trial comparing pegylated interferon alpha 2a/ribavirin versus pegylated interferon alpha 2b/ribavirin in the treatment of chronic hepatitis C. American Journal of Gastroenterology2004;99(10):237. ">Sinha 2004</a>; <a href="./references#CD005642-bbs2-0002" title="BerakH , HorbanA , WasilewskiM , StanczakJJ , Kolakowska‐RzadzkaA . Randomized, open label trial comparing efficacy and safety of pegylated interferon alfa 2A vs alfa 2B treatment of patients with chronic hepatitis C infected with non 2/3 genotypes‐12 week virological response analysis. Hepatology2005;42(4 S1):684A. ">Berak 2005</a>; <a href="./references#CD005642-bbs2-0006" title="KolakowskaA , BerokH , WasilewskiM , HorbonA . Relevance between fibrosis and response to treatment with peginterferon alfa2a vs alfa2b with ribavirin in chronic hepatitis C genotype 3 patients. Randomized open label study. Hepatology2008;48(4):1278. ">Kolakowska 2008</a>). </p> </section> <section id="CD005642-sec-0061"> <h4 class="title">Excluded studies</h4> <p>Fourteen publications were excluded for the reasons shown in the table 'Characteristics of excluded studies' (<a href="#CD005642-sec-0061">Excluded studies</a>). </p> </section> </section> <section id="CD005642-sec-0062"> <h3 class="title">Risk of bias in included studies</h3> <p>All trials had one or more domains with high risk of bias. Accordingly, all information in our review originated from trials that were assessed as trials with high risk of bias (<a href="#CD005642-fig-0001">Figure 1</a>; <a href="#CD005642-fig-0002">Figure 2</a>). Eleven trials had sequence generation and nine had allocation concealment with low risk of bias. Blinding of the outcome assessors, however, was not clear in most of the trials. We considered this bias less important for the outcome sustained virological response. Two trials without risk of blinding bias reported results regarding sustained virological response (<a href="./references#CD005642-bbs2-0005" title="KamalMS , AhmedA , MahmoudS , NabeghL , ElGoharyI , ObadanI , et al. Enhanced efficacy of pegylated interferon alpha‐2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomised trial and quality of life analysis. Liver International2011;31:401‐11. ">Kamal 2011</a>; <a href="./references#CD005642-bbs2-0011" title="MiyaseS , HaraokaK , OuchidaY , MorishitaY , FujiyamaS . Randomized trial of peginterferon a‐2a plus ribavirin versus peginterferon a‐2b plus ribavirin for chronic hepatitis C in Japanese patients. Journal of Gastroenterology2012;47(9):1014‐21. MiyaseS , MorishitaY , HaraokaK , OuchidaY , FujiyamaS . PEGIFNalpha‐2A plus ribavirin shows higher SVR rate compare with PEGIFNalpha‐2B plus ribavirin in elderly patients with chronic hepatitis C specially in IL‐28B major allele. Journal of Hepatology2012;56(Suppl 2):S451. ">Miyase 2012</a>). Incomplete outcome data were adequately addressed in 10 trials. It was difficult to assess selective outcome reporting due to the unavailability of the trial protocols. Most trials did not report on the primary outcomes of our review. Five trials had funding with possible conflict of interest (<a href="./references#CD005642-bbs2-0003" title="BrunoR , SacchiP , CiappinaV , ZochettiC , PatrunoS , MaiocchiL , et al. Viral dynamics and pharmacokinetics of peginterferon alpha‐2a and peginterferon alpha‐2b in naive patients with chronic hepatitis C: a randomized, controlled study. Antiviral Therapy2004;9(4):491‐7. BrunoR , SacchiP , MaiocchiL , ZocchettiC , CiappinaV , PatrunoS , et al. Area‐under‐the‐curve for peginterferon alpha‐2a and peginterferon alpha‐2b is not related to body weight in treatment‐naive patients with chronic hepatitis C. Antiviral Therapy2005;10(2):201‐5. BrunoR , SacchiP , ScagnolariC , TorrianiF , MaiocchiL , PatrunoS , et al. Pharmacodynamics of peginterferon alpha‐2a and peginterferon alpha‐2b in interferon‐naïve patients with chronic hepatitis C: a randomized, controlled study. Alimentary Pharmacology &amp; Therapeutics2007;26(3):369‐76. ">Bruno 2004</a>; <a href="./references#CD005642-bbs2-0014" title="SilvaM , PooJ , WagnerF , JacksonM , CutlerD , GraceM , et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa‐2b and peginterferon alfa‐2a in patients with chronic hepatitis C (COMPARE). Hepatology2006;45(2):204‐13. SilvaM , Poo‐RamirezJL , WagnerF , JacksonM , LaughlinM . Compare trial: Updated data. Hepatology2008;49(2):288‐9. SilvaM , Poo‐RamirezJL , WagnerF , JacksonM , LaughlinM . Comparison of peginterferon‐alpha2a and peginterferon‐alpha2B pharmacokinetics and pharmacodynamic in compare, a randomized, prospective, blinded trial. Hepatology2004;40(4 S1):192A. ">Silva 2006</a>; <a href="./references#CD005642-bbs2-0004" title="DiBisceglieAM , GhalibRH , HamzehFM , RustgiVK . Early virologic response after peginterferon alpha‐2a plus ribavirin or peginterferon alpha‐2b plus ribavirin treatment in patients with chronic hepatitis C. Viral Hepatitis2007;14(10):721‐9. DiBisceglieAM , RustgiVK , ThuluvathP , DavisM , GhalibR , LyonsMF , et al. Pharmacokinetics and pharmacodynamics of pegylated interferon alfa‐2A or alfa‐2B with ribavirin in treatment naive patients with genotype 1 chronic hepatitis C. Hepatology2004;40(S4):734A. ">Di Bisceglie 2007</a>; <a href="./references#CD005642-bbs2-0010" title="McHutchisonJG , LawitzEJ , ShiffmanML , MuirAJ , GallerGW , McConeJ , et al. Peginterferon alfa‐2b or alfa‐2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine2009;361(6):580‐93. ">McHutchison 2009</a>; <a href="./references#CD005642-bbs2-0009" title="MarcellinP , FornsX , GoeserT , FerenciP , NevensF , CarosiG , et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa‐2a or ‐2b to patients with chronic hepatitis C. Gastroenterology2011;140:459‐68. [DOI: 10.1053/j.gastro.2010.10.046] ">Marcellin 2011</a>). </p> <div class="figure" id="CD005642-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included trial." data-id="CD005642-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included trial. </p> </div> </div> </div> <div class="figure" id="CD005642-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included trials." data-id="CD005642-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included trials. </p> </div> </div> </div> </section> <section id="CD005642-sec-0063"> <h3 class="title" id="CD005642-sec-0063">Effects of interventions</h3> <p>See: <a href="./full#CD005642-tbl-0001"><b>Summary of findings for the main comparison</b> Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C</a> </p> <section id="CD005642-sec-0064"> <h4 class="title">All‐cause mortality</h4> <p>Only one trial reported all‐cause mortality (<a href="./references#CD005642-bbs2-0010" title="McHutchisonJG , LawitzEJ , ShiffmanML , MuirAJ , GallerGW , McConeJ , et al. Peginterferon alfa‐2b or alfa‐2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine2009;361(6):580‐93. ">McHutchison 2009</a>). The authors reported 12 patients who died during the treatment or follow‐up period. Six patients died in the peginterferon alpha‐2a group and six patients died in the peginterferon alpha‐2b group (RR 1.97, 95% CI 0.64 to 6.08) (<a href="./references#CD005642-fig-0012" title="">Analysis 1.1</a>). Only two deaths were considered by the authors to be possibly related to the intervention drug: one person, who was treated with peginterferon alpha‐2b, committed suicide six months after the end of treatment; and another, who was treated with peginterferon alpha‐2a, died due to myocardial infarction. In order to detect or reject a RR reduction of 20%, the calculated required information size was n = 132,938 patients. Accordingly, we had less than 1% of the required information size, and we could not make any conclusions about the potential similarities or differences regarding the effects of the two peginterferons on all‐cause mortality. </p> </section> <section id="CD005642-sec-0065"> <h4 class="title">Liver‐related morbidity</h4> <p>One trial with 36 patients reported on liver‐related morbidity (hyperbilirubinaemia) (<a href="./references#CD005642-bbs2-0014" title="SilvaM , PooJ , WagnerF , JacksonM , CutlerD , GraceM , et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa‐2b and peginterferon alfa‐2a in patients with chronic hepatitis C (COMPARE). Hepatology2006;45(2):204‐13. SilvaM , Poo‐RamirezJL , WagnerF , JacksonM , LaughlinM . Compare trial: Updated data. Hepatology2008;49(2):288‐9. SilvaM , Poo‐RamirezJL , WagnerF , JacksonM , LaughlinM . Comparison of peginterferon‐alpha2a and peginterferon‐alpha2B pharmacokinetics and pharmacodynamic in compare, a randomized, prospective, blinded trial. Hepatology2004;40(4 S1):192A. ">Silva 2006</a>). Six patients in the peginterferon alpha‐2a group and two patients in the peginterferon alpha‐2b group had hyperbilirubinaemia (RR 3.00, 95% CI 0.70 to12.93) (<a href="./references#CD005642-fig-0013" title="">Analysis 1.2</a>). In order to detect or reject a RR reduction of 20%, the required information size should be at least n = 1480 patients. This was far above the number we had in the included trials, and we could not make any firm conclusions about potential similarities or differences regarding the effects of the two peginterferons on liver‐related morbidity. </p> </section> <section id="CD005642-sec-0066"> <h4 class="title">Adverse events</h4> </section> <section id="CD005642-sec-0067"> <h4 class="title">Serious adverse events</h4> <p>The authors of four trials reported serious adverse events according to the International Conference on Harmonisation (ICH) Guidelines (<a href="./references#CD005642-bbs2-0072" title="International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR &amp; ICH Guidelines. Vol. 1, PA 19063‐2043, USA: Barnett International/PAREXEL, 1997. ">ICH‐GCP 1997</a>) (<a href="./references#CD005642-bbs2-0007" title="LagunoM , CifuentesC , MurillasJ , VelosoS , LarrousseM , PayerasA , et al. Randomized trial comparing pegylated interferon alpha‐2b versus pegylated interferon alpha‐2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology2009;49(1):22‐31. ">Laguno 2009</a>; <a href="./references#CD005642-bbs2-0010" title="McHutchisonJG , LawitzEJ , ShiffmanML , MuirAJ , GallerGW , McConeJ , et al. Peginterferon alfa‐2b or alfa‐2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine2009;361(6):580‐93. ">McHutchison 2009</a>; <a href="./references#CD005642-bbs2-0012" title="RumiM , AghemoA , PratiGM , D'AmbrosioR , DonatoMF , RussoR , et al. Randomized study comparing peginterferon‐alfa2a plus ribavirin and peginterferon‐alfa2b plus ribavirin in naïve patients with chronic hepatitis C: final results of the Milan Safety Tolerability (MIST) study. Hepatology2008;48(4):A212. RumiM , AghemoA , PratiGM , D'AmbrosioR , DonatoMF , RussoR , et al. Randomized study of peginterferon‐∝2a plus ribavirin vs peginterferon‐∝2b plus ribavirin in chronic hepatitis C. Gastroenterology2010;138(1):108‐15. ">Rumi 2010</a>; <a href="./references#CD005642-bbs2-0005" title="KamalMS , AhmedA , MahmoudS , NabeghL , ElGoharyI , ObadanI , et al. Enhanced efficacy of pegylated interferon alpha‐2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomised trial and quality of life analysis. Liver International2011;31:401‐11. ">Kamal 2011</a>). The proportion of patients with serious adverse events, in four trials, was quite low. In the trial which included HIV co‐infected patients, adverse events occurred in 55% of the patients (<a href="./references#CD005642-bbs2-0007" title="LagunoM , CifuentesC , MurillasJ , VelosoS , LarrousseM , PayerasA , et al. Randomized trial comparing pegylated interferon alpha‐2b versus pegylated interferon alpha‐2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology2009;49(1):22‐31. ">Laguno 2009</a>). The meta‐analysis yielded a RR of 1.12 (95% CI 0.95 to 1.30) using the fixed ‐effect model (<a href="./references#CD005642-fig-0014" title="">Analysis 1.3</a>). Using RR as the measure of effect, the Cochran homogeneity test statistic yielded a P value of 0.78 and the heterogeneity was I<sup>2</sup> = 0%. Because our meta‐analysis did not reach the required information size (n = 6115), we used trial sequential monitoring boundaries, calculated with TSA, to adjust the thresholds for statistical significance accordingly. Using the random‐effects model, the resulting cumulative test statistic (Z‐score) did not cross the adjusted threshold for statistical significance, thus yielding a non‐significant difference between the two peginterferons regarding serious adverse events (<a href="#CD005642-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD005642-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Trial sequential analysis (TSA): peginterferon alpha‐2a versus peginterferon alpha‐2b on the outcome serious adverse events.  The diversity‐adjusted required information size of n = 4799 patients was calculated based upon a proportion of 13.0% of patients with serious adverse events in the peginterferon alpha‐2b group, a relative risk reduction of 20% in peginterferon alpha‐2a group, an alpha (type I error) of 5%, a beta (type II error) of 20%, and a diversity (D) of 0%. The solid blue curve presents the cumulative meta‐analysis Z‐score and the inward sloping red curves present the two‐sided Lan‐DeMets trial sequential monitoring boundaries. The cumulative Z‐score reaches the area of futility delineated by the two trial sequential monitoring boundaries." data-id="CD005642-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial sequential analysis (TSA): peginterferon alpha‐2a versus peginterferon alpha‐2b on the outcome serious adverse events.<br/> The diversity‐adjusted required information size of n = 4799 patients was calculated based upon a proportion of 13.0% of patients with serious adverse events in the peginterferon alpha‐2b group, a relative risk reduction of 20% in peginterferon alpha‐2a group, an alpha (type I error) of 5%, a beta (type II error) of 20%, and a diversity (D) of 0%. The solid blue curve presents the cumulative meta‐analysis Z‐score and the inward sloping red curves present the two‐sided Lan‐DeMets trial sequential monitoring boundaries. The cumulative Z‐score reaches the area of futility delineated by the two trial sequential monitoring boundaries. </p> </div> </div> </div> </section> <section id="CD005642-sec-0068"> <h4 class="title">Adverse events leading to treatment discontinuation</h4> <p>The meta‐analysis of adverse events leading to treatment discontinuation, using data from 12 trials, yielded a RR of 0.84 (95% CI 0.57 to 1.22) using the random‐effects model (<a href="./references#CD005642-fig-0015" title="">Analysis 1.4</a>) (<a href="./references#CD005642-bbs2-0003" title="BrunoR , SacchiP , CiappinaV , ZochettiC , PatrunoS , MaiocchiL , et al. Viral dynamics and pharmacokinetics of peginterferon alpha‐2a and peginterferon alpha‐2b in naive patients with chronic hepatitis C: a randomized, controlled study. Antiviral Therapy2004;9(4):491‐7. BrunoR , SacchiP , MaiocchiL , ZocchettiC , CiappinaV , PatrunoS , et al. Area‐under‐the‐curve for peginterferon alpha‐2a and peginterferon alpha‐2b is not related to body weight in treatment‐naive patients with chronic hepatitis C. Antiviral Therapy2005;10(2):201‐5. BrunoR , SacchiP , ScagnolariC , TorrianiF , MaiocchiL , PatrunoS , et al. Pharmacodynamics of peginterferon alpha‐2a and peginterferon alpha‐2b in interferon‐naïve patients with chronic hepatitis C: a randomized, controlled study. Alimentary Pharmacology &amp; Therapeutics2007;26(3):369‐76. ">Bruno 2004</a>; <a href="./references#CD005642-bbs2-0015" title="SinhaS , GulurP , PatelV , Hage‐NassarG , TennerS . A randomized prospective clinical trial comparing pegylated interferon alpha 2a/ribavirin versus pegylated interferon alpha 2b/ribavirin in the treatment of chronic hepatitis C. American Journal of Gastroenterology2004;99(10):237. ">Sinha 2004</a>; <a href="./references#CD005642-bbs2-0002" title="BerakH , HorbanA , WasilewskiM , StanczakJJ , Kolakowska‐RzadzkaA . Randomized, open label trial comparing efficacy and safety of pegylated interferon alfa 2A vs alfa 2B treatment of patients with chronic hepatitis C infected with non 2/3 genotypes‐12 week virological response analysis. Hepatology2005;42(4 S1):684A. ">Berak 2005</a>; <a href="./references#CD005642-bbs2-0014" title="SilvaM , PooJ , WagnerF , JacksonM , CutlerD , GraceM , et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa‐2b and peginterferon alfa‐2a in patients with chronic hepatitis C (COMPARE). Hepatology2006;45(2):204‐13. SilvaM , Poo‐RamirezJL , WagnerF , JacksonM , LaughlinM . Compare trial: Updated data. Hepatology2008;49(2):288‐9. SilvaM , Poo‐RamirezJL , WagnerF , JacksonM , LaughlinM . Comparison of peginterferon‐alpha2a and peginterferon‐alpha2B pharmacokinetics and pharmacodynamic in compare, a randomized, prospective, blinded trial. Hepatology2004;40(4 S1):192A. ">Silva 2006</a>; <a href="./references#CD005642-bbs2-0017" title="YeniceN , MehtapO , GumrahM , AricanN . The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turkish Journal of Gastroenterology2006;17(2):94‐8. ">Yenice 2006</a>; <a href="./references#CD005642-bbs2-0004" title="DiBisceglieAM , GhalibRH , HamzehFM , RustgiVK . Early virologic response after peginterferon alpha‐2a plus ribavirin or peginterferon alpha‐2b plus ribavirin treatment in patients with chronic hepatitis C. Viral Hepatitis2007;14(10):721‐9. DiBisceglieAM , RustgiVK , ThuluvathP , DavisM , GhalibR , LyonsMF , et al. Pharmacokinetics and pharmacodynamics of pegylated interferon alfa‐2A or alfa‐2B with ribavirin in treatment naive patients with genotype 1 chronic hepatitis C. Hepatology2004;40(S4):734A. ">Di Bisceglie 2007</a>; <a href="./references#CD005642-bbs2-0013" title="ScottoG , FazioV , FornabaioC , TartagliaA , DiTullioR , SaracinoA , et al. Early and sustained virological response in non‐responders with chronic hepatitis C; a randomized open‐label study of pegylated interferon‐α‐2a versus pegylated interferon‐α‐2b. Drugs2008;68(6):791‐801. ScottoG , FazioV , FornabaioC , TartagliaA , DiTullioR , SaracinoA , et al. Peg‐interferon alpha‐2a versus peg‐interferon alpha‐2b in non responders with HCV active chronic hepatitis: A pilot study. Interferon and Cytokine Research2008;28:623–30. ">Scotto 2008</a>; <a href="./references#CD005642-bbs2-0007" title="LagunoM , CifuentesC , MurillasJ , VelosoS , LarrousseM , PayerasA , et al. Randomized trial comparing pegylated interferon alpha‐2b versus pegylated interferon alpha‐2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology2009;49(1):22‐31. ">Laguno 2009</a>; <a href="./references#CD005642-bbs2-0010" title="McHutchisonJG , LawitzEJ , ShiffmanML , MuirAJ , GallerGW , McConeJ , et al. Peginterferon alfa‐2b or alfa‐2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine2009;361(6):580‐93. ">McHutchison 2009</a>; <a href="./references#CD005642-bbs2-0001" title="AscioneA , DeLucaM , TartaglioneMT , LampasiF , LanzaAG , PicciottoFP , et al. Peginterferon alfa‐2a plus ribavirin Is more effective than peginterferon alfa‐2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology2010;138(1):116‐22. AscioneA , DeLucaM , TartaglioneMT , LampasiF , LanzaAG , PicciottoFP , et al. Peginterferon alpha‐2a plus ribavirin versus peginterferon alpha‐2b plus ribavirin in naive patients with chronic hepatitis C virus infection: results of a prospective randomised trial. Abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver. Hepatology2008;48(S2):370. ">Ascione 2010</a>; <a href="./references#CD005642-bbs2-0012" title="RumiM , AghemoA , PratiGM , D'AmbrosioR , DonatoMF , RussoR , et al. Randomized study comparing peginterferon‐alfa2a plus ribavirin and peginterferon‐alfa2b plus ribavirin in naïve patients with chronic hepatitis C: final results of the Milan Safety Tolerability (MIST) study. Hepatology2008;48(4):A212. RumiM , AghemoA , PratiGM , D'AmbrosioR , DonatoMF , RussoR , et al. Randomized study of peginterferon‐∝2a plus ribavirin vs peginterferon‐∝2b plus ribavirin in chronic hepatitis C. Gastroenterology2010;138(1):108‐15. ">Rumi 2010</a>; <a href="./references#CD005642-bbs2-0005" title="KamalMS , AhmedA , MahmoudS , NabeghL , ElGoharyI , ObadanI , et al. Enhanced efficacy of pegylated interferon alpha‐2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomised trial and quality of life analysis. Liver International2011;31:401‐11. ">Kamal 2011</a>; <a href="./references#CD005642-bbs2-0011" title="MiyaseS , HaraokaK , OuchidaY , MorishitaY , FujiyamaS . Randomized trial of peginterferon a‐2a plus ribavirin versus peginterferon a‐2b plus ribavirin for chronic hepatitis C in Japanese patients. Journal of Gastroenterology2012;47(9):1014‐21. MiyaseS , MorishitaY , HaraokaK , OuchidaY , FujiyamaS . PEGIFNalpha‐2A plus ribavirin shows higher SVR rate compare with PEGIFNalpha‐2B plus ribavirin in elderly patients with chronic hepatitis C specially in IL‐28B major allele. Journal of Hepatology2012;56(Suppl 2):S451. ">Miyase 2012</a>). Using RR as the measure of effect, the Cochran homogeneity test statistic yielded a P value of 0.05 and the heterogeneity was I<sup>2</sup> = 44%. Due to funnel plot asymmetry we could not exclude possible bias (<a href="#CD005642-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD005642-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Peginterferon alpha‐2a versus peginterferon alpha‐2b, outcome: 1.4. Adverse events leading to treatment discontinuation." data-id="CD005642-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Peginterferon alpha‐2a versus peginterferon alpha‐2b, outcome: 1.4. Adverse events leading to treatment discontinuation. </p> </div> </div> </div> <p>Because our meta‐analysis did not reach the required information size (n = 12,382), we used trial sequential monitoring boundaries calculated with TSA to adjust the thresholds for statistical significance accordingly. Using the random‐effects model, the resulting cumulative test statistic (Z‐score) did not cross the adjusted threshold for statistical significance. The Z‐score crossed the trial sequential monitoring boundary for futility. Accordingly, we could reject a 20% difference in causation of adverse events leading to discontinuation of the treatment between the two peginterferons (<a href="#CD005642-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD005642-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Trial sequential analysis (TSA): peginterferon alpha‐2a versus peginterferon alpha‐2b on the outcome adverse events leading to treatment discontinuation.  The diversity‐adjusted required information size of n = 12,832 patients was calculated based upon a proportion of 9.0% of patients with treatment discontinuation in the peginterferon alpha‐2b group, a relative risk reduction of 20% in peginterferon alpha‐2a group, an alpha (type I error) of 5%, a beta (type II error) of 20%, and a diversity (D) of 81%. The solid blue curve presents the cumulative meta‐analysis Z‐score and the inward sloping red curves present the adjusted threshold for statistical significance according to the two‐sided Lan‐DeMets trial sequential monitoring boundaries. The cumulative Z‐score does not cross any of the monitoring boundaries and does not reach the area of futility delineated by the two trial sequential monitoring boundaries which are not even drawn by the program due to the fact that the distance between the acquired and the required information size is too large." data-id="CD005642-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial sequential analysis (TSA): peginterferon alpha‐2a versus peginterferon alpha‐2b on the outcome adverse events leading to treatment discontinuation.<br/> The diversity‐adjusted required information size of n = 12,832 patients was calculated based upon a proportion of 9.0% of patients with treatment discontinuation in the peginterferon alpha‐2b group, a relative risk reduction of 20% in peginterferon alpha‐2a group, an alpha (type I error) of 5%, a beta (type II error) of 20%, and a diversity (D) of 81%. The solid blue curve presents the cumulative meta‐analysis Z‐score and the inward sloping red curves present the adjusted threshold for statistical significance according to the two‐sided Lan‐DeMets trial sequential monitoring boundaries. The cumulative Z‐score does not cross any of the monitoring boundaries and does not reach the area of futility delineated by the two trial sequential monitoring boundaries which are not even drawn by the program due to the fact that the distance between the acquired and the required information size is too large. </p> </div> </div> </div> </section> <section id="CD005642-sec-0069"> <h4 class="title">Other (non‐serious) adverse events</h4> <p>In nine included trials, the authors reported on numerous adverse events not leading to treatment discontinuation (<a href="./references#CD005642-bbs2-0014" title="SilvaM , PooJ , WagnerF , JacksonM , CutlerD , GraceM , et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa‐2b and peginterferon alfa‐2a in patients with chronic hepatitis C (COMPARE). Hepatology2006;45(2):204‐13. SilvaM , Poo‐RamirezJL , WagnerF , JacksonM , LaughlinM . Compare trial: Updated data. Hepatology2008;49(2):288‐9. SilvaM , Poo‐RamirezJL , WagnerF , JacksonM , LaughlinM . Comparison of peginterferon‐alpha2a and peginterferon‐alpha2B pharmacokinetics and pharmacodynamic in compare, a randomized, prospective, blinded trial. Hepatology2004;40(4 S1):192A. ">Silva 2006</a>; <a href="./references#CD005642-bbs2-0004" title="DiBisceglieAM , GhalibRH , HamzehFM , RustgiVK . Early virologic response after peginterferon alpha‐2a plus ribavirin or peginterferon alpha‐2b plus ribavirin treatment in patients with chronic hepatitis C. Viral Hepatitis2007;14(10):721‐9. DiBisceglieAM , RustgiVK , ThuluvathP , DavisM , GhalibR , LyonsMF , et al. Pharmacokinetics and pharmacodynamics of pegylated interferon alfa‐2A or alfa‐2B with ribavirin in treatment naive patients with genotype 1 chronic hepatitis C. Hepatology2004;40(S4):734A. ">Di Bisceglie 2007</a>; <a href="./references#CD005642-bbs2-0013" title="ScottoG , FazioV , FornabaioC , TartagliaA , DiTullioR , SaracinoA , et al. Early and sustained virological response in non‐responders with chronic hepatitis C; a randomized open‐label study of pegylated interferon‐α‐2a versus pegylated interferon‐α‐2b. Drugs2008;68(6):791‐801. ScottoG , FazioV , FornabaioC , TartagliaA , DiTullioR , SaracinoA , et al. Peg‐interferon alpha‐2a versus peg‐interferon alpha‐2b in non responders with HCV active chronic hepatitis: A pilot study. Interferon and Cytokine Research2008;28:623–30. ">Scotto 2008</a>; <a href="./references#CD005642-bbs2-0007" title="LagunoM , CifuentesC , MurillasJ , VelosoS , LarrousseM , PayerasA , et al. Randomized trial comparing pegylated interferon alpha‐2b versus pegylated interferon alpha‐2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology2009;49(1):22‐31. ">Laguno 2009</a>; <a href="./references#CD005642-bbs2-0010" title="McHutchisonJG , LawitzEJ , ShiffmanML , MuirAJ , GallerGW , McConeJ , et al. Peginterferon alfa‐2b or alfa‐2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine2009;361(6):580‐93. ">McHutchison 2009</a>; <a href="./references#CD005642-bbs2-0001" title="AscioneA , DeLucaM , TartaglioneMT , LampasiF , LanzaAG , PicciottoFP , et al. Peginterferon alfa‐2a plus ribavirin Is more effective than peginterferon alfa‐2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology2010;138(1):116‐22. AscioneA , DeLucaM , TartaglioneMT , LampasiF , LanzaAG , PicciottoFP , et al. Peginterferon alpha‐2a plus ribavirin versus peginterferon alpha‐2b plus ribavirin in naive patients with chronic hepatitis C virus infection: results of a prospective randomised trial. Abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver. Hepatology2008;48(S2):370. ">Ascione 2010</a>; <a href="./references#CD005642-bbs2-0012" title="RumiM , AghemoA , PratiGM , D'AmbrosioR , DonatoMF , RussoR , et al. Randomized study comparing peginterferon‐alfa2a plus ribavirin and peginterferon‐alfa2b plus ribavirin in naïve patients with chronic hepatitis C: final results of the Milan Safety Tolerability (MIST) study. Hepatology2008;48(4):A212. RumiM , AghemoA , PratiGM , D'AmbrosioR , DonatoMF , RussoR , et al. Randomized study of peginterferon‐∝2a plus ribavirin vs peginterferon‐∝2b plus ribavirin in chronic hepatitis C. Gastroenterology2010;138(1):108‐15. ">Rumi 2010</a>; <a href="./references#CD005642-bbs2-0005" title="KamalMS , AhmedA , MahmoudS , NabeghL , ElGoharyI , ObadanI , et al. Enhanced efficacy of pegylated interferon alpha‐2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomised trial and quality of life analysis. Liver International2011;31:401‐11. ">Kamal 2011</a>; <a href="./references#CD005642-bbs2-0011" title="MiyaseS , HaraokaK , OuchidaY , MorishitaY , FujiyamaS . Randomized trial of peginterferon a‐2a plus ribavirin versus peginterferon a‐2b plus ribavirin for chronic hepatitis C in Japanese patients. Journal of Gastroenterology2012;47(9):1014‐21. MiyaseS , MorishitaY , HaraokaK , OuchidaY , FujiyamaS . PEGIFNalpha‐2A plus ribavirin shows higher SVR rate compare with PEGIFNalpha‐2B plus ribavirin in elderly patients with chronic hepatitis C specially in IL‐28B major allele. Journal of Hepatology2012;56(Suppl 2):S451. ">Miyase 2012</a>) but which surely could have influenced adherence to the treatment protocol (<a href="./references#CD005642-bbs2-0007" title="LagunoM , CifuentesC , MurillasJ , VelosoS , LarrousseM , PayerasA , et al. Randomized trial comparing pegylated interferon alpha‐2b versus pegylated interferon alpha‐2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology2009;49(1):22‐31. ">Laguno 2009</a>). Adverse events included haematological changes (for example, neutropenia, thrombocytopenia, and anaemia), psychological (for example, depression), and other systemic adverse events (for example, fatigue, headache, insomnia, fever, nausea, and dyspnoea). However, the reporting of adverse events not leading to treatment discontinuation was poor and inconsistent across all included trials and prevented any statistical analysis. </p> </section> <section id="CD005642-sec-0070"> <h4 class="title">Assessing quality of life</h4> <p>Although quality of life is a very important outcome for the patients, it was rarely reported in the randomised clinical trials. Only one trial assessed quality of life in both treatment groups (peginterferon alpha‐2a versus peginterferon alpha‐2b) during and after the treatment (<a href="./references#CD005642-bbs2-0005" title="KamalMS , AhmedA , MahmoudS , NabeghL , ElGoharyI , ObadanI , et al. Enhanced efficacy of pegylated interferon alpha‐2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomised trial and quality of life analysis. Liver International2011;31:401‐11. ">Kamal 2011</a>). Using the Short Form 36 and Chronic Liver Disease Questionnaires (CLDQ), Kamal et al concluded that quality of life after the treatment was significantly better in the peginterferon alpha‐2a group than in the peginterferon alpha‐2b group regarding physical functioning, vitality, emotional role, bodily pain, and almost all domains of the CLDQ, overall score 5.9 versus 5.5 (P = 0.01) (peginterferon alpha‐2a versus peginterferon alpha‐2b). </p> </section> <section id="CD005642-sec-0071"> <h4 class="title">Sustained virological response</h4> <p>The meta‐analysis using intention‐to‐treat analysis for sustained virological response included 12 trials assessing 5013 patients (<a href="./references#CD005642-bbs2-0015" title="SinhaS , GulurP , PatelV , Hage‐NassarG , TennerS . A randomized prospective clinical trial comparing pegylated interferon alpha 2a/ribavirin versus pegylated interferon alpha 2b/ribavirin in the treatment of chronic hepatitis C. American Journal of Gastroenterology2004;99(10):237. ">Sinha 2004</a>; <a href="./references#CD005642-bbs2-0017" title="YeniceN , MehtapO , GumrahM , AricanN . The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turkish Journal of Gastroenterology2006;17(2):94‐8. ">Yenice 2006</a>; <a href="./references#CD005642-bbs2-0006" title="KolakowskaA , BerokH , WasilewskiM , HorbonA . Relevance between fibrosis and response to treatment with peginterferon alfa2a vs alfa2b with ribavirin in chronic hepatitis C genotype 3 patients. Randomized open label study. Hepatology2008;48(4):1278. ">Kolakowska 2008</a>; <a href="./references#CD005642-bbs2-0013" title="ScottoG , FazioV , FornabaioC , TartagliaA , DiTullioR , SaracinoA , et al. Early and sustained virological response in non‐responders with chronic hepatitis C; a randomized open‐label study of pegylated interferon‐α‐2a versus pegylated interferon‐α‐2b. Drugs2008;68(6):791‐801. ScottoG , FazioV , FornabaioC , TartagliaA , DiTullioR , SaracinoA , et al. Peg‐interferon alpha‐2a versus peg‐interferon alpha‐2b in non responders with HCV active chronic hepatitis: A pilot study. Interferon and Cytokine Research2008;28:623–30. ">Scotto 2008</a>; <a href="./references#CD005642-bbs2-0007" title="LagunoM , CifuentesC , MurillasJ , VelosoS , LarrousseM , PayerasA , et al. Randomized trial comparing pegylated interferon alpha‐2b versus pegylated interferon alpha‐2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology2009;49(1):22‐31. ">Laguno 2009</a>; <a href="./references#CD005642-bbs2-0010" title="McHutchisonJG , LawitzEJ , ShiffmanML , MuirAJ , GallerGW , McConeJ , et al. Peginterferon alfa‐2b or alfa‐2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine2009;361(6):580‐93. ">McHutchison 2009</a>; <a href="./references#CD005642-bbs2-0001" title="AscioneA , DeLucaM , TartaglioneMT , LampasiF , LanzaAG , PicciottoFP , et al. Peginterferon alfa‐2a plus ribavirin Is more effective than peginterferon alfa‐2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology2010;138(1):116‐22. AscioneA , DeLucaM , TartaglioneMT , LampasiF , LanzaAG , PicciottoFP , et al. Peginterferon alpha‐2a plus ribavirin versus peginterferon alpha‐2b plus ribavirin in naive patients with chronic hepatitis C virus infection: results of a prospective randomised trial. Abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver. Hepatology2008;48(S2):370. ">Ascione 2010</a>; <a href="./references#CD005642-bbs2-0012" title="RumiM , AghemoA , PratiGM , D'AmbrosioR , DonatoMF , RussoR , et al. Randomized study comparing peginterferon‐alfa2a plus ribavirin and peginterferon‐alfa2b plus ribavirin in naïve patients with chronic hepatitis C: final results of the Milan Safety Tolerability (MIST) study. Hepatology2008;48(4):A212. RumiM , AghemoA , PratiGM , D'AmbrosioR , DonatoMF , RussoR , et al. Randomized study of peginterferon‐∝2a plus ribavirin vs peginterferon‐∝2b plus ribavirin in chronic hepatitis C. Gastroenterology2010;138(1):108‐15. ">Rumi 2010</a>; <a href="./references#CD005642-bbs2-0005" title="KamalMS , AhmedA , MahmoudS , NabeghL , ElGoharyI , ObadanI , et al. Enhanced efficacy of pegylated interferon alpha‐2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomised trial and quality of life analysis. Liver International2011;31:401‐11. ">Kamal 2011</a>; <a href="./references#CD005642-bbs2-0008" title="MachTH , CieślaA , WarunekW , Janas‐SkulinaU , CiborD , OwczarekD . Efficacy of pegylated interferon alfa‑2aor alfa‑2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b. Polskie Archiwum Medycyny Wewnetrznej2011;121:434‐40. ">Mach 2011</a>; <a href="./references#CD005642-bbs2-0009" title="MarcellinP , FornsX , GoeserT , FerenciP , NevensF , CarosiG , et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa‐2a or ‐2b to patients with chronic hepatitis C. Gastroenterology2011;140:459‐68. [DOI: 10.1053/j.gastro.2010.10.046] ">Marcellin 2011</a>; <a href="./references#CD005642-bbs2-0011" title="MiyaseS , HaraokaK , OuchidaY , MorishitaY , FujiyamaS . Randomized trial of peginterferon a‐2a plus ribavirin versus peginterferon a‐2b plus ribavirin for chronic hepatitis C in Japanese patients. Journal of Gastroenterology2012;47(9):1014‐21. MiyaseS , MorishitaY , HaraokaK , OuchidaY , FujiyamaS . PEGIFNalpha‐2A plus ribavirin shows higher SVR rate compare with PEGIFNalpha‐2B plus ribavirin in elderly patients with chronic hepatitis C specially in IL‐28B major allele. Journal of Hepatology2012;56(Suppl 2):S451. ">Miyase 2012</a>) and yielded an estimated effect in favour of peginterferon alpha‐2a in the random‐effects model (RR 1.12, 95% CI 1.06 to 1.18) (<a href="./references#CD005642-fig-0017" title="">Analysis 1.6</a>). Using RR as the measure of effect, the Cochran homogeneity test statistic yielded a P value of 0.53 and the heterogeneity was I<sup>2</sup> = 0%. The number needed to treat (NNT) to obtain an extra patient with a sustained virological response was estimated to be 25 patients (95% CI 14 to 100 patients). </p> <p>A funnel plot of the included trials showed no significant asymmetry (<a href="#CD005642-fig-0006">Figure 6</a>). For the outcome sustained virological response we estimated that the meta‐analysis needed to include a total of 5471 patients in order to detect or reject a RR reduction of 10%. We used trial sequential monitoring boundaries to assess statistical significance. Using the random‐effects model, the resulting cumulative test statistic (Z‐score) crossed the trial sequential monitoring boundary, thus yielding a robust statistically significant difference between the two peginterferons regarding sparse data and repetitive testing (<a href="#CD005642-fig-0007">Figure 7</a>). </p> <div class="figure" id="CD005642-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: Peginterferon alpha‐2a versus peginterferon alpha‐2b, outcome: 1.8 Sustained virological response." data-id="CD005642-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: Peginterferon alpha‐2a versus peginterferon alpha‐2b, outcome: 1.8 Sustained virological response. </p> </div> </div> </div> <div class="figure" id="CD005642-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Trial sequential analysis (TSA): peginterferon alpha‐2a versus peginterferon alpha‐2b on the outcome sustained virological response.   The diversity‐adjusted required information size of n = 4257 patients was calculated based upon a proportion of 49.6 % of patients with sustained virological response in the peginterferon alpha‐2b group, a relative risk reduction of a 10% in peginterferon alpha‐2a group, an alpha (type I error) of 5%, a beta (type II error) of 10%, and a diversity (D) of 51%. The solid blue curve presents the cumulative meta‐analysis Z‐score and the inward sloping red curves present the adjusted threshold for statistical significance according to the two‐sided Lan‐DeMets trial sequential monitoring boundaries. The cumulative Z‐score reaches the area of futility (delineated by the two trial sequential monitoring boundaries), but then it crosses both the conventional significance boundary (two tailed P = 0.05) and the trial sequential monitoring boundary." data-id="CD005642-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial sequential analysis (TSA): peginterferon alpha‐2a versus peginterferon alpha‐2b on the outcome sustained virological response. <br/> The diversity‐adjusted required information size of n = 4257 patients was calculated based upon a proportion of 49.6 % of patients with sustained virological response in the peginterferon alpha‐2b group, a relative risk reduction of a 10% in peginterferon alpha‐2a group, an alpha (type I error) of 5%, a beta (type II error) of 10%, and a diversity (D) of 51%. The solid blue curve presents the cumulative meta‐analysis Z‐score and the inward sloping red curves present the adjusted threshold for statistical significance according to the two‐sided Lan‐DeMets trial sequential monitoring boundaries. The cumulative Z‐score reaches the area of futility (delineated by the two trial sequential monitoring boundaries), but then it crosses both the conventional significance boundary (two tailed P = 0.05) and the trial sequential monitoring boundary. </p> </div> </div> </div> <section id="CD005642-sec-0072"> <h5 class="title">Subgroup and sensitivity analyses</h5> <p>Data from 10 trials of patients infected with hepatitis C genotype 1 and genotype 4 (<a href="./references#CD005642-bbs2-0017" title="YeniceN , MehtapO , GumrahM , AricanN . The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turkish Journal of Gastroenterology2006;17(2):94‐8. ">Yenice 2006</a>; <a href="./references#CD005642-bbs2-0013" title="ScottoG , FazioV , FornabaioC , TartagliaA , DiTullioR , SaracinoA , et al. Early and sustained virological response in non‐responders with chronic hepatitis C; a randomized open‐label study of pegylated interferon‐α‐2a versus pegylated interferon‐α‐2b. Drugs2008;68(6):791‐801. ScottoG , FazioV , FornabaioC , TartagliaA , DiTullioR , SaracinoA , et al. Peg‐interferon alpha‐2a versus peg‐interferon alpha‐2b in non responders with HCV active chronic hepatitis: A pilot study. Interferon and Cytokine Research2008;28:623–30. ">Scotto 2008</a>; <a href="./references#CD005642-bbs2-0007" title="LagunoM , CifuentesC , MurillasJ , VelosoS , LarrousseM , PayerasA , et al. Randomized trial comparing pegylated interferon alpha‐2b versus pegylated interferon alpha‐2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology2009;49(1):22‐31. ">Laguno 2009</a>; <a href="./references#CD005642-bbs2-0010" title="McHutchisonJG , LawitzEJ , ShiffmanML , MuirAJ , GallerGW , McConeJ , et al. Peginterferon alfa‐2b or alfa‐2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine2009;361(6):580‐93. ">McHutchison 2009</a>; <a href="./references#CD005642-bbs2-0001" title="AscioneA , DeLucaM , TartaglioneMT , LampasiF , LanzaAG , PicciottoFP , et al. Peginterferon alfa‐2a plus ribavirin Is more effective than peginterferon alfa‐2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology2010;138(1):116‐22. AscioneA , DeLucaM , TartaglioneMT , LampasiF , LanzaAG , PicciottoFP , et al. Peginterferon alpha‐2a plus ribavirin versus peginterferon alpha‐2b plus ribavirin in naive patients with chronic hepatitis C virus infection: results of a prospective randomised trial. Abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver. Hepatology2008;48(S2):370. ">Ascione 2010</a>; <a href="./references#CD005642-bbs2-0012" title="RumiM , AghemoA , PratiGM , D'AmbrosioR , DonatoMF , RussoR , et al. Randomized study comparing peginterferon‐alfa2a plus ribavirin and peginterferon‐alfa2b plus ribavirin in naïve patients with chronic hepatitis C: final results of the Milan Safety Tolerability (MIST) study. Hepatology2008;48(4):A212. RumiM , AghemoA , PratiGM , D'AmbrosioR , DonatoMF , RussoR , et al. Randomized study of peginterferon‐∝2a plus ribavirin vs peginterferon‐∝2b plus ribavirin in chronic hepatitis C. Gastroenterology2010;138(1):108‐15. ">Rumi 2010</a>; <a href="./references#CD005642-bbs2-0005" title="KamalMS , AhmedA , MahmoudS , NabeghL , ElGoharyI , ObadanI , et al. Enhanced efficacy of pegylated interferon alpha‐2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomised trial and quality of life analysis. Liver International2011;31:401‐11. ">Kamal 2011</a>; <a href="./references#CD005642-bbs2-0008" title="MachTH , CieślaA , WarunekW , Janas‐SkulinaU , CiborD , OwczarekD . Efficacy of pegylated interferon alfa‑2aor alfa‑2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b. Polskie Archiwum Medycyny Wewnetrznej2011;121:434‐40. ">Mach 2011</a>; <a href="./references#CD005642-bbs2-0009" title="MarcellinP , FornsX , GoeserT , FerenciP , NevensF , CarosiG , et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa‐2a or ‐2b to patients with chronic hepatitis C. Gastroenterology2011;140:459‐68. [DOI: 10.1053/j.gastro.2010.10.046] ">Marcellin 2011</a>; <a href="./references#CD005642-bbs2-0011" title="MiyaseS , HaraokaK , OuchidaY , MorishitaY , FujiyamaS . Randomized trial of peginterferon a‐2a plus ribavirin versus peginterferon a‐2b plus ribavirin for chronic hepatitis C in Japanese patients. Journal of Gastroenterology2012;47(9):1014‐21. MiyaseS , MorishitaY , HaraokaK , OuchidaY , FujiyamaS . PEGIFNalpha‐2A plus ribavirin shows higher SVR rate compare with PEGIFNalpha‐2B plus ribavirin in elderly patients with chronic hepatitis C specially in IL‐28B major allele. Journal of Hepatology2012;56(Suppl 2):S451. ">Miyase 2012</a>) yielded a RR in favour of peginterferon alpha‐2a on the outcome sustained virological response (RR 1.15, 95% CI 1.06 to 1.26) using the random‐effects model (<a href="./references#CD005642-fig-0018" title="">Analysis 2.1</a>). Using RR as the measure of effect, the Cochran homogeneity test statistic yielded a P value of 0.0004 and the heterogeneity was I<sup>2</sup> = 23% (<a href="./references#CD005642-fig-0018" title="">Analysis 2.1</a>). For sustained virological response in the genotype 1 and 4 infected patients, we estimated that for the required information size a meta‐analysis needed to include a total of n = 6375 patients to detect or reject a RR reduction of 10%. Because our present meta‐analysis did not reach the required information size, we used trial sequential monitoring boundaries to assess the risk of random error. Using the random‐effects model, the resulting cumulative test statistic (Z‐score) crossed the monitoring boundary, thus yielding a robust statistically significant difference between the two peginterferons (<a href="#CD005642-fig-0008">Figure 8</a>).<br/> <br/> Data from five trials of patients infected with hepatitis C genotype 2 and genotype 3 (<a href="./references#CD005642-bbs2-0006" title="KolakowskaA , BerokH , WasilewskiM , HorbonA . Relevance between fibrosis and response to treatment with peginterferon alfa2a vs alfa2b with ribavirin in chronic hepatitis C genotype 3 patients. Randomized open label study. Hepatology2008;48(4):1278. ">Kolakowska 2008</a>; <a href="./references#CD005642-bbs2-0013" title="ScottoG , FazioV , FornabaioC , TartagliaA , DiTullioR , SaracinoA , et al. Early and sustained virological response in non‐responders with chronic hepatitis C; a randomized open‐label study of pegylated interferon‐α‐2a versus pegylated interferon‐α‐2b. Drugs2008;68(6):791‐801. ScottoG , FazioV , FornabaioC , TartagliaA , DiTullioR , SaracinoA , et al. Peg‐interferon alpha‐2a versus peg‐interferon alpha‐2b in non responders with HCV active chronic hepatitis: A pilot study. Interferon and Cytokine Research2008;28:623–30. ">Scotto 2008</a>; <a href="./references#CD005642-bbs2-0007" title="LagunoM , CifuentesC , MurillasJ , VelosoS , LarrousseM , PayerasA , et al. Randomized trial comparing pegylated interferon alpha‐2b versus pegylated interferon alpha‐2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology2009;49(1):22‐31. ">Laguno 2009</a>; <a href="./references#CD005642-bbs2-0001" title="AscioneA , DeLucaM , TartaglioneMT , LampasiF , LanzaAG , PicciottoFP , et al. Peginterferon alfa‐2a plus ribavirin Is more effective than peginterferon alfa‐2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology2010;138(1):116‐22. AscioneA , DeLucaM , TartaglioneMT , LampasiF , LanzaAG , PicciottoFP , et al. Peginterferon alpha‐2a plus ribavirin versus peginterferon alpha‐2b plus ribavirin in naive patients with chronic hepatitis C virus infection: results of a prospective randomised trial. Abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver. Hepatology2008;48(S2):370. ">Ascione 2010</a>; <a href="./references#CD005642-bbs2-0012" title="RumiM , AghemoA , PratiGM , D'AmbrosioR , DonatoMF , RussoR , et al. Randomized study comparing peginterferon‐alfa2a plus ribavirin and peginterferon‐alfa2b plus ribavirin in naïve patients with chronic hepatitis C: final results of the Milan Safety Tolerability (MIST) study. Hepatology2008;48(4):A212. RumiM , AghemoA , PratiGM , D'AmbrosioR , DonatoMF , RussoR , et al. Randomized study of peginterferon‐∝2a plus ribavirin vs peginterferon‐∝2b plus ribavirin in chronic hepatitis C. Gastroenterology2010;138(1):108‐15. ">Rumi 2010</a>) yielded a RR in favour of peginterferon alpha‐2a on the outcome sustained virological response (RR 1.11, 95% CI 1.02 to 1.22) using the random‐effects model (<a href="./references#CD005642-fig-0018" title="">Analysis 2.1</a>). Using RR as the measure of effect, the Cochran homogeneity test statistic yielded a P value of 0.89 and the heterogeneity was I<sup>2</sup> = 0% (<a href="./references#CD005642-fig-0018" title="">Analysis 2.1</a>). For sustained virological response in the genotype 2 and 3 infected patients, we estimated that a meta‐analysis needed to include a total of n = 1113 patients in order to detect or reject a RR reduction of 10%. Because our present meta‐analysis did not reach the required information size, we used trial sequential monitoring boundaries to assess the risk of random error. Using the random‐effects model, the resulting cumulative test statistic (Z‐score) did not cross any of the monitoring boundaries, thus showing that we may lack evidence in this subgroup (<a href="#CD005642-fig-0009">Figure 9</a>).<br/> <br/> Data from 11 trials of patients naive to previous antiviral intervention (<a href="./references#CD005642-bbs2-0015" title="SinhaS , GulurP , PatelV , Hage‐NassarG , TennerS . A randomized prospective clinical trial comparing pegylated interferon alpha 2a/ribavirin versus pegylated interferon alpha 2b/ribavirin in the treatment of chronic hepatitis C. American Journal of Gastroenterology2004;99(10):237. ">Sinha 2004</a>; <a href="./references#CD005642-bbs2-0017" title="YeniceN , MehtapO , GumrahM , AricanN . The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turkish Journal of Gastroenterology2006;17(2):94‐8. ">Yenice 2006</a>; <a href="./references#CD005642-bbs2-0006" title="KolakowskaA , BerokH , WasilewskiM , HorbonA . Relevance between fibrosis and response to treatment with peginterferon alfa2a vs alfa2b with ribavirin in chronic hepatitis C genotype 3 patients. Randomized open label study. Hepatology2008;48(4):1278. ">Kolakowska 2008</a>; <a href="./references#CD005642-bbs2-0007" title="LagunoM , CifuentesC , MurillasJ , VelosoS , LarrousseM , PayerasA , et al. Randomized trial comparing pegylated interferon alpha‐2b versus pegylated interferon alpha‐2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology2009;49(1):22‐31. ">Laguno 2009</a>; <a href="./references#CD005642-bbs2-0010" title="McHutchisonJG , LawitzEJ , ShiffmanML , MuirAJ , GallerGW , McConeJ , et al. Peginterferon alfa‐2b or alfa‐2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine2009;361(6):580‐93. ">McHutchison 2009</a>; <a href="./references#CD005642-bbs2-0001" title="AscioneA , DeLucaM , TartaglioneMT , LampasiF , LanzaAG , PicciottoFP , et al. Peginterferon alfa‐2a plus ribavirin Is more effective than peginterferon alfa‐2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology2010;138(1):116‐22. AscioneA , DeLucaM , TartaglioneMT , LampasiF , LanzaAG , PicciottoFP , et al. Peginterferon alpha‐2a plus ribavirin versus peginterferon alpha‐2b plus ribavirin in naive patients with chronic hepatitis C virus infection: results of a prospective randomised trial. Abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver. Hepatology2008;48(S2):370. ">Ascione 2010</a>; <a href="./references#CD005642-bbs2-0012" title="RumiM , AghemoA , PratiGM , D'AmbrosioR , DonatoMF , RussoR , et al. Randomized study comparing peginterferon‐alfa2a plus ribavirin and peginterferon‐alfa2b plus ribavirin in naïve patients with chronic hepatitis C: final results of the Milan Safety Tolerability (MIST) study. Hepatology2008;48(4):A212. RumiM , AghemoA , PratiGM , D'AmbrosioR , DonatoMF , RussoR , et al. Randomized study of peginterferon‐∝2a plus ribavirin vs peginterferon‐∝2b plus ribavirin in chronic hepatitis C. Gastroenterology2010;138(1):108‐15. ">Rumi 2010</a>; <a href="./references#CD005642-bbs2-0005" title="KamalMS , AhmedA , MahmoudS , NabeghL , ElGoharyI , ObadanI , et al. Enhanced efficacy of pegylated interferon alpha‐2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomised trial and quality of life analysis. Liver International2011;31:401‐11. ">Kamal 2011</a>; <a href="./references#CD005642-bbs2-0008" title="MachTH , CieślaA , WarunekW , Janas‐SkulinaU , CiborD , OwczarekD . Efficacy of pegylated interferon alfa‑2aor alfa‑2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b. Polskie Archiwum Medycyny Wewnetrznej2011;121:434‐40. ">Mach 2011</a>; <a href="./references#CD005642-bbs2-0009" title="MarcellinP , FornsX , GoeserT , FerenciP , NevensF , CarosiG , et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa‐2a or ‐2b to patients with chronic hepatitis C. Gastroenterology2011;140:459‐68. [DOI: 10.1053/j.gastro.2010.10.046] ">Marcellin 2011</a>; <a href="./references#CD005642-bbs2-0011" title="MiyaseS , HaraokaK , OuchidaY , MorishitaY , FujiyamaS . Randomized trial of peginterferon a‐2a plus ribavirin versus peginterferon a‐2b plus ribavirin for chronic hepatitis C in Japanese patients. Journal of Gastroenterology2012;47(9):1014‐21. MiyaseS , MorishitaY , HaraokaK , OuchidaY , FujiyamaS . PEGIFNalpha‐2A plus ribavirin shows higher SVR rate compare with PEGIFNalpha‐2B plus ribavirin in elderly patients with chronic hepatitis C specially in IL‐28B major allele. Journal of Hepatology2012;56(Suppl 2):S451. ">Miyase 2012</a>) yielded a RR in favour of peginterferon alpha‐2a on the outcome sustained virological response (RR 1.12, 95% CI 1.06 to 1.18) using the random‐effects model (<a href="./references#CD005642-fig-0019" title="">Analysis 2.2</a>; <a href="#CD005642-fig-0001">Figure 1</a>0). Using RR as the measure of effect, the Cochran homogeneity test statistic yielded a P value of 0.0001 and the heterogeneity was I<sup>2</sup> = 0% (<a href="./references#CD005642-fig-0019" title="">Analysis 2.2</a>). For sustained virological response in naive patients, we estimated that a required information size of 4083 patients was needed in order to detect or reject a RR of 10%. Because our present meta‐analysis did not reach the required information size, we used trial sequential monitoring boundaries to assess the risk of random error. Using the random‐effects model, the resulting cumulative test statistic (Z‐score) crossed the monitoring boundary, thus yielding a robust statistically significant difference between the two peginterferons. We used a funnel plot to explore the bias of the included trials and there was no significant asymmetry in the trials with naive patients (<a href="#CD005642-fig-0001">Figure 1</a>0). </p> <div class="figure" id="CD005642-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Trial sequential analysis (TSA): peginterferon alpha‐2a versus peginterferon alpha‐2b on the two subgroup analysis sustained virological response in participants infected with hepatitis C genotype 1 and 4.   The diversity‐adjusted required information size of n = 6375 patients was calculated based upon a proportion of 44.9% of patients with sustained virological response in the peginterferon alpha‐2b group, a relative risk reduction of a 10% in peginterferon alpha‐2a group, an alpha (type I error) of 5%, a beta (type II error) of 10%, and a diversity (D) of 45%. The solid blue curve presents the cumulative meta‐analysis test Z‐score and the inward sloping red curves present the two‐sided Lan‐DeMets trial sequential monitoring boundaries. The cumulative Z‐score almost reaches the area of futility (delineated by the two trial sequential monitoring boundaries), but then it crosses both the conventional significance boundary (two tailed P = 0.05 ) and the trial sequential monitoring boundary." data-id="CD005642-fig-0008" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial sequential analysis (TSA): peginterferon alpha‐2a versus peginterferon alpha‐2b on the two subgroup analysis sustained virological response in participants infected with hepatitis C genotype 1 and 4. <br/> The diversity‐adjusted required information size of n = 6375 patients was calculated based upon a proportion of 44.9% of patients with sustained virological response in the peginterferon alpha‐2b group, a relative risk reduction of a 10% in peginterferon alpha‐2a group, an alpha (type I error) of 5%, a beta (type II error) of 10%, and a diversity (D) of 45%. The solid blue curve presents the cumulative meta‐analysis test Z‐score and the inward sloping red curves present the two‐sided Lan‐DeMets trial sequential monitoring boundaries. The cumulative Z‐score almost reaches the area of futility (delineated by the two trial sequential monitoring boundaries), but then it crosses both the conventional significance boundary (two tailed P = 0.05 ) and the trial sequential monitoring boundary. </p> </div> </div> </div> <div class="figure" id="CD005642-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Trial sequential analysis (TSA): peginterferon alpha‐2a versus peginterferon alpha‐2b on the two subgroup analysis sustained virological response in patients infected with hepatitis C genotype 2 and 3.The diversity‐adjusted required information size of n = 1113 patients was calculated based upon a proportion of 81.4% of patients with sustained virological response in the peginterferon alpha‐2b group, a relative risk reduction of a 10% in peginterferon alpha‐2a group, an alpha (type I error) of 5%, a beta (type II error) of 10%, and a diversity (D) of 0%. The solid blue curve presents the cumulative meta‐analysis Z‐score and the inward sloping red curves present the two‐sided Lan‐DeMets trial sequential monitoring boundaries. The cumulative Z‐score does not reach the area of futility (delineated by the two trial sequential monitoring boundaries), but it crosses the conventional significance boundary (two tailed P = 0.05). However, the cumulative Z‐score does not cross the trial sequential monitoring boundary." data-id="CD005642-fig-0009" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial sequential analysis (TSA): peginterferon alpha‐2a versus peginterferon alpha‐2b on the two subgroup analysis sustained virological response in patients infected with hepatitis C genotype 2 and 3.The diversity‐adjusted required information size of n = 1113 patients was calculated based upon a proportion of 81.4% of patients with sustained virological response in the peginterferon alpha‐2b group, a relative risk reduction of a 10% in peginterferon alpha‐2a group, an alpha (type I error) of 5%, a beta (type II error) of 10%, and a diversity (D) of 0%. The solid blue curve presents the cumulative meta‐analysis Z‐score and the inward sloping red curves present the two‐sided Lan‐DeMets trial sequential monitoring boundaries. The cumulative Z‐score does not reach the area of futility (delineated by the two trial sequential monitoring boundaries), but it crosses the conventional significance boundary (two tailed P = 0.05). However, the cumulative Z‐score does not cross the trial sequential monitoring boundary. </p> </div> </div> </div> <p>Data from eight trials with low risk of randomisation bias (<a href="./references#CD005642-bbs2-0015" title="SinhaS , GulurP , PatelV , Hage‐NassarG , TennerS . A randomized prospective clinical trial comparing pegylated interferon alpha 2a/ribavirin versus pegylated interferon alpha 2b/ribavirin in the treatment of chronic hepatitis C. American Journal of Gastroenterology2004;99(10):237. ">Sinha 2004</a>; <a href="./references#CD005642-bbs2-0013" title="ScottoG , FazioV , FornabaioC , TartagliaA , DiTullioR , SaracinoA , et al. Early and sustained virological response in non‐responders with chronic hepatitis C; a randomized open‐label study of pegylated interferon‐α‐2a versus pegylated interferon‐α‐2b. Drugs2008;68(6):791‐801. ScottoG , FazioV , FornabaioC , TartagliaA , DiTullioR , SaracinoA , et al. Peg‐interferon alpha‐2a versus peg‐interferon alpha‐2b in non responders with HCV active chronic hepatitis: A pilot study. Interferon and Cytokine Research2008;28:623–30. ">Scotto 2008</a>; <a href="./references#CD005642-bbs2-0007" title="LagunoM , CifuentesC , MurillasJ , VelosoS , LarrousseM , PayerasA , et al. Randomized trial comparing pegylated interferon alpha‐2b versus pegylated interferon alpha‐2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology2009;49(1):22‐31. ">Laguno 2009</a>; <a href="./references#CD005642-bbs2-0010" title="McHutchisonJG , LawitzEJ , ShiffmanML , MuirAJ , GallerGW , McConeJ , et al. Peginterferon alfa‐2b or alfa‐2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine2009;361(6):580‐93. ">McHutchison 2009</a>; <a href="./references#CD005642-bbs2-0001" title="AscioneA , DeLucaM , TartaglioneMT , LampasiF , LanzaAG , PicciottoFP , et al. Peginterferon alfa‐2a plus ribavirin Is more effective than peginterferon alfa‐2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology2010;138(1):116‐22. AscioneA , DeLucaM , TartaglioneMT , LampasiF , LanzaAG , PicciottoFP , et al. Peginterferon alpha‐2a plus ribavirin versus peginterferon alpha‐2b plus ribavirin in naive patients with chronic hepatitis C virus infection: results of a prospective randomised trial. Abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver. Hepatology2008;48(S2):370. ">Ascione 2010;</a><a href="./references#CD005642-bbs2-0012" title="RumiM , AghemoA , PratiGM , D'AmbrosioR , DonatoMF , RussoR , et al. Randomized study comparing peginterferon‐alfa2a plus ribavirin and peginterferon‐alfa2b plus ribavirin in naïve patients with chronic hepatitis C: final results of the Milan Safety Tolerability (MIST) study. Hepatology2008;48(4):A212. RumiM , AghemoA , PratiGM , D'AmbrosioR , DonatoMF , RussoR , et al. Randomized study of peginterferon‐∝2a plus ribavirin vs peginterferon‐∝2b plus ribavirin in chronic hepatitis C. Gastroenterology2010;138(1):108‐15. ">Rumi 2010</a>; <a href="./references#CD005642-bbs2-0005" title="KamalMS , AhmedA , MahmoudS , NabeghL , ElGoharyI , ObadanI , et al. Enhanced efficacy of pegylated interferon alpha‐2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomised trial and quality of life analysis. Liver International2011;31:401‐11. ">Kamal 2011</a>; <a href="./references#CD005642-bbs2-0009" title="MarcellinP , FornsX , GoeserT , FerenciP , NevensF , CarosiG , et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa‐2a or ‐2b to patients with chronic hepatitis C. Gastroenterology2011;140:459‐68. [DOI: 10.1053/j.gastro.2010.10.046] ">Marcellin 2011</a>) yielded a RR in favour of peginterferon alpha‐2a on sustained virological response (RR 1.12, 95% CI 1.05 to 1.20) using the random‐effects model (<a href="./references#CD005642-fig-0020" title="">Analysis 2.3</a>). Using RR as the measure of effect, the Cochran homogeneity test statistic yielded a P value of 0.34 and the heterogeneity was I<sup>2</sup> = 13% (<a href="./references#CD005642-fig-0020" title="">Analysis 2.3</a>). Sustained virological response in the four trials with high risk of randomisation bias (<a href="./references#CD005642-bbs2-0017" title="YeniceN , MehtapO , GumrahM , AricanN . The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turkish Journal of Gastroenterology2006;17(2):94‐8. ">Yenice 2006</a>; <a href="./references#CD005642-bbs2-0006" title="KolakowskaA , BerokH , WasilewskiM , HorbonA . Relevance between fibrosis and response to treatment with peginterferon alfa2a vs alfa2b with ribavirin in chronic hepatitis C genotype 3 patients. Randomized open label study. Hepatology2008;48(4):1278. ">Kolakowska 2008</a>; <a href="./references#CD005642-bbs2-0008" title="MachTH , CieślaA , WarunekW , Janas‐SkulinaU , CiborD , OwczarekD . Efficacy of pegylated interferon alfa‑2aor alfa‑2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b. Polskie Archiwum Medycyny Wewnetrznej2011;121:434‐40. ">Mach 2011</a>; <a href="./references#CD005642-bbs2-0011" title="MiyaseS , HaraokaK , OuchidaY , MorishitaY , FujiyamaS . Randomized trial of peginterferon a‐2a plus ribavirin versus peginterferon a‐2b plus ribavirin for chronic hepatitis C in Japanese patients. Journal of Gastroenterology2012;47(9):1014‐21. MiyaseS , MorishitaY , HaraokaK , OuchidaY , FujiyamaS . PEGIFNalpha‐2A plus ribavirin shows higher SVR rate compare with PEGIFNalpha‐2B plus ribavirin in elderly patients with chronic hepatitis C specially in IL‐28B major allele. Journal of Hepatology2012;56(Suppl 2):S451. ">Miyase 2012</a>) remained the same (RR 1.16, 95% CI 1.02 to 1.33) using the random‐effects model (<a href="./references#CD005642-fig-0020" title="">Analysis 2.3</a>). Using RR as the measure of effect, the Cochran homogeneity test statistic yielded a P value of 0.62 and the heterogeneity was I<sup>2</sup> = 0% (<a href="./references#CD005642-fig-0020" title="">Analysis 2.3</a>). For the sustained virological response in the trials with low risk of randomisation bias, we estimated that a meta‐analysis needed to include a total of 5624 patients in order to detect or reject a RR reduction of 10%. Because our present meta‐analysis did not reach the required information size, we used trial sequential monitoring boundaries to assess the risk of random error. Using the random‐effects model, the resulting cumulative test statistic (Z‐score) reached the area of futility, thus yielding a robust statistically significant difference between the two peginterferons regarding sparse data and repetitive testing (<a href="#CD005642-fig-0010">Figure 10</a>). </p> <div class="figure" id="CD005642-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Trial sequential analysis (TSA): peginterferon alpha‐2a versus peginterferon alpha‐2b on the subgroup analysis on the outcome sustained virological response in trials with low risk of randomisation bias.  The diversity‐adjusted required information size of n = 5,624 patients was calculated based upon a proportion of 42.4 % of patients with sustained virological response in the peginterferon alpha‐2b group, a relative risk reduction of a 10% in peginterferon alpha‐2a group, an alpha (type I error) of 5%, a beta (type II error) of 10%, and a diversity (D) of 71%. The solid blue curve presents the cumulative meta‐analysis Z‐score which reaches the area of futility (delineated by the two trial sequential monitoring boundaries), but then crosses both the conventional significance boundary (two tailed P = 0.05 not shown on the figure) and the trial sequential monitoring boundary." data-id="CD005642-fig-0010" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial sequential analysis (TSA): peginterferon alpha‐2a versus peginterferon alpha‐2b on the subgroup analysis on the outcome sustained virological response in trials with low risk of randomisation bias.<br/> The diversity‐adjusted required information size of n = 5,624 patients was calculated based upon a proportion of 42.4 % of patients with sustained virological response in the peginterferon alpha‐2b group, a relative risk reduction of a 10% in peginterferon alpha‐2a group, an alpha (type I error) of 5%, a beta (type II error) of 10%, and a diversity (D) of 71%. The solid blue curve presents the cumulative meta‐analysis Z‐score which reaches the area of futility (delineated by the two trial sequential monitoring boundaries), but then crosses both the conventional significance boundary (two tailed P = 0.05 not shown on the figure) and the trial sequential monitoring boundary. </p> </div> </div> </div> <p>A subgroup analysis in the two trials with low risk of bias according to blinding (<a href="./references#CD005642-bbs2-0005" title="KamalMS , AhmedA , MahmoudS , NabeghL , ElGoharyI , ObadanI , et al. Enhanced efficacy of pegylated interferon alpha‐2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomised trial and quality of life analysis. Liver International2011;31:401‐11. ">Kamal 2011</a>; <a href="./references#CD005642-bbs2-0011" title="MiyaseS , HaraokaK , OuchidaY , MorishitaY , FujiyamaS . Randomized trial of peginterferon a‐2a plus ribavirin versus peginterferon a‐2b plus ribavirin for chronic hepatitis C in Japanese patients. Journal of Gastroenterology2012;47(9):1014‐21. MiyaseS , MorishitaY , HaraokaK , OuchidaY , FujiyamaS . PEGIFNalpha‐2A plus ribavirin shows higher SVR rate compare with PEGIFNalpha‐2B plus ribavirin in elderly patients with chronic hepatitis C specially in IL‐28B major allele. Journal of Hepatology2012;56(Suppl 2):S451. ">Miyase 2012</a>) yielded a RR in favour of peginterferon alpha‐2a on sustained virological response (RR 1.29, 95% CI 1.10 to 1.51) using the random‐effects model (<a href="./references#CD005642-fig-0021" title="">Analysis 2.4</a>). Using RR as the measure of effect, the Cochran homogeneity test statistic yielded a P value of 0.95 and the heterogeneity was I<sup>2</sup> = 0% (<a href="./references#CD005642-fig-0021" title="">Analysis 2.4</a>). For sustained virological response in trials with low risk of bias according to blinding, we estimated that the needed required information size was 2079 patients in order to detect or reject a RR of 10%. Because our present meta‐analysis did not reach the required information size of 2079, we used trial sequential monitoring boundaries to assess the risk of random error. Using the random‐effects model, the resulting cumulative test statistic (Z‐score) did not break the monitoring boundaries, thus yielding no statistically significant difference between the two peginterferons (<a href="#CD005642-fig-0011">Figure 11</a>). </p> <div class="figure" id="CD005642-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Trial sequential analysis (TSA): peginterferon alpha‐2a versus peginterferon alpha‐2b on the subgroup analysis on the outcome sustained virological response in trials with low risk of blinding bias.  The diversity‐adjusted required information size of n = 2079 patients was calculated based upon a proportion of 68% of patients with sustained virological response in the peginterferon alpha‐2b group, a relative risk reduction of a 10% in peginterferon alpha‐2a group, an alpha (type I error) of 5%, a beta (type II error) of 10%, and a diversity (D) of 0%. The solid blue curve presents the cumulative meta‐analysis Z‐score and the inward sloping red curves present the two‐sided Lan‐DeMets trial sequential monitoring boundaries. The trial sequential monitoring boundaries were not broken by the cumulative Z‐curve." data-id="CD005642-fig-0011" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial sequential analysis (TSA): peginterferon alpha‐2a versus peginterferon alpha‐2b on the subgroup analysis on the outcome sustained virological response in trials with low risk of blinding bias.<br/> The diversity‐adjusted required information size of n = 2079 patients was calculated based upon a proportion of 68% of patients with sustained virological response in the peginterferon alpha‐2b group, a relative risk reduction of a 10% in peginterferon alpha‐2a group, an alpha (type I error) of 5%, a beta (type II error) of 10%, and a diversity (D) of 0%. The solid blue curve presents the cumulative meta‐analysis Z‐score and the inward sloping red curves present the two‐sided Lan‐DeMets trial sequential monitoring boundaries. The trial sequential monitoring boundaries were not broken by the cumulative Z‐curve. </p> </div> </div> </div> <p>Ten trials which had a high risk of bias due to lack of blinding (<a href="./references#CD005642-bbs2-0015" title="SinhaS , GulurP , PatelV , Hage‐NassarG , TennerS . A randomized prospective clinical trial comparing pegylated interferon alpha 2a/ribavirin versus pegylated interferon alpha 2b/ribavirin in the treatment of chronic hepatitis C. American Journal of Gastroenterology2004;99(10):237. ">Sinha 2004</a>; <a href="./references#CD005642-bbs2-0017" title="YeniceN , MehtapO , GumrahM , AricanN . The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turkish Journal of Gastroenterology2006;17(2):94‐8. ">Yenice 2006</a>; <a href="./references#CD005642-bbs2-0006" title="KolakowskaA , BerokH , WasilewskiM , HorbonA . Relevance between fibrosis and response to treatment with peginterferon alfa2a vs alfa2b with ribavirin in chronic hepatitis C genotype 3 patients. Randomized open label study. Hepatology2008;48(4):1278. ">Kolakowska 2008</a>; <a href="./references#CD005642-bbs2-0013" title="ScottoG , FazioV , FornabaioC , TartagliaA , DiTullioR , SaracinoA , et al. Early and sustained virological response in non‐responders with chronic hepatitis C; a randomized open‐label study of pegylated interferon‐α‐2a versus pegylated interferon‐α‐2b. Drugs2008;68(6):791‐801. ScottoG , FazioV , FornabaioC , TartagliaA , DiTullioR , SaracinoA , et al. Peg‐interferon alpha‐2a versus peg‐interferon alpha‐2b in non responders with HCV active chronic hepatitis: A pilot study. Interferon and Cytokine Research2008;28:623–30. ">Scotto 2008</a>; <a href="./references#CD005642-bbs2-0007" title="LagunoM , CifuentesC , MurillasJ , VelosoS , LarrousseM , PayerasA , et al. Randomized trial comparing pegylated interferon alpha‐2b versus pegylated interferon alpha‐2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology2009;49(1):22‐31. ">Laguno 2009</a>; <a href="./references#CD005642-bbs2-0010" title="McHutchisonJG , LawitzEJ , ShiffmanML , MuirAJ , GallerGW , McConeJ , et al. Peginterferon alfa‐2b or alfa‐2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine2009;361(6):580‐93. ">McHutchison 2009</a>; <a href="./references#CD005642-bbs2-0001" title="AscioneA , DeLucaM , TartaglioneMT , LampasiF , LanzaAG , PicciottoFP , et al. Peginterferon alfa‐2a plus ribavirin Is more effective than peginterferon alfa‐2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology2010;138(1):116‐22. AscioneA , DeLucaM , TartaglioneMT , LampasiF , LanzaAG , PicciottoFP , et al. Peginterferon alpha‐2a plus ribavirin versus peginterferon alpha‐2b plus ribavirin in naive patients with chronic hepatitis C virus infection: results of a prospective randomised trial. Abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver. Hepatology2008;48(S2):370. ">Ascione 2010</a>; <a href="./references#CD005642-bbs2-0012" title="RumiM , AghemoA , PratiGM , D'AmbrosioR , DonatoMF , RussoR , et al. Randomized study comparing peginterferon‐alfa2a plus ribavirin and peginterferon‐alfa2b plus ribavirin in naïve patients with chronic hepatitis C: final results of the Milan Safety Tolerability (MIST) study. Hepatology2008;48(4):A212. RumiM , AghemoA , PratiGM , D'AmbrosioR , DonatoMF , RussoR , et al. Randomized study of peginterferon‐∝2a plus ribavirin vs peginterferon‐∝2b plus ribavirin in chronic hepatitis C. Gastroenterology2010;138(1):108‐15. ">Rumi 2010</a>; <a href="./references#CD005642-bbs2-0008" title="MachTH , CieślaA , WarunekW , Janas‐SkulinaU , CiborD , OwczarekD . Efficacy of pegylated interferon alfa‑2aor alfa‑2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b. Polskie Archiwum Medycyny Wewnetrznej2011;121:434‐40. ">Mach 2011</a>; <a href="./references#CD005642-bbs2-0009" title="MarcellinP , FornsX , GoeserT , FerenciP , NevensF , CarosiG , et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa‐2a or ‐2b to patients with chronic hepatitis C. Gastroenterology2011;140:459‐68. [DOI: 10.1053/j.gastro.2010.10.046] ">Marcellin 2011</a>) also yielded a RR in favour of peginterferon alpha‐2a on sustained virological response (RR 1.10, 95% CI 1.06 to 1.14). Using RR as the measure of effect, the Cochran homogeneity test statistic yielded a P value of 0.69 and the heterogeneity was I<sup>2</sup> = 0% (<a href="./references#CD005642-fig-0021" title="">Analysis 2.4</a>). Excluding the trial that included patients with HIV co‐infection did not noticeably change the meta‐analysed estimate (<a href="./references#CD005642-fig-0022" title="">Analysis 2.5</a>). </p> </section> </section> <section id="CD005642-sec-0073"> <h4 class="title">Summary of findings</h4> <p>We constructed 'Summary of findings' table using The Grading of Recommendations Assessment, Development, and Evaluation guidelines (GRADE) (<a href="./references#CD005642-bbs2-0064" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical Research Ed.)2008;336(7650):924‐6. ">Guyatt 2008</a>). The information provided on the 'Summary of findings' table shows that we are very uncertain regarding the effects of the interventions on all‐cause mortality, liver‐related morbidity, all other adverse events, and quality of life which we have judged to be of low or very low quality evidence (<a href="./full#CD005642-tbl-0001">summary of findings Table for the main comparison</a>). We have only low level confidence in the current evidence on harms measured as serious adverse events and adverse events leading to discontinuation of treatment for a number of different reasons. Furthermore, the table reveals that we had moderate confidence in the current evidence on treatment benefits measured as sustained virological response because all trial are with high risk of bias. The reason was that 5 out of 17 trials did not report on this outcome, raising suspicion of outcome reporting bias. Because the meta‐analysis for sustained virological response included 12 trials, we drew a funnel plot to explore bias and did not find significant asymmetry. The meta‐analysis included a seemingly reasonable mix of small and large trials yielding fairly consistent results, thus giving little concern regarding the presence of bias in the trials reporting the outcome (<a href="./full#CD005642-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD005642-sec-0074" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD005642-sec-0074"></div> <section id="CD005642-sec-0075"> <h3 class="title" id="CD005642-sec-0075">Summary of main results</h3> <p>In this systematic review we have summarised the available evidence from randomised clinical trials comparing peginterferon alpha‐2a versus peginterferon alpha‐2b, both given in combination with orally administered ribavirin administered in doses in accordance with the weight of the patient. Our results suggest that only one trial reported on mortality (<a href="./references#CD005642-bbs2-0010" title="McHutchisonJG , LawitzEJ , ShiffmanML , MuirAJ , GallerGW , McConeJ , et al. Peginterferon alfa‐2b or alfa‐2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine2009;361(6):580‐93. ">McHutchison 2009</a>); only one trial reported on liver‐related morbidity (<a href="./references#CD005642-bbs2-0014" title="SilvaM , PooJ , WagnerF , JacksonM , CutlerD , GraceM , et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa‐2b and peginterferon alfa‐2a in patients with chronic hepatitis C (COMPARE). Hepatology2006;45(2):204‐13. SilvaM , Poo‐RamirezJL , WagnerF , JacksonM , LaughlinM . Compare trial: Updated data. Hepatology2008;49(2):288‐9. SilvaM , Poo‐RamirezJL , WagnerF , JacksonM , LaughlinM . Comparison of peginterferon‐alpha2a and peginterferon‐alpha2B pharmacokinetics and pharmacodynamic in compare, a randomized, prospective, blinded trial. Hepatology2004;40(4 S1):192A. ">Silva 2006</a>); and no trial reported on liver‐related mortality. Therefore, our present knowledge regarding patient‐important outcomes is very sparse. Our results also suggest that the two peginterferons are comparable in regard to adverse events leading to treatment discontinuation and serious and non‐serious adverse events. However, evidence on adverse events is also sparse and the meta‐analysis on adverse events is likely to be underpowered to detect any significant differences. Likewise, evidence on quality of life was sparse. The combination of peginterferon alpha‐2a and weight‐based ribavirin may achieve a significantly higher sustained virological response than the combination of peginterferon alpha‐2b and weight‐based ribavirin. </p> </section> <section id="CD005642-sec-0076"> <h3 class="title" id="CD005642-sec-0076">Overall completeness and applicability of evidence</h3> <p>The GRADE (<a href="./references#CD005642-bbs2-0064" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical Research Ed.)2008;336(7650):924‐6. ">Guyatt 2008</a>) summary of findings table reveals that, in general, we can have moderate confidence in the current evidence on treatment benefits measured as sustained virological response and we can only have low confidence in the current evidence on harms measured as all‐cause mortality, liver‐related morbidity, serious adverse events, and adverse events leading to treatment discontinuation (<a href="./full#CD005642-tbl-0001">summary of findings Table for the main comparison</a>). Information to assess the risk of bias was incomplete in a few trials with small numbers of participants. However, our sensitivity analyses did not show any important change in the intervention effects when we focused on trials with lower risk of bias. In our study, the trials that adequately reported on the trial methodology are large trials and they dominate the estimates of intervention effects from the meta‐analyses. Therefore, it is less likely that the pooled estimates are biased. In the meta‐analysis for sustained virological response, there were no serious inconsistencies across trials and the meta‐analysis crossed the Lan‐DeMets monitoring boundary (trial sequential monitoring boundary) leaving any random error less likely. The comparison of the largest trial (<a href="./references#CD005642-bbs2-0010" title="McHutchisonJG , LawitzEJ , ShiffmanML , MuirAJ , GallerGW , McConeJ , et al. Peginterferon alfa‐2b or alfa‐2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine2009;361(6):580‐93. ">McHutchison 2009</a>) with the second and third largest trials (<a href="./references#CD005642-bbs2-0001" title="AscioneA , DeLucaM , TartaglioneMT , LampasiF , LanzaAG , PicciottoFP , et al. Peginterferon alfa‐2a plus ribavirin Is more effective than peginterferon alfa‐2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology2010;138(1):116‐22. AscioneA , DeLucaM , TartaglioneMT , LampasiF , LanzaAG , PicciottoFP , et al. Peginterferon alpha‐2a plus ribavirin versus peginterferon alpha‐2b plus ribavirin in naive patients with chronic hepatitis C virus infection: results of a prospective randomised trial. Abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver. Hepatology2008;48(S2):370. ">Ascione 2010</a>; <a href="./references#CD005642-bbs2-0012" title="RumiM , AghemoA , PratiGM , D'AmbrosioR , DonatoMF , RussoR , et al. Randomized study comparing peginterferon‐alfa2a plus ribavirin and peginterferon‐alfa2b plus ribavirin in naïve patients with chronic hepatitis C: final results of the Milan Safety Tolerability (MIST) study. Hepatology2008;48(4):A212. RumiM , AghemoA , PratiGM , D'AmbrosioR , DonatoMF , RussoR , et al. Randomized study of peginterferon‐∝2a plus ribavirin vs peginterferon‐∝2b plus ribavirin in chronic hepatitis C. Gastroenterology2010;138(1):108‐15. ">Rumi 2010</a>) yielded discrepancies however. The largest trial, which was funded by the manufacturer of peginterferon alpha‐2b, observed the smallest benefit of peginterferon alpha‐2a whereas the second and third largest trials both reported peginterferon alpha‐2a to be significantly superior to peginterferon alpha‐2b, and these trials were not funded by either of the two manufacturers. It is well known that industry bias may affect the outcomes and interpretation of trials (<a href="./references#CD005642-bbs2-0034" title="Als‐NielsenB , ChenW , GluudC , KjaergardLL . Association of funding and conclusions in randomized drug trials: A reflection of treatment effect or adverse events?. JAMA2003;290(7):921‐8. ">Als‐Nielsen 2003</a>; <a href="./references#CD005642-bbs2-0080" title="LexchinJ , BeroLA , DjulbegovicB , ClarkO . Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ (Clinical Research Ed.)2003;326:1167‐70. ">Lexchin 2003</a>; <a href="./references#CD005642-bbs2-0081" title="LundhA , SismondoS , LexchinJ , BusuiocOA , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2] ">Lundh 2012</a>). </p> </section> <section id="CD005642-sec-0077"> <h3 class="title" id="CD005642-sec-0077">Quality of the evidence</h3> <p>Because the meta‐analysis for sustained virological response included 12 trials, we drew a funnel plot to explore bias (<a href="#CD005642-fig-0006">Figure 6</a>). There was no significant asymmetry. The meta‐analysis included a seemingly reasonable mix of small and large trials yielding fairly consistent results, which gives little concern about the presence of publication bias and other biases. When we included only trials without risk of bias due to other factors than lack of blinding, the results remained the same regarding sustained virological response. This effect did not pass the test of trial sequential analysis (<a href="#CD005642-fig-0011">Figure 11</a>). However, we have some concerns in regard to indirectness. In the identified trials, virological response was the predominant measure of benefit. Many of the trials measured sustained virological response, which is currently the commonly used non‐validated surrogate outcome (<a href="./references#CD005642-bbs2-0061" title="GluudC , BrokJ , GongY , KoretzRL . Hepatology may have problems with putative surrogate outcome measures. Journal of Hepatology2007;46(4):734‐42. ">Gluud 2007</a>). Recent large cohort studies show a correlation between the presence of viraemia and mortality (<a href="./references#CD005642-bbs2-0032" title="AdeelAB , XiaoQW , CharityGM . Effect of hepatitis C virus and its treatment on survival. Hepatology2009;50(2):387‐92. ">Adeel 2009</a>; <a href="./references#CD005642-bbs2-0068" title="HirofumiU , SherriOS , KatsuhiroH , KotaroK , FumisatoS , ShujiK , et al. Increased rate of death related to presence of viremia among hepatitis C virus antibody‐positive subjects in a community‐based cohort study. Hepatology2009;50(2):393‐9. ">Hirofumi 2009</a>). However, it is important to remember that sustained virological response (and early virological response and end of treatment virological response) are still only non‐validated surrogate outcomes for antiviral intervention effects (<a href="./references#CD005642-bbs2-0061" title="GluudC , BrokJ , GongY , KoretzRL . Hepatology may have problems with putative surrogate outcome measures. Journal of Hepatology2007;46(4):734‐42. ">Gluud 2007</a>; <a href="./references#CD005642-bbs2-0076" title="KoretzRL , PleguezueloM , ArvanitiV , BaenaPB , CiriaR , GurusamyKS , et al. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD003617.pub2] ">Koretz 2013</a>; <a href="./references#CD005642-bbs2-0063" title="GurusamyKS , WilsonE , KoretzRL , AllenVB , DavidsonBR , BurroughsAK , et al. Is sustained virological response a marker of treatment efficacy in patients with chronic hepatitis C viral infection with no response or relapse to previous antiviral intervention?. PLoS ONE2014;8(12):e83313. ">Gurusamy 2014</a>). We do not know the effects of the interventions on patient‐relevant outcomes (<a href="./references#CD005642-bbs2-0061" title="GluudC , BrokJ , GongY , KoretzRL . Hepatology may have problems with putative surrogate outcome measures. Journal of Hepatology2007;46(4):734‐42. ">Gluud 2007</a>). Because randomised clinical trials need to inform clinical practice, patient‐relevant outcomes such as risk of liver failure, hepatocellular carcinoma, and mortality would be of greater interest to patients and clinicians. Nevertheless, to be able to report on these outcomes, a much larger sample size and a follow‐up of several years would be required. Currently, no randomised clinical trials comparing the two peginterferons are of such a size or duration. </p> <p>There were serious discrepancies across trials in the meta‐analysis on adverse events. The proportions of observed adverse events differed greatly across the trials, and the direction of effect was also heterogeneous. It is noteworthy that the IDEAL trial (<a href="./references#CD005642-bbs2-0010" title="McHutchisonJG , LawitzEJ , ShiffmanML , MuirAJ , GallerGW , McConeJ , et al. Peginterferon alfa‐2b or alfa‐2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine2009;361(6):580‐93. ">McHutchison 2009</a>) included three intervention groups, one for peginterferon alpha‐2a and two for peginterferon alpha‐2b. The two peginterferon alpha‐2b groups consisted of the usual 1.5 µg/kg/week dose and a low 1.0 µg/kg/week dose. The usual dose group yielded a similar proportion of adverse events as the peginterferon alpha‐2a group, whereas the low dose peginterferon alpha‐2b group yielded a lower proportion of the group with adverse events. Including or excluding the low dose peginterferon alpha‐2b group from the meta‐analysis had no visible impact on the estimated adverse events however. Furthermore, the meta‐analysis on adverse events leading to treatment discontinuation had low precision. The frequency of all other adverse events varied greatly among the included trials. In the majority of the included trials each patient had at least four to six adverse events during the treatment (<a href="./references#CD005642-bbs2-0004" title="DiBisceglieAM , GhalibRH , HamzehFM , RustgiVK . Early virologic response after peginterferon alpha‐2a plus ribavirin or peginterferon alpha‐2b plus ribavirin treatment in patients with chronic hepatitis C. Viral Hepatitis2007;14(10):721‐9. DiBisceglieAM , RustgiVK , ThuluvathP , DavisM , GhalibR , LyonsMF , et al. Pharmacokinetics and pharmacodynamics of pegylated interferon alfa‐2A or alfa‐2B with ribavirin in treatment naive patients with genotype 1 chronic hepatitis C. Hepatology2004;40(S4):734A. ">Di Bisceglie 2007</a>; <a href="./references#CD005642-bbs2-0007" title="LagunoM , CifuentesC , MurillasJ , VelosoS , LarrousseM , PayerasA , et al. Randomized trial comparing pegylated interferon alpha‐2b versus pegylated interferon alpha‐2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology2009;49(1):22‐31. ">Laguno 2009</a>; <a href="./references#CD005642-bbs2-0001" title="AscioneA , DeLucaM , TartaglioneMT , LampasiF , LanzaAG , PicciottoFP , et al. Peginterferon alfa‐2a plus ribavirin Is more effective than peginterferon alfa‐2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology2010;138(1):116‐22. AscioneA , DeLucaM , TartaglioneMT , LampasiF , LanzaAG , PicciottoFP , et al. Peginterferon alpha‐2a plus ribavirin versus peginterferon alpha‐2b plus ribavirin in naive patients with chronic hepatitis C virus infection: results of a prospective randomised trial. Abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver. Hepatology2008;48(S2):370. ">Ascione 2010</a>; <a href="./references#CD005642-bbs2-0012" title="RumiM , AghemoA , PratiGM , D'AmbrosioR , DonatoMF , RussoR , et al. Randomized study comparing peginterferon‐alfa2a plus ribavirin and peginterferon‐alfa2b plus ribavirin in naïve patients with chronic hepatitis C: final results of the Milan Safety Tolerability (MIST) study. Hepatology2008;48(4):A212. RumiM , AghemoA , PratiGM , D'AmbrosioR , DonatoMF , RussoR , et al. Randomized study of peginterferon‐∝2a plus ribavirin vs peginterferon‐∝2b plus ribavirin in chronic hepatitis C. Gastroenterology2010;138(1):108‐15. ">Rumi 2010</a>; <a href="./references#CD005642-bbs2-0011" title="MiyaseS , HaraokaK , OuchidaY , MorishitaY , FujiyamaS . Randomized trial of peginterferon a‐2a plus ribavirin versus peginterferon a‐2b plus ribavirin for chronic hepatitis C in Japanese patients. Journal of Gastroenterology2012;47(9):1014‐21. MiyaseS , MorishitaY , HaraokaK , OuchidaY , FujiyamaS . PEGIFNalpha‐2A plus ribavirin shows higher SVR rate compare with PEGIFNalpha‐2B plus ribavirin in elderly patients with chronic hepatitis C specially in IL‐28B major allele. Journal of Hepatology2012;56(Suppl 2):S451. ">Miyase 2012</a>), but there are some trials where patients experienced no or only one adverse event (<a href="./references#CD005642-bbs2-0013" title="ScottoG , FazioV , FornabaioC , TartagliaA , DiTullioR , SaracinoA , et al. Early and sustained virological response in non‐responders with chronic hepatitis C; a randomized open‐label study of pegylated interferon‐α‐2a versus pegylated interferon‐α‐2b. Drugs2008;68(6):791‐801. ScottoG , FazioV , FornabaioC , TartagliaA , DiTullioR , SaracinoA , et al. Peg‐interferon alpha‐2a versus peg‐interferon alpha‐2b in non responders with HCV active chronic hepatitis: A pilot study. Interferon and Cytokine Research2008;28:623–30. ">Scotto 2008</a>; <a href="./references#CD005642-bbs2-0010" title="McHutchisonJG , LawitzEJ , ShiffmanML , MuirAJ , GallerGW , McConeJ , et al. Peginterferon alfa‐2b or alfa‐2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine2009;361(6):580‐93. ">McHutchison 2009</a>; <a href="./references#CD005642-bbs2-0005" title="KamalMS , AhmedA , MahmoudS , NabeghL , ElGoharyI , ObadanI , et al. Enhanced efficacy of pegylated interferon alpha‐2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomised trial and quality of life analysis. Liver International2011;31:401‐11. ">Kamal 2011</a>). Such a discrepancy in reporting adverse events imposes the necessity of uniform reporting of the adverse events in future trials. A post hoc calculation of the required information size to detect a minimally important difference of 10% relative risk reduction, based on the assumption of an average population risk of 10% and employing a 5% maximum type I error and 80% power, suggested that a minimum of 27,000 patients should be randomised to obtain a conclusive meta‐analysis on adverse events. The current number of patients in the meta‐analysis on adverse events is approximately 5000 (that is, less than 20% of what is required). </p> <p>There have been some concerns regarding the non‐standardisation of the ribavirin dose across trials. The weight‐based dose of ribavirin ranged from 800 mg to 1400 mg. However, the weight cut‐off varied among trials as well as within the same trial. In the largest included trial (<a href="./references#CD005642-bbs2-0010" title="McHutchisonJG , LawitzEJ , ShiffmanML , MuirAJ , GallerGW , McConeJ , et al. Peginterferon alfa‐2b or alfa‐2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine2009;361(6):580‐93. ">McHutchison 2009</a>), patients weighing from 40 kg to 65 kg received a lower dose of ribavirin (800 mg) in the peginterferon alpha‐2b group compared with a higher dose of ribavirin (1000 mg) in the peginterferon alpha‐2a group. Patients in the peginterferon alpha‐2b group achieved a lower sustained virological response compared with patients in the peginterferon alpha‐2a group (39% versus 41%). Patients weighing more than 105 kg received a higher dose of ribavirin in the peginterferon alpha‐2b group (1400 mg) compared with a lower dose of ribavirin (1200 mg) in the peginterferon alpha‐2a group. Patients in the peginterferon alpha‐2b group achieved a slightly higher sustained virological response compared with patients in the peginterferon alpha‐2a group (43% versus 39%) (<a href="./references#CD005642-bbs2-0010" title="McHutchisonJG , LawitzEJ , ShiffmanML , MuirAJ , GallerGW , McConeJ , et al. Peginterferon alfa‐2b or alfa‐2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine2009;361(6):580‐93. ">McHutchison 2009</a>). It is also interesting that in the same trial, patients who developed anaemia and thus required ribavirin dose reduction achieved a higher sustained virological response than the patients who did not require a ribavirin dose reduction (<a href="./references#CD005642-bbs2-0010" title="McHutchisonJG , LawitzEJ , ShiffmanML , MuirAJ , GallerGW , McConeJ , et al. Peginterferon alfa‐2b or alfa‐2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine2009;361(6):580‐93. ">McHutchison 2009</a>). Accordingly, we do not think that the varying doses of ribavirin have any major confounding influence on our observations regarding the effects of the type of peginterferon. More research needs to be done to explore the optimal ribavirin dose. A ribavirin dose reduction due to adverse events was reported in only seven trials (<a href="./references#CD005642-bbs2-0017" title="YeniceN , MehtapO , GumrahM , AricanN . The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turkish Journal of Gastroenterology2006;17(2):94‐8. ">Yenice 2006</a>; <a href="./references#CD005642-bbs2-0013" title="ScottoG , FazioV , FornabaioC , TartagliaA , DiTullioR , SaracinoA , et al. Early and sustained virological response in non‐responders with chronic hepatitis C; a randomized open‐label study of pegylated interferon‐α‐2a versus pegylated interferon‐α‐2b. Drugs2008;68(6):791‐801. ScottoG , FazioV , FornabaioC , TartagliaA , DiTullioR , SaracinoA , et al. Peg‐interferon alpha‐2a versus peg‐interferon alpha‐2b in non responders with HCV active chronic hepatitis: A pilot study. Interferon and Cytokine Research2008;28:623–30. ">Scotto 2008</a>; <a href="./references#CD005642-bbs2-0010" title="McHutchisonJG , LawitzEJ , ShiffmanML , MuirAJ , GallerGW , McConeJ , et al. Peginterferon alfa‐2b or alfa‐2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine2009;361(6):580‐93. ">McHutchison 2009</a>; <a href="./references#CD005642-bbs2-0001" title="AscioneA , DeLucaM , TartaglioneMT , LampasiF , LanzaAG , PicciottoFP , et al. Peginterferon alfa‐2a plus ribavirin Is more effective than peginterferon alfa‐2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology2010;138(1):116‐22. AscioneA , DeLucaM , TartaglioneMT , LampasiF , LanzaAG , PicciottoFP , et al. Peginterferon alpha‐2a plus ribavirin versus peginterferon alpha‐2b plus ribavirin in naive patients with chronic hepatitis C virus infection: results of a prospective randomised trial. Abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver. Hepatology2008;48(S2):370. ">Ascione 2010</a>; <a href="./references#CD005642-bbs2-0012" title="RumiM , AghemoA , PratiGM , D'AmbrosioR , DonatoMF , RussoR , et al. Randomized study comparing peginterferon‐alfa2a plus ribavirin and peginterferon‐alfa2b plus ribavirin in naïve patients with chronic hepatitis C: final results of the Milan Safety Tolerability (MIST) study. Hepatology2008;48(4):A212. RumiM , AghemoA , PratiGM , D'AmbrosioR , DonatoMF , RussoR , et al. Randomized study of peginterferon‐∝2a plus ribavirin vs peginterferon‐∝2b plus ribavirin in chronic hepatitis C. Gastroenterology2010;138(1):108‐15. ">Rumi 2010</a>; <a href="./references#CD005642-bbs2-0005" title="KamalMS , AhmedA , MahmoudS , NabeghL , ElGoharyI , ObadanI , et al. Enhanced efficacy of pegylated interferon alpha‐2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomised trial and quality of life analysis. Liver International2011;31:401‐11. ">Kamal 2011</a>; <a href="./references#CD005642-bbs2-0011" title="MiyaseS , HaraokaK , OuchidaY , MorishitaY , FujiyamaS . Randomized trial of peginterferon a‐2a plus ribavirin versus peginterferon a‐2b plus ribavirin for chronic hepatitis C in Japanese patients. Journal of Gastroenterology2012;47(9):1014‐21. MiyaseS , MorishitaY , HaraokaK , OuchidaY , FujiyamaS . PEGIFNalpha‐2A plus ribavirin shows higher SVR rate compare with PEGIFNalpha‐2B plus ribavirin in elderly patients with chronic hepatitis C specially in IL‐28B major allele. Journal of Hepatology2012;56(Suppl 2):S451. ">Miyase 2012</a>). Six of these trials applied one and the same dose reduction to all trial groups (<a href="./references#CD005642-bbs2-0017" title="YeniceN , MehtapO , GumrahM , AricanN . The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turkish Journal of Gastroenterology2006;17(2):94‐8. ">Yenice 2006</a>; <a href="./references#CD005642-bbs2-0013" title="ScottoG , FazioV , FornabaioC , TartagliaA , DiTullioR , SaracinoA , et al. Early and sustained virological response in non‐responders with chronic hepatitis C; a randomized open‐label study of pegylated interferon‐α‐2a versus pegylated interferon‐α‐2b. Drugs2008;68(6):791‐801. ScottoG , FazioV , FornabaioC , TartagliaA , DiTullioR , SaracinoA , et al. Peg‐interferon alpha‐2a versus peg‐interferon alpha‐2b in non responders with HCV active chronic hepatitis: A pilot study. Interferon and Cytokine Research2008;28:623–30. ">Scotto 2008</a>; <a href="./references#CD005642-bbs2-0001" title="AscioneA , DeLucaM , TartaglioneMT , LampasiF , LanzaAG , PicciottoFP , et al. Peginterferon alfa‐2a plus ribavirin Is more effective than peginterferon alfa‐2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology2010;138(1):116‐22. AscioneA , DeLucaM , TartaglioneMT , LampasiF , LanzaAG , PicciottoFP , et al. Peginterferon alpha‐2a plus ribavirin versus peginterferon alpha‐2b plus ribavirin in naive patients with chronic hepatitis C virus infection: results of a prospective randomised trial. Abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver. Hepatology2008;48(S2):370. ">Ascione 2010</a>; <a href="./references#CD005642-bbs2-0012" title="RumiM , AghemoA , PratiGM , D'AmbrosioR , DonatoMF , RussoR , et al. Randomized study comparing peginterferon‐alfa2a plus ribavirin and peginterferon‐alfa2b plus ribavirin in naïve patients with chronic hepatitis C: final results of the Milan Safety Tolerability (MIST) study. Hepatology2008;48(4):A212. RumiM , AghemoA , PratiGM , D'AmbrosioR , DonatoMF , RussoR , et al. Randomized study of peginterferon‐∝2a plus ribavirin vs peginterferon‐∝2b plus ribavirin in chronic hepatitis C. Gastroenterology2010;138(1):108‐15. ">Rumi 2010</a>; <a href="./references#CD005642-bbs2-0005" title="KamalMS , AhmedA , MahmoudS , NabeghL , ElGoharyI , ObadanI , et al. Enhanced efficacy of pegylated interferon alpha‐2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomised trial and quality of life analysis. Liver International2011;31:401‐11. ">Kamal 2011</a>; <a href="./references#CD005642-bbs2-0011" title="MiyaseS , HaraokaK , OuchidaY , MorishitaY , FujiyamaS . Randomized trial of peginterferon a‐2a plus ribavirin versus peginterferon a‐2b plus ribavirin for chronic hepatitis C in Japanese patients. Journal of Gastroenterology2012;47(9):1014‐21. MiyaseS , MorishitaY , HaraokaK , OuchidaY , FujiyamaS . PEGIFNalpha‐2A plus ribavirin shows higher SVR rate compare with PEGIFNalpha‐2B plus ribavirin in elderly patients with chronic hepatitis C specially in IL‐28B major allele. Journal of Hepatology2012;56(Suppl 2):S451. ">Miyase 2012</a>). Only one trial applied a different ribavirin dose reduction to the intervention groups (<a href="./references#CD005642-bbs2-0010" title="McHutchisonJG , LawitzEJ , ShiffmanML , MuirAJ , GallerGW , McConeJ , et al. Peginterferon alfa‐2b or alfa‐2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine2009;361(6):580‐93. ">McHutchison 2009</a>). Our estimate did not change noticeably when we excluded the latter trial from our meta‐analysis for the outcome sustained virological response.  </p> <p>Selective outcome reporting was difficult to assess in this review. Most of the included trials were not adequately registered or did not have their protocols publicly available prior to the trial completion. The risk of bias from selective reporting was considered low if the trial protocol was available and all of the pre‐specified outcomes that were of interest in the review were reported. It turned out that protocols were not available for all trials but two (<a href="./references#CD005642-bbs2-0010" title="McHutchisonJG , LawitzEJ , ShiffmanML , MuirAJ , GallerGW , McConeJ , et al. Peginterferon alfa‐2b or alfa‐2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine2009;361(6):580‐93. ">McHutchison 2009</a>; <a href="./references#CD005642-bbs2-0005" title="KamalMS , AhmedA , MahmoudS , NabeghL , ElGoharyI , ObadanI , et al. Enhanced efficacy of pegylated interferon alpha‐2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomised trial and quality of life analysis. Liver International2011;31:401‐11. ">Kamal 2011</a>)<i>.</i> The outcomes reported in the protocols (sustained virological response and adverse events) matched the outcomes that were reported (<a href="./references#CD005642-bbs2-0010" title="McHutchisonJG , LawitzEJ , ShiffmanML , MuirAJ , GallerGW , McConeJ , et al. Peginterferon alfa‐2b or alfa‐2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine2009;361(6):580‐93. ">McHutchison 2009</a>; <a href="./references#CD005642-bbs2-0005" title="KamalMS , AhmedA , MahmoudS , NabeghL , ElGoharyI , ObadanI , et al. Enhanced efficacy of pegylated interferon alpha‐2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomised trial and quality of life analysis. Liver International2011;31:401‐11. ">Kamal 2011</a>)<i>.</i> We also considered that low risk of reporting bias was present if the trial reported both the sustained virological response and adverse events. However, since the other primary outcomes that were of interest in this review related to morbidity and mortality and were rarely reported in any of the included trials, we could have chosen to assess all the trials as having high risk of reporting bias due to the lack of reporting of important, patient‐relevant outcomes. Hopefully, the initiation of the World Health Organization (WHO) International Clinical Trials Registry Platform coupled with timely and correct registrations of trials will facilitate such assessments for future trials (<a href="./references#CD005642-bbs2-0111" title="WHO . International Clinical Trials Registry Platform (ICTRP). www.who.int/ictrp/en/ (accessed 27 May 2013). ">WHO 2009</a>). Another limitation in this review was insufficient reporting of the included trials. Investigators of future trials are, therefore, well advised to adhere to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines (<a href="./references#CD005642-bbs2-0042" title="ChanAW , TetzlaffJM , AltmanDG , LaupacisA , GøtzschePC , Krleža‐JerićK . SPIRIT 2013 statement: defining standard protocol items for clinical trials. Annals of Internal Medicine2013;158:200‐7. ">Chan 2013</a>) and the Consolidated Standards for Reporting of Trials (CONSORT) (<a href="./references#CD005642-bbs2-0084" title="MoherD , HopewellS , SchulzKF , MontoriV , GøtzschePC , DevereauxPJ , et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. International Journal of Surgery2012;10:28‐55. ">Moher 2012</a>) in order to improve the quality of trial reports. </p> </section> <section id="CD005642-sec-0078"> <h3 class="title" id="CD005642-sec-0078">Potential biases in the review process</h3> <p>The strengths of this Cochrane Hepato‐Biliary Group systematic review are that it builds on a peer‐reviewed published protocol (<a href="./references#CD005642-bbs2-0116" title="AwadT , ThorlundK , HauserG , StimacD , MabroukM , GluudC . Peginterferon alpha‐2a is associated with higher sustained virological response than peginterferon alfa‐2b in chronic hepatitis C: systematic review of randomized trials. Hepatology2010;51(4):1176‐84. ">Awad 2010</a>), uses extensive searches until October 2013, considers the risks of systematic errors (bias, that is overestimation of benefits and underestimation of harms), and considers risks of random errors (play of chance) by adjusting the threshold for statistical significance according to the information and strength of evidence in the cumulative meta‐analysis. </p> <p>A possible limitation is the unavailability of full reports of all the included trials. Two out of the 12 trials that provided data on sustained virological response for the meta‐analysis are only available as abstracts. However, we were able to successfully retrieve the necessary data for one of the two abstracts via e‐mail correspondence with the authors, and thus the risk of bias assessment of the included trial was carried out satisfactorily. Our sensitivity analyses did not show any important changes in our results whether including or excluding the trials. In our review, the trials that were published as a full paper are large and dominated the meta‐analysed estimates of effects. Moreover, empirical evidence suggests that trials that fail to refute the null hypothesis have lower odds of getting published, especially those not funded by industry (<a href="./references#CD005642-bbs2-0034" title="Als‐NielsenB , ChenW , GluudC , KjaergardLL . Association of funding and conclusions in randomized drug trials: A reflection of treatment effect or adverse events?. JAMA2003;290(7):921‐8. ">Als‐Nielsen 2003</a>; <a href="./references#CD005642-bbs2-0079" title="LeeK , BacchettiP , SimI . Publication of clinical trials supporting successful new drug applications: A literature analysis. PLoS Medicine2008;5(9):e191. ">Lee 2008</a>; <a href="./references#CD005642-bbs2-0071" title="HopewellS , LoudonK , ClarkeMJ , OxmanAD , DickersinK . Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.MR000006.pub3] ">Hopewell 2009</a>). Thus, many of the included abstracts may have a low probability of getting published as full articles. In fact, including these abstracts in our systematic review may likely be a strength rather than a limitation. By including abstracts we consider the complete available body of evidence. By excluding abstracts we would only obtain a subset that is defined through present‐day biased publication mechanisms. This would considerably increase the likelihood of publication bias. These potential limitations and concerns may lower our confidence in the estimates of intervention effect. However, in our meta‐analysis of sustained virological response there is no apparent heterogeneity (I<sup>2</sup> = 0%) and the direction of the treatment effect is the same across all included trials. Further research is unlikely to change our confidence in the estimate of the effect. It is a common misconception that large randomised trials are generally more reliable than meta‐analyses. The reason this misconception has prevailed is due to a number of highly cited papers that compared large trials with low risk of bias to meta‐analyses of small trials with high risk of bias. This is of course an unfair comparison. In empirical studies where large trials with low risk of bias are compared to a meta‐analysis of small trials with low risk of bias, the results from the two are typically non‐discrepant. In the case of the IDEAL trial (<a href="./references#CD005642-bbs2-0010" title="McHutchisonJG , LawitzEJ , ShiffmanML , MuirAJ , GallerGW , McConeJ , et al. Peginterferon alfa‐2b or alfa‐2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine2009;361(6):580‐93. ">McHutchison 2009</a>), the results still show an effect, albeit small, in favour of peginterferon alpha‐2a. There are many examples of large trials that, merely by the play of chance, underestimate (or overestimate) the true treatment effect. </p> </section> <section id="CD005642-sec-0079"> <h3 class="title" id="CD005642-sec-0079">Agreements and disagreements with other studies or reviews</h3> <p>There are several meta‐analyses that have been published recently which compare the efficacy and safety of the two pegylated interferons (<a href="./references#CD005642-bbs2-0033" title="AlavianSM , BehnavaB , TabatabaeiSV . The comparative efficacy and safety of peginterferon alpha‐2a vs. 2b for the treatment of chronic HCV infection: a meta‐analysis. Hepatitis Monthly2010;10:121‐31. ">Alavian 2010</a>; <a href="./references#CD005642-bbs2-0037" title="BarrosFMR , CheinquerH , BorgesLG , SantosE . Is there any difference between the effects of therapy with peginterferon‐alpha‐2a versus standard‐dose peginterferon‐alpha‐2b? A meta‐analysis comparing both treatments plus ribavirin in genotype 1/4 chronic hepatitis C virus (HCV) infection patients. Value in Health2010;13:A368. ">Barros 2010c</a>; <a href="./references#CD005642-bbs2-0043" title="CheinquerH , BarrosFMR , BorgesLG , SantosE , BuschinelliCT . Systematic review and meta‐analysis of published randomised controlled trials comparing the efficacy of peginterferon‐alpha‐2a versus peginterferon alpha‐2b both plus ribavirin in chronic hepatitis C patients. Value in Health2010;13:A69. ">Cheinquer 2010</a>; <a href="./references#CD005642-bbs2-0114" title="ZhaoS , LiuE , ChenP , ChengD , LuS , YuQ , et al. A comparison of peginterferon α‐2a and α‐2b for treatment‐naive patients with chronic hepatitis C virus: A meta‐analysis of randomised trials. Clinical Therapeutics2010;32:1565‐77. ">Zhao 2010</a>; <a href="./references#CD005642-bbs2-0044" title="CoppolaN , PisaturoM , SagnelliC , TonzielloG , SagnelliE , AngelilloIF . Efficacy and tolerability of peginterferon α‐2a and α‐2b in patients with chronic hepatitis C by genotype 1: A meta‐analysis. Digestive and Liver Diseases2011;43(Suppl):S94. ">Coppola 2011</a>; <a href="./references#CD005642-bbs2-0102" title="SingalAK , JampanaSC , AnandBS . Peginterferon alfa‐2a is superior to peginterferon alfa‐2b in the treatment of naïve patients with hepatitis C virus infection: meta‐analysis of randomized controlled trials. Digestive Diseases and Sciences2011;56:2221‐26. ">Singal 2011</a>; <a href="./references#CD005642-bbs2-0050" title="DruytsE , MillsEJ , NachegaJ , O’ReganC , CooperCL . Differences in clinical outcomes among hepatitis C genotype 1‐infected patients treated with peginterferon alpha‐2a or peginterferon alpha‐2b plus ribavirin: a meta‐analysis. Clinical and Experimental Gastroenterology2012;5:11‐21. ">Druyits 2012</a>; <a href="./references#CD005642-bbs2-0093" title="Romero‐GomezM , PlanasR , SolaR , Garcıa‐SamaniegoJ , DiagoM , CrespoJ , et al. Peginterferon alpha‐2A achieves higher early virological responses (RVR and CEVR) than peginterferon alpha‐2B in chronic Hepatitis C: Meta‐analysis of randomized clinical trials (RCT). Journal of Hepatology2012;56:S456. ">Romero‐Gomez 2012</a>; <a href="./references#CD005642-bbs2-0055" title="FloriN , FunakoshiN , DunyY , ValatsJC , BismuthM , ChristophorouD , et al. Pegylated interferon‐a2a and ribavirin versus pegylated interferon‐a2b and ribavirin in chronic hepatitis C. A meta‐analysis. Drugs2013;73:263‐77. ">Flori 2013</a>; <a href="./references#CD005642-bbs2-0113" title="YangZ , ZhuangL , YangL , ChenX . Efficacy and tolerability of peginterferon A‐2a and peginterferon A‐2b, both plus ribavirin, for chronic hepatitis C: A meta‐analysis of randomized controlled trials. Gastroenterology Research and Practice2013;2013:739029. ">Yang 2013</a>). Four of them have been published as abstracts only (<a href="./references#CD005642-bbs2-0037" title="BarrosFMR , CheinquerH , BorgesLG , SantosE . Is there any difference between the effects of therapy with peginterferon‐alpha‐2a versus standard‐dose peginterferon‐alpha‐2b? A meta‐analysis comparing both treatments plus ribavirin in genotype 1/4 chronic hepatitis C virus (HCV) infection patients. Value in Health2010;13:A368. ">Barros 2010c</a>; <a href="./references#CD005642-bbs2-0043" title="CheinquerH , BarrosFMR , BorgesLG , SantosE , BuschinelliCT . Systematic review and meta‐analysis of published randomised controlled trials comparing the efficacy of peginterferon‐alpha‐2a versus peginterferon alpha‐2b both plus ribavirin in chronic hepatitis C patients. Value in Health2010;13:A69. ">Cheinquer 2010</a>; <a href="./references#CD005642-bbs2-0044" title="CoppolaN , PisaturoM , SagnelliC , TonzielloG , SagnelliE , AngelilloIF . Efficacy and tolerability of peginterferon α‐2a and α‐2b in patients with chronic hepatitis C by genotype 1: A meta‐analysis. Digestive and Liver Diseases2011;43(Suppl):S94. ">Coppola 2011</a>; <a href="./references#CD005642-bbs2-0093" title="Romero‐GomezM , PlanasR , SolaR , Garcıa‐SamaniegoJ , DiagoM , CrespoJ , et al. Peginterferon alpha‐2A achieves higher early virological responses (RVR and CEVR) than peginterferon alpha‐2B in chronic Hepatitis C: Meta‐analysis of randomized clinical trials (RCT). Journal of Hepatology2012;56:S456. ">Romero‐Gomez 2012</a>) and, despite the different numbers of included studies, the common conclusion is that pegylated interferon alpha‐2a has advances over pegylated interferon alpha‐2b. Six meta‐analyses that were published as full papers (<a href="./references#CD005642-bbs2-0033" title="AlavianSM , BehnavaB , TabatabaeiSV . The comparative efficacy and safety of peginterferon alpha‐2a vs. 2b for the treatment of chronic HCV infection: a meta‐analysis. Hepatitis Monthly2010;10:121‐31. ">Alavian 2010</a>; <a href="./references#CD005642-bbs2-0114" title="ZhaoS , LiuE , ChenP , ChengD , LuS , YuQ , et al. A comparison of peginterferon α‐2a and α‐2b for treatment‐naive patients with chronic hepatitis C virus: A meta‐analysis of randomised trials. Clinical Therapeutics2010;32:1565‐77. ">Zhao 2010</a>; <a href="./references#CD005642-bbs2-0102" title="SingalAK , JampanaSC , AnandBS . Peginterferon alfa‐2a is superior to peginterferon alfa‐2b in the treatment of naïve patients with hepatitis C virus infection: meta‐analysis of randomized controlled trials. Digestive Diseases and Sciences2011;56:2221‐26. ">Singal 2011</a>; <a href="./references#CD005642-bbs2-0050" title="DruytsE , MillsEJ , NachegaJ , O’ReganC , CooperCL . Differences in clinical outcomes among hepatitis C genotype 1‐infected patients treated with peginterferon alpha‐2a or peginterferon alpha‐2b plus ribavirin: a meta‐analysis. Clinical and Experimental Gastroenterology2012;5:11‐21. ">Druyits 2012</a>; <a href="./references#CD005642-bbs2-0055" title="FloriN , FunakoshiN , DunyY , ValatsJC , BismuthM , ChristophorouD , et al. Pegylated interferon‐a2a and ribavirin versus pegylated interferon‐a2b and ribavirin in chronic hepatitis C. A meta‐analysis. Drugs2013;73:263‐77. ">Flori 2013</a>; <a href="./references#CD005642-bbs2-0113" title="YangZ , ZhuangL , YangL , ChenX . Efficacy and tolerability of peginterferon A‐2a and peginterferon A‐2b, both plus ribavirin, for chronic hepatitis C: A meta‐analysis of randomized controlled trials. Gastroenterology Research and Practice2013;2013:739029. ">Yang 2013</a>) also uniformly report the superior efficacy of pegylated interferon alpha‐2a over pegylated interferon alpha‐2b while the safety profile remains similar for both treatments. Two meta‐analyses are not comparable to ours because of the different search strategy and inclusion criteria in one (<a href="./references#CD005642-bbs2-0050" title="DruytsE , MillsEJ , NachegaJ , O’ReganC , CooperCL . Differences in clinical outcomes among hepatitis C genotype 1‐infected patients treated with peginterferon alpha‐2a or peginterferon alpha‐2b plus ribavirin: a meta‐analysis. Clinical and Experimental Gastroenterology2012;5:11‐21. ">Druyits 2012</a>) and because non‐randomised trials were included for assessment of benefits in the other (<a href="./references#CD005642-bbs2-0055" title="FloriN , FunakoshiN , DunyY , ValatsJC , BismuthM , ChristophorouD , et al. Pegylated interferon‐a2a and ribavirin versus pegylated interferon‐a2b and ribavirin in chronic hepatitis C. A meta‐analysis. Drugs2013;73:263‐77. ">Flori 2013</a>). The authors did not assess the risk of bias of the included trials (<a href="./references#CD005642-bbs2-0050" title="DruytsE , MillsEJ , NachegaJ , O’ReganC , CooperCL . Differences in clinical outcomes among hepatitis C genotype 1‐infected patients treated with peginterferon alpha‐2a or peginterferon alpha‐2b plus ribavirin: a meta‐analysis. Clinical and Experimental Gastroenterology2012;5:11‐21. ">Druyits 2012</a>). The other four meta‐analyses have similar search strategies and outcomes as ours but included both fewer trials and smaller number of patients (<a href="./references#CD005642-bbs2-0033" title="AlavianSM , BehnavaB , TabatabaeiSV . The comparative efficacy and safety of peginterferon alpha‐2a vs. 2b for the treatment of chronic HCV infection: a meta‐analysis. Hepatitis Monthly2010;10:121‐31. ">Alavian 2010</a>; <a href="./references#CD005642-bbs2-0114" title="ZhaoS , LiuE , ChenP , ChengD , LuS , YuQ , et al. A comparison of peginterferon α‐2a and α‐2b for treatment‐naive patients with chronic hepatitis C virus: A meta‐analysis of randomised trials. Clinical Therapeutics2010;32:1565‐77. ">Zhao 2010</a>; <a href="./references#CD005642-bbs2-0102" title="SingalAK , JampanaSC , AnandBS . Peginterferon alfa‐2a is superior to peginterferon alfa‐2b in the treatment of naïve patients with hepatitis C virus infection: meta‐analysis of randomized controlled trials. Digestive Diseases and Sciences2011;56:2221‐26. ">Singal 2011</a>; <a href="./references#CD005642-bbs2-0113" title="YangZ , ZhuangL , YangL , ChenX . Efficacy and tolerability of peginterferon A‐2a and peginterferon A‐2b, both plus ribavirin, for chronic hepatitis C: A meta‐analysis of randomized controlled trials. Gastroenterology Research and Practice2013;2013:739029. ">Yang 2013</a>). They excluded conference abstracts or limited the participants to only naive patients. The conclusions of those three meta‐analyses are in concordance with our conclusions on the higher efficacy of pegylated interferon alpha‐2a on sustained virological response and comparable safety profile with pegylated interferon alpha‐2b. </p> <p>Current evidence suggests that peginterferon alpha‐2a is significantly better than peginterferon alpha‐2b regarding sustained virological response, which is the clearance of the virus from the blood. However, there is insufficient evidence to detect any differences regarding effects on clinical outcomes (liver complications and mortality) as well as harms (adverse events). Future trials need to study the correlation between sustained virological response and risk of cirrhosis, hepatocellular carcinoma, and mortality. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD005642-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/urn:x-wiley:14651858:media:CD005642:CD005642-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_t/tCD005642-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included trial." data-id="CD005642-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included trial. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/full#CD005642-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005642-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/urn:x-wiley:14651858:media:CD005642:CD005642-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_t/tCD005642-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included trials." data-id="CD005642-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included trials. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/full#CD005642-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005642-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/urn:x-wiley:14651858:media:CD005642:CD005642-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_t/tCD005642-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis (TSA): peginterferon alpha‐2a versus peginterferon alpha‐2b on the outcome serious adverse events.  The diversity‐adjusted required information size of n = 4799 patients was calculated based upon a proportion of 13.0% of patients with serious adverse events in the peginterferon alpha‐2b group, a relative risk reduction of 20% in peginterferon alpha‐2a group, an alpha (type I error) of 5%, a beta (type II error) of 20%, and a diversity (D) of 0%. The solid blue curve presents the cumulative meta‐analysis Z‐score and the inward sloping red curves present the two‐sided Lan‐DeMets trial sequential monitoring boundaries. The cumulative Z‐score reaches the area of futility delineated by the two trial sequential monitoring boundaries." data-id="CD005642-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Trial sequential analysis (TSA): peginterferon alpha‐2a versus peginterferon alpha‐2b on the outcome serious adverse events.<br/> The diversity‐adjusted required information size of n = 4799 patients was calculated based upon a proportion of 13.0% of patients with serious adverse events in the peginterferon alpha‐2b group, a relative risk reduction of 20% in peginterferon alpha‐2a group, an alpha (type I error) of 5%, a beta (type II error) of 20%, and a diversity (D) of 0%. The solid blue curve presents the cumulative meta‐analysis Z‐score and the inward sloping red curves present the two‐sided Lan‐DeMets trial sequential monitoring boundaries. The cumulative Z‐score reaches the area of futility delineated by the two trial sequential monitoring boundaries. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/full#CD005642-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005642-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/urn:x-wiley:14651858:media:CD005642:CD005642-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_t/tCD005642-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Peginterferon alpha‐2a versus peginterferon alpha‐2b, outcome: 1.4. Adverse events leading to treatment discontinuation." data-id="CD005642-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Peginterferon alpha‐2a versus peginterferon alpha‐2b, outcome: 1.4. Adverse events leading to treatment discontinuation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/full#CD005642-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005642-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/urn:x-wiley:14651858:media:CD005642:CD005642-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_t/tCD005642-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis (TSA): peginterferon alpha‐2a versus peginterferon alpha‐2b on the outcome adverse events leading to treatment discontinuation.  The diversity‐adjusted required information size of n = 12,832 patients was calculated based upon a proportion of 9.0% of patients with treatment discontinuation in the peginterferon alpha‐2b group, a relative risk reduction of 20% in peginterferon alpha‐2a group, an alpha (type I error) of 5%, a beta (type II error) of 20%, and a diversity (D) of 81%. The solid blue curve presents the cumulative meta‐analysis Z‐score and the inward sloping red curves present the adjusted threshold for statistical significance according to the two‐sided Lan‐DeMets trial sequential monitoring boundaries. The cumulative Z‐score does not cross any of the monitoring boundaries and does not reach the area of futility delineated by the two trial sequential monitoring boundaries which are not even drawn by the program due to the fact that the distance between the acquired and the required information size is too large." data-id="CD005642-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Trial sequential analysis (TSA): peginterferon alpha‐2a versus peginterferon alpha‐2b on the outcome adverse events leading to treatment discontinuation.<br/> The diversity‐adjusted required information size of n = 12,832 patients was calculated based upon a proportion of 9.0% of patients with treatment discontinuation in the peginterferon alpha‐2b group, a relative risk reduction of 20% in peginterferon alpha‐2a group, an alpha (type I error) of 5%, a beta (type II error) of 20%, and a diversity (D) of 81%. The solid blue curve presents the cumulative meta‐analysis Z‐score and the inward sloping red curves present the adjusted threshold for statistical significance according to the two‐sided Lan‐DeMets trial sequential monitoring boundaries. The cumulative Z‐score does not cross any of the monitoring boundaries and does not reach the area of futility delineated by the two trial sequential monitoring boundaries which are not even drawn by the program due to the fact that the distance between the acquired and the required information size is too large. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/full#CD005642-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005642-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/urn:x-wiley:14651858:media:CD005642:CD005642-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_t/tCD005642-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: Peginterferon alpha‐2a versus peginterferon alpha‐2b, outcome: 1.8 Sustained virological response." data-id="CD005642-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: Peginterferon alpha‐2a versus peginterferon alpha‐2b, outcome: 1.8 Sustained virological response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/full#CD005642-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005642-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/urn:x-wiley:14651858:media:CD005642:CD005642-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_t/tCD005642-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis (TSA): peginterferon alpha‐2a versus peginterferon alpha‐2b on the outcome sustained virological response.   The diversity‐adjusted required information size of n = 4257 patients was calculated based upon a proportion of 49.6 % of patients with sustained virological response in the peginterferon alpha‐2b group, a relative risk reduction of a 10% in peginterferon alpha‐2a group, an alpha (type I error) of 5%, a beta (type II error) of 10%, and a diversity (D) of 51%. The solid blue curve presents the cumulative meta‐analysis Z‐score and the inward sloping red curves present the adjusted threshold for statistical significance according to the two‐sided Lan‐DeMets trial sequential monitoring boundaries. The cumulative Z‐score reaches the area of futility (delineated by the two trial sequential monitoring boundaries), but then it crosses both the conventional significance boundary (two tailed P = 0.05) and the trial sequential monitoring boundary." data-id="CD005642-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Trial sequential analysis (TSA): peginterferon alpha‐2a versus peginterferon alpha‐2b on the outcome sustained virological response. <br/> The diversity‐adjusted required information size of n = 4257 patients was calculated based upon a proportion of 49.6 % of patients with sustained virological response in the peginterferon alpha‐2b group, a relative risk reduction of a 10% in peginterferon alpha‐2a group, an alpha (type I error) of 5%, a beta (type II error) of 10%, and a diversity (D) of 51%. The solid blue curve presents the cumulative meta‐analysis Z‐score and the inward sloping red curves present the adjusted threshold for statistical significance according to the two‐sided Lan‐DeMets trial sequential monitoring boundaries. The cumulative Z‐score reaches the area of futility (delineated by the two trial sequential monitoring boundaries), but then it crosses both the conventional significance boundary (two tailed P = 0.05) and the trial sequential monitoring boundary. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/full#CD005642-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005642-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/urn:x-wiley:14651858:media:CD005642:CD005642-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_t/tCD005642-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis (TSA): peginterferon alpha‐2a versus peginterferon alpha‐2b on the two subgroup analysis sustained virological response in participants infected with hepatitis C genotype 1 and 4.   The diversity‐adjusted required information size of n = 6375 patients was calculated based upon a proportion of 44.9% of patients with sustained virological response in the peginterferon alpha‐2b group, a relative risk reduction of a 10% in peginterferon alpha‐2a group, an alpha (type I error) of 5%, a beta (type II error) of 10%, and a diversity (D) of 45%. The solid blue curve presents the cumulative meta‐analysis test Z‐score and the inward sloping red curves present the two‐sided Lan‐DeMets trial sequential monitoring boundaries. The cumulative Z‐score almost reaches the area of futility (delineated by the two trial sequential monitoring boundaries), but then it crosses both the conventional significance boundary (two tailed P = 0.05 ) and the trial sequential monitoring boundary." data-id="CD005642-fig-0008" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Trial sequential analysis (TSA): peginterferon alpha‐2a versus peginterferon alpha‐2b on the two subgroup analysis sustained virological response in participants infected with hepatitis C genotype 1 and 4. <br/> The diversity‐adjusted required information size of n = 6375 patients was calculated based upon a proportion of 44.9% of patients with sustained virological response in the peginterferon alpha‐2b group, a relative risk reduction of a 10% in peginterferon alpha‐2a group, an alpha (type I error) of 5%, a beta (type II error) of 10%, and a diversity (D) of 45%. The solid blue curve presents the cumulative meta‐analysis test Z‐score and the inward sloping red curves present the two‐sided Lan‐DeMets trial sequential monitoring boundaries. The cumulative Z‐score almost reaches the area of futility (delineated by the two trial sequential monitoring boundaries), but then it crosses both the conventional significance boundary (two tailed P = 0.05 ) and the trial sequential monitoring boundary. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/full#CD005642-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005642-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/urn:x-wiley:14651858:media:CD005642:CD005642-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_t/tCD005642-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis (TSA): peginterferon alpha‐2a versus peginterferon alpha‐2b on the two subgroup analysis sustained virological response in patients infected with hepatitis C genotype 2 and 3.The diversity‐adjusted required information size of n = 1113 patients was calculated based upon a proportion of 81.4% of patients with sustained virological response in the peginterferon alpha‐2b group, a relative risk reduction of a 10% in peginterferon alpha‐2a group, an alpha (type I error) of 5%, a beta (type II error) of 10%, and a diversity (D) of 0%. The solid blue curve presents the cumulative meta‐analysis Z‐score and the inward sloping red curves present the two‐sided Lan‐DeMets trial sequential monitoring boundaries. The cumulative Z‐score does not reach the area of futility (delineated by the two trial sequential monitoring boundaries), but it crosses the conventional significance boundary (two tailed P = 0.05). However, the cumulative Z‐score does not cross the trial sequential monitoring boundary." data-id="CD005642-fig-0009" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Trial sequential analysis (TSA): peginterferon alpha‐2a versus peginterferon alpha‐2b on the two subgroup analysis sustained virological response in patients infected with hepatitis C genotype 2 and 3.The diversity‐adjusted required information size of n = 1113 patients was calculated based upon a proportion of 81.4% of patients with sustained virological response in the peginterferon alpha‐2b group, a relative risk reduction of a 10% in peginterferon alpha‐2a group, an alpha (type I error) of 5%, a beta (type II error) of 10%, and a diversity (D) of 0%. The solid blue curve presents the cumulative meta‐analysis Z‐score and the inward sloping red curves present the two‐sided Lan‐DeMets trial sequential monitoring boundaries. The cumulative Z‐score does not reach the area of futility (delineated by the two trial sequential monitoring boundaries), but it crosses the conventional significance boundary (two tailed P = 0.05). However, the cumulative Z‐score does not cross the trial sequential monitoring boundary. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/full#CD005642-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005642-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/urn:x-wiley:14651858:media:CD005642:CD005642-AFig-FIG10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_t/tCD005642-AFig-FIG10.png" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis (TSA): peginterferon alpha‐2a versus peginterferon alpha‐2b on the subgroup analysis on the outcome sustained virological response in trials with low risk of randomisation bias.  The diversity‐adjusted required information size of n = 5,624 patients was calculated based upon a proportion of 42.4 % of patients with sustained virological response in the peginterferon alpha‐2b group, a relative risk reduction of a 10% in peginterferon alpha‐2a group, an alpha (type I error) of 5%, a beta (type II error) of 10%, and a diversity (D) of 71%. The solid blue curve presents the cumulative meta‐analysis Z‐score which reaches the area of futility (delineated by the two trial sequential monitoring boundaries), but then crosses both the conventional significance boundary (two tailed P = 0.05 not shown on the figure) and the trial sequential monitoring boundary." data-id="CD005642-fig-0010" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Trial sequential analysis (TSA): peginterferon alpha‐2a versus peginterferon alpha‐2b on the subgroup analysis on the outcome sustained virological response in trials with low risk of randomisation bias.<br/> The diversity‐adjusted required information size of n = 5,624 patients was calculated based upon a proportion of 42.4 % of patients with sustained virological response in the peginterferon alpha‐2b group, a relative risk reduction of a 10% in peginterferon alpha‐2a group, an alpha (type I error) of 5%, a beta (type II error) of 10%, and a diversity (D) of 71%. The solid blue curve presents the cumulative meta‐analysis Z‐score which reaches the area of futility (delineated by the two trial sequential monitoring boundaries), but then crosses both the conventional significance boundary (two tailed P = 0.05 not shown on the figure) and the trial sequential monitoring boundary. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/full#CD005642-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005642-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/urn:x-wiley:14651858:media:CD005642:CD005642-AFig-FIG11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_t/tCD005642-AFig-FIG11.png" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis (TSA): peginterferon alpha‐2a versus peginterferon alpha‐2b on the subgroup analysis on the outcome sustained virological response in trials with low risk of blinding bias.  The diversity‐adjusted required information size of n = 2079 patients was calculated based upon a proportion of 68% of patients with sustained virological response in the peginterferon alpha‐2b group, a relative risk reduction of a 10% in peginterferon alpha‐2a group, an alpha (type I error) of 5%, a beta (type II error) of 10%, and a diversity (D) of 0%. The solid blue curve presents the cumulative meta‐analysis Z‐score and the inward sloping red curves present the two‐sided Lan‐DeMets trial sequential monitoring boundaries. The trial sequential monitoring boundaries were not broken by the cumulative Z‐curve." data-id="CD005642-fig-0011" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Trial sequential analysis (TSA): peginterferon alpha‐2a versus peginterferon alpha‐2b on the subgroup analysis on the outcome sustained virological response in trials with low risk of blinding bias.<br/> The diversity‐adjusted required information size of n = 2079 patients was calculated based upon a proportion of 68% of patients with sustained virological response in the peginterferon alpha‐2b group, a relative risk reduction of a 10% in peginterferon alpha‐2a group, an alpha (type I error) of 5%, a beta (type II error) of 10%, and a diversity (D) of 0%. The solid blue curve presents the cumulative meta‐analysis Z‐score and the inward sloping red curves present the two‐sided Lan‐DeMets trial sequential monitoring boundaries. The trial sequential monitoring boundaries were not broken by the cumulative Z‐curve. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/full#CD005642-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-AFig-FIG11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005642-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/urn:x-wiley:14651858:media:CD005642:CD005642-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_t/tCD005642-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Peginterferon alpha‐2a versus peginterferon alpha‐2b, Outcome 1 All‐cause mortality." data-id="CD005642-fig-0012" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Peginterferon alpha‐2a versus peginterferon alpha‐2b, Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/references#CD005642-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005642-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/urn:x-wiley:14651858:media:CD005642:CD005642-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_t/tCD005642-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Peginterferon alpha‐2a versus peginterferon alpha‐2b, Outcome 2 Liver‐related morbidity." data-id="CD005642-fig-0013" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Peginterferon alpha‐2a versus peginterferon alpha‐2b, Outcome 2 Liver‐related morbidity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/references#CD005642-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005642-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/urn:x-wiley:14651858:media:CD005642:CD005642-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_t/tCD005642-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Peginterferon alpha‐2a versus peginterferon alpha‐2b, Outcome 3 Serious adverse events." data-id="CD005642-fig-0014" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Peginterferon alpha‐2a versus peginterferon alpha‐2b, Outcome 3 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/references#CD005642-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005642-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/urn:x-wiley:14651858:media:CD005642:CD005642-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_t/tCD005642-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Peginterferon alpha‐2a versus peginterferon alpha‐2b, Outcome 4 Adverse events leading to treatment discontinuation." data-id="CD005642-fig-0015" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Peginterferon alpha‐2a versus peginterferon alpha‐2b, Outcome 4 Adverse events leading to treatment discontinuation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/references#CD005642-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005642-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/urn:x-wiley:14651858:media:CD005642:CD005642-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_t/tCD005642-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Peginterferon alpha‐2a versus peginterferon alpha‐2b, Outcome 5 All other (non serious) adverse events." data-id="CD005642-fig-0016" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Peginterferon alpha‐2a versus peginterferon alpha‐2b, Outcome 5 All other (non serious) adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/references#CD005642-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005642-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/urn:x-wiley:14651858:media:CD005642:CD005642-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_t/tCD005642-CMP-001-06.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Peginterferon alpha‐2a versus peginterferon alpha‐2b, Outcome 6 Sustained virological response." data-id="CD005642-fig-0017" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Peginterferon alpha‐2a versus peginterferon alpha‐2b, Outcome 6 Sustained virological response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/references#CD005642-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005642-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/urn:x-wiley:14651858:media:CD005642:CD005642-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_t/tCD005642-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis, Outcome 1 Sustained virological response according to genotype." data-id="CD005642-fig-0018" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis, Outcome 1 Sustained virological response according to genotype. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/references#CD005642-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005642-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/urn:x-wiley:14651858:media:CD005642:CD005642-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_t/tCD005642-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis, Outcome 2 Sustanied virological response according to treatment history." data-id="CD005642-fig-0019" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis, Outcome 2 Sustanied virological response according to treatment history. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/references#CD005642-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005642-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/urn:x-wiley:14651858:media:CD005642:CD005642-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_t/tCD005642-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis, Outcome 3 Sustained virological response according to risk of bias from randomisation." data-id="CD005642-fig-0020" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis, Outcome 3 Sustained virological response according to risk of bias from randomisation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/references#CD005642-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005642-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/urn:x-wiley:14651858:media:CD005642:CD005642-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_t/tCD005642-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis, Outcome 4 Sustained virological response according to risk of bias from blinding." data-id="CD005642-fig-0021" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis, Outcome 4 Sustained virological response according to risk of bias from blinding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/references#CD005642-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005642-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/urn:x-wiley:14651858:media:CD005642:CD005642-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_t/tCD005642-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis, Outcome 5 Sustained virological response in patients without HIV co‐infection." data-id="CD005642-fig-0022" src="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis, Outcome 5 Sustained virological response in patients without HIV co‐infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/references#CD005642-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/media/CDSR/CD005642/image_n/nCD005642-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD005642-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with chronic hepatitis C.<br/> <b>Settings:</b> mainly out‐patients in tertiary and teaching hospitals.<br/> <b>Intervention:</b> peginterferon alpha‐2a versus peginterferon alpha‐2b. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Peginterferon alpha‐2b</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Peginterferon alpha‐2a </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>All‐cause mortality</b> <br/> Deaths during and after the treatment<br/> Follow‐up: 48 to 72 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.97</b> <br/> (0.64 to 6.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3070<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> <br/> (2 to 18) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> <br/> (2 to 18) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Liver‐related morbidity</b> <br/> Number of events<br/> Follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3</b> <br/> (0.7 to 12.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>36<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>2</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>111 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>333 per 1000</b> <br/> (78 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>111 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>333 per 1000</b> <br/> (78 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Serious adverse events</b> <br/> Number of events<br/> Follow‐up: 48 to 72 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.12</b> <br/> (0.95 to 1.3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3900<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>114 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>127 per 1000</b> <br/> (108 to 148) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b> <br/> (66 to 91) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events leading to treatment discontinuation</b> <br/> Number of events<br/> Follow‐up: 48‐72 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.84</b> <br/> (0.57 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>5340<br/> (12 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,4,5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>99 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> <br/> (56 to 120) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>80 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> <br/> (46 to 98) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All other (non‐serious) adverse events</b> <br/> Follow‐up: 48 to 72 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4981<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>4,5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> <br/> SF 36 and CLDQ<br/> Follow‐up: 48 to 71 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>434<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>7,8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Sustained virological response</b> <br/> Absence of viraemia 24 weeks after the treatment<br/> Follow‐up: 48 to 72 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.12</b> <br/> (1.06 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>5013<br/> (12 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<sup>9,10</sup> <br/> <b>moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>421 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>480 per 1000</b> <br/> (451 to 510) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>510 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>581 per 1000</b> <br/> (546 to 617) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> The trial is at low risk of bias due to the allocation sequence generation and allocation concealment.<br/> <sup>2</sup>Data from only one trial, wide confidence interval. Incomplete outcome data. Very low due to imprecision.<br/> <sup>3</sup>Post hoc required information size calculation based on a 10% risk of adverse events in the peginterferon alpha‐2b group, a minimally important difference of 10%, a 5% type I error, and a 80% power, suggests that a minimum of 27,000 patients need to be randomised for a conclusive meta‐analysis on adverse events. The current number of patients is only approximately 5000.<br/> <sup>4</sup>Wide confidence interval. Low due to imprecision.<br/> <sup>5</sup>Trials yield widely differing estimates of effect. Low due to imprecision.<br/> <sup>6</sup> Reporting of all other adverse events was poor and inconsistent across all included trials. The proportions of observed adverse events differ substantially across the trials, and the direction of effect is heterogeneous. Because the event proportion is relatively low across all trials, all of the included trials may be subject to considerable random errors, thus explaining the apparent heterogeneity in direction of estimates.<br/> <sup>7</sup> Data from only one trial. Low due to imprecision<br/> <sup>8</sup> Investigators fail to report the details necessary for calculating the effect estimate of the quality of life assessment. Very low due to imprecision.<br/> <sup>9</sup>Sustained virological response does not seem to be a valid surrogate marker for assessing HCV treatment efficacy of interferon retreatment. Moderate quality of evidence due to indirectness due to surrogate and risk of bias.<br/> <sup>10</sup>All trials are with high risk of bias. Sensitivity analyses did not show any important change in the intervention effects when we focused on trials with lower risk of bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/full#CD005642-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005642-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Peginterferon alpha‐2a versus peginterferon alpha‐2b</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.97 [0.64, 6.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Liver‐related morbidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.70, 12.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3900</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.95, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events leading to treatment discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.57, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All other (non serious) adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Sustained virological response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [1.06, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Peginterferon alpha‐2a versus peginterferon alpha‐2b</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/references#CD005642-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005642-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Sustained virological response according to genotype <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Genotype 1 or 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [1.06, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Genotype 2 or 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [1.02, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Sustanied virological response according to treatment history <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Naive patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5031</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [1.06, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Non‐responders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.47, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Sustained virological response according to risk of bias from randomisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [1.06, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Trials with low risk of bias from randomisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [1.05, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Trials with high risk of bias from randomisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>608</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [1.02, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Sustained virological response according to risk of bias from blinding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Trials with blinding protecting against detection bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [1.10, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Trials without blinding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4756</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [1.04, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Sustained virological response in patients without HIV co‐infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [1.06, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005642.pub3/references#CD005642-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD005642.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD005642-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD005642-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD005642-note-0001">Français</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005642\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005642\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005642\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005642\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005642\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005642\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005642\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005642\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005642\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005642\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005642\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005642\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005642\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005642\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005642\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005642\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005642\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005642\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PrHmaMrX&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005642.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005642.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD005642.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD005642.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005642.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725619518"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005642.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725619522"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005642.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e7faa4c40f466',t:'MTc0MDcyNTYxOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 